Investigating G protein-coupled receptor 35 signalling and its role in cardiovascular disease by Divorty, Nina
  
 
 
 
 
 
 
Divorty, Nina (2017) Investigating G protein-coupled receptor 35 signalling 
and its role in cardiovascular disease. PhD thesis. 
 
 
 
http://theses.gla.ac.uk/8235/  
 
 
 
 
Copyright and moral rights for this work are retained by the author 
A copy can be downloaded for personal non-commercial research or study, without prior 
permission or charge 
This work cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
Enlighten:Theses 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Investigating G protein-coupled receptor 35 
signalling and its role in cardiovascular disease 
 
 
Nina Jennifer Divorty 
BSc (Hons), MRes 
 
 
 
Submitted in fulfilment of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
Institute of Molecular, Cell and Systems Biology and 
Institute of Cardiovascular and Medical Sciences 
 
College of Medical, Veterinary and Life Sciences 
 
University of Glasgow 
 
February 2017 
  
ii 
 
Abstract 
G protein-coupled receptors (GPCRs) are an important source of drug targets 
with diverse therapeutic applications. Orphan GPCRs, which have unknown 
endogenous ligands or physiological functions, represent a pool of potential 
therapeutic targets that could provide novel or improved treatments for a wide 
range of diseases. G protein-coupled receptor 35 (GPR35) is an orphan receptor 
that has been associated with several diseases and physiological processes, 
including gastrointenstinal disease, pain transduction, inflammation and 
cardiovascular disease. However, the precise function of GPR35 in these 
processes is yet to be elucidated. Cardiovascular disease, including hypertension 
and heart failure, remains a large global disease burden, suggesting that current 
treatments are inadequate and that novel insights might be beneficial. 
Therefore, the role of GPR35 in cardiovascular disease was investigated in order 
to assess its potential as a therapeutic target. 
To provide insight into the potential mechanisms of GPR35 actions in the 
cardiovascular system, GPR35 signalling was investigated in detail in vitro. 
Agonist-dependent phosphorylation was observed at five sites in the GPR35 
C-terminal tail, which differentially influenced β-arrestin recruitment. Both 
agonist-dependent phosphorylation and β-arrestin-1/2, but not Gα12/13, were 
essential for agonist-induced internalisation of GPR35, an important process in 
the desensitisation of the G protein-mediated response. Conversely, agonist-
induced reorganisation of the actin cytoskeleton was dependent on Gα12/13, but 
not phosphorylation or β-arrestin. 
To assess the role of GPR35 in cardiovascular disease, its actions were 
investigated in three in vivo models. A GPR35 knockout mouse had no abnormal 
cardiovascular phenotype under basal conditions, with no detectable differences 
in blood pressure, cardiac function, vascular reactivity or end-organ morphology 
compared with the wild type background strain. However, GPR35 knockout mice 
were resistant to hypertension and cardiac dysfunction induced by 2-week 
infusion of angiotensin II. Furthermore, administration of the GPR35 agonist 
amlexanox exacerbated both hypertension and end-organ damage in the stroke-
prone spontaneously hypertensive rat. 
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These findings demonstrate a pathological role for GPR35 in the development of 
hypertension and its associated end-organ damage. It is likely that this is a result 
of Gα13-mediated effects of GPR35 on the actin cytoskeleton in cardiovascular 
tissues, although this requires further investigation in primary cell models. These 
studies suggest that antagonism of GPR35 could be a novel therapeutic strategy 
to treat hypertension and/or heart failure. The findings must now be validated 
by antagonising GPR35 in in vivo disease models, in order to evaluate the 
therapeutic value of this strategy. 
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Chapter 1 Introduction 
1.1 G protein-coupled receptors in drug discovery 
1.1.1 The G protein-coupled receptor superfamily 
The G protein-coupled receptor (GPCR) superfamily is the largest family of 
membrane proteins in the human proteome, comprising cell surface receptors 
for a wide variety of stimuli including hormones, neurotransmitters, chemokines, 
metabolites, ions and more. As such, GPCRs have important roles in an extensive 
range of physiological processes, and have been studied intensively for several 
decades. The family is characterised by a common seven-transmembrane 
-helical fold, with family members sharing a high degree of structural similarity 
in the transmembrane bundle. Other structural features include an extracellular 
domain consisting of the N-terminal domain and three flexible extracellular 
loops (ECLs) and an intracellular domain consisting of three intracellular loops 
(ICLs) and a C-terminal tail. These regions are more variable and confer much of 
each receptor’s ligand-binding and signalling specificity (Katritch et al., 2012). 
1.1.2 GPCRs as therapeutic targets 
Due to their ubiquity in physiological processes, GPCRs and their ligands are 
often implicated in pathophysiology and disease. This, together with their 
accessibility at the cell membrane, makes the family an important source of 
therapeutic targets. By various different estimates, approximately 30% of all 
FDA-approved drugs target GPCRs (Overington et al., 2006, Rask-Andersen et al., 
2011, Garland, 2013). These have diverse therapeutic applications including the 
treatment of neuropsychiatric disorders, cardiovascular disease, allergy, pain, 
obesity and diabetes, and include many of the all-time bestselling drugs (Table 
1-1) (Zambrowicz and Sands, 2003, Garland, 2013).  New GPCR-targeting drugs 
are still being discovered, accounting for 19% of new molecular entities 
approved between 2010 and 2012 (Garland, 2013). Furthermore, relatively 
recent developments in the field have uncovered novel facets of GPCR 
signalling, such as biased agonism, that can be further exploited to develop 
novel and improved therapeutics (Whalen et al., 2011, Luttrell et al., 2015). 
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GPCRs therefore remain at the forefront of drug discovery and hold great 
potential as therapeutic targets for the future. 
Table 1-1 Selected bestselling drugs that target GPCRs 
Drug GPCR target Therapeutic application 
Claritin (loratidine) Histamine H1 receptor Allergy 
Diovan (valsartan) AT1 angiotensin receptor Hypertension, heart failure 
Plavix (clopidogrel) P2Y12 purinergic receptor Heart attack, stroke 
Serevent (salmeterol) β2 adrenergic receptor Asthma, COPD 
Seroquel (quetiapine) 5-HT/dopamine receptors Psychosis, depression 
Singulair (montelukast) Leukotriene receptor Asthma, allergy 
Zyprexa (olanzapine) 5-HT/dopamine receptors Psychosis 
Adapted from (Zambrowicz and Sands, 2003). (COPD = chronic obstructive pulmonary disease; 
5-HT = 5-hydroxytryptamine.) 
1.1.3 Orphan GPCRs 
Although GPCRs are generally very valuable drug targets, the vast majority of 
approved drugs act at a select few family members: the histamine H1 receptor, 
the α1A and α2A adrenergic receptors, the M1, M2 and M3 muscarinic receptors, the 
dopamine D2 receptor and the 5-HT2A serotonin receptor (Garland, 2013). Of 365 
non-olfactory GPCRs, less than one third are currently utilised as drug targets. 
More than 120 are orphan GPCRs – receptors that have not yet been paired with 
a cognate endogenous ligand (Davenport et al., 2013, Alexander et al., 2015). 
Often, these orphan receptors are poorly characterised and have unknown 
physiological functions. However, given the importance of GPCR signal 
transduction in a wide range of cellular processes, it is thought that many 
orphan GPCRs must have therapeutically relevant roles. These receptors 
therefore represent a pool of previously unexploited potential therapeutic 
targets, and ongoing research efforts are being applied to ‘deorphanise’ these 
receptors and elucidate their roles in various diseases. 
1.1.4 Deorphanisation strategies 
Historically, GPCR drug targets were identified using a ‘classical pharmacology’, 
ligand-based approach, in which biologically active compounds are isolated, for 
example from tissue extracts, and used to generate lead compounds, 
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subsequently leading to target identification. This approach was used for some 
of the most therapeutically successful GPCR targets, such as the β-adrenergic 
receptors – which were identified as receptors for adrenaline in 1948 and 
subsequently targeted by β blockers – and the histamine receptors, which were 
used to screen for early anti-allergy drugs in the 1930s, and remain important 
targets today (Wachter and Gilbert, 2012, Jones, 2016). However, advances in 
homology screening techniques (whereby novel genes are amplified using 
primers for homologous sequences), and later the publication of the human 
genome, gave rise to a large pool of orphan receptor targets, and so a new 
strategy for drug discovery emerged (Lander et al., 2001). ‘Reverse 
pharmacology’ uses the receptor target as a starting point, utilising the cloned 
receptor to screen for endogenous and synthetic ligands (Lecca and Abbracchio, 
2008). These tool compounds can subsequently be used to investigate the 
receptor’s pharmacological properties and biological function (Lecca and 
Abbracchio, 2008, Kolar et al., 2016). The reverse pharmacology approach has 
been applied successfully to deorphanise a number of important drug targets, 
such as the early deorphanisation of the 5-HT1A serotonin receptor (Fargin et al., 
1988) and the dopamine D2 receptor (Bunzow et al., 1988). It has also been 
instrumental in the identification of novel endogenous ligands and previously 
unknown transmitter systems, as with the discovery of orexins and their 
receptors as regulators of wakefulness and appetite (Sakurai et al., 1998). 
Following on from these early successes, the approach continues to yield 
promising new drug targets, such as free fatty acid receptor 1 (FFA1), formerly 
the orphan GPR40, which is now an attractive therapeutic target in type 2 
diabetes (Itoh et al., 2003, Li et al., 2016). 
Some knowledge of the coupling and signalling profile of an orphan GPCR is 
beneficial to developing screening assays for deorphanisation. G protein and 
second messenger activity assays such as guanosine triphosphate (GTP)-γS, cyclic 
adenosine monophosphate (cAMP), and intracellular calcium ([Ca2+]i) assays have 
proven successful in deorphanisation and surrogate ligand screens (Briscoe et al., 
2003, Takeda et al., 2003, Jenkins et al., 2010, Meyer et al., 2013). Components 
of the desensitisation and internalisation cycle, especially translocation of the 
adaptor protein β-arrestin, have also been utilised in screening efforts (Oakley 
et al., 2006, Neetoo-Isseljee et al., 2013). It is therefore important to 
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understand how these processes vary among GPCRs in order to properly interpret 
screens for orphan receptors. 
Today, novel technologies are being applied to the reverse pharmacology model 
in order to deorphanise poorly characterised receptors. The recent accumulation 
of high quality crystal structures has enabled in silico homology modelling, which 
in combination with virtual screening is a powerful means of identifying 
surrogate ligands for orphan receptors that have few or no tool compounds with 
which to probe their function (Ngo et al., 2016b). This approach has been used 
to identify high potency synthetic ‘surrogate’ ligands for orphan receptors such 
as GPR17, a proposed target in neurodegenerative disease (Eberini et al., 2011), 
and GPR37L1, which has been associated with neuroprotection and hypertension 
(Ngo et al., 2016a). 
1.1.5 Orphan GPCRs as drug targets  
While identifying the endogenous ligands for orphan receptors is desirable, 
deorphanisation is not always necessary to identify potential therapeutic value. 
In fact, identifying a therapeutically relevant function for an orphan receptor is 
usually a prerequisite for amassing sufficient interest to make a concerted 
deorphanisation effort. Often, important physiological and pathophysiological 
roles can be inferred from tissue distribution or phenotypic studies. Transgenic 
and knockout mice can be valuable tools in interrogating the functions of poorly 
characterised receptors. For example, the orphan GPR88 is expressed in areas of 
the brain associated with schizophrenia (Logue et al., 2009). GPR88 knockout 
mice showed behavioural defects associated with the striatal dopamine system, 
implicating it as a potential therapeutic target in CNS disorders (Logue et al., 
2009). Similarly, GPR55 – a recently deorphanised endocannabinoid receptor – is 
moderately expressed in epithelia (Pérez-Gómez et al., 2013). Its role in 
tumorigenesis was first discovered in a knockout mouse study, and it is now an 
emerging therapeutic target and biomarker in cancer (Pérez-Gómez et al., 2013, 
Andradas et al., 2016, Singh et al., 2016). 
Another argument for the therapeutic value of orphan GPCRs is the possibility of 
ligand-independent functions for these receptors (Levoye and Jockers, 2008). 
This includes both constitutive activity (the ability to activate downstream 
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signalling in the absence of agonist) and modulation of other proteins’ activities. 
Constitutive activity not only provides a possible rationale for why some 
receptors defy deorphanisation efforts via traditional screening assays (which 
depend upon agonist-induced stabilisation of the active receptor conformation), 
but also enables targeting by inverse agonists, which effectively antagonise the 
receptor by reducing signalling below the constitutive level (Bond and Ijzerman, 
2006). Modulation of other proteins, for example through heteromerisation with 
other GPCRs and membrane proteins, also provides opportunities for therapeutic 
targeting of orphan GPCRs. The orphan GPR50 has been shown to interact with 
the closely related MT1 melatonin receptor and inhibit both high affinity binding 
of the endogenous agonist and agonist-induced recruitment of G protein (Levoye 
et al., 2006). Heteromerisation of GPCRs is now known to be an important 
modulator of trafficking and signalling for many GPCRs, and has been 
demonstrated in native tissues for several therapeutically relevant receptors 
(Gomes et al., 2016). There is a strong possibility that some orphan receptors 
are involved in heteromeric interactions with non-orphan GPCRs, or even with 
other membrane proteins, and targeting these interactions is another possible 
therapeutic strategy. 
1.2 GPCR signalling 
1.2.1 Diversity among GPCRs 
There are more than 800 GPCR genes in the human genome, each with a specific 
set of ligand-binding and downstream signalling capacities. The superfamily can 
be phylogenetically grouped into six families or classes (Fredriksson et al., 2003, 
Nordström et al., 2011). The Rhodopsin family, also known as Class A, is by far 
the largest family, and encompasses a wide range of protein and small-molecule 
receptors, including a large group of olfactory receptors (Fredriksson et al., 
2003). Class A GPCRs have short extracellular N-terminal domains, and ligands 
generally bind within the transmembrane helical region (Fredriksson et al., 
2003). Despite sharing several important anchor motifs in the transmembrane 
bundle, structural variation in the ligand-binding pockets of Class A receptors 
provides a diverse array of ligand specificities within the family (Katritch et al., 
2012). 
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The remaining families are considerably smaller and have less diverse ligands 
than the Rhodopsin family. Class B1 or Secretin family GPCRs bind to a group of 
peptides with high sequence similarity, including glucagon and glucagon-like 
peptide, and are characterised by a relatively short N-terminus containing 
conserved Cys bridges (Fredriksson et al., 2003). Class B2 or Adhesion family 
GPCRs have heavily glycosylated, variable-length N-termini containing adhesion-
like domains; these receptors undergo autocatalytic processing and are involved 
in cell adhesion signalling (Hamann et al., 2015). Class C or the Glutamate 
family consists mostly of metabotropic glutamate receptors, which have long N-
terminal domains that bind directly to the ligands (Bräuner-Osborne et al., 
2007). The Frizzled family bind to Wnt family glycoproteins and are involved in 
developmental processes (Slusarski et al., 1997). Finally, the Taste2 receptors 
were previously grouped with the Frizzled family, but have recently been 
reclassified as a separate family of sensory receptors (Nordström et al., 2011, 
Munk et al., 2016) 
1.2.2 GPCR activation 
The fundamental function of GPCRs is to transduce extracellular signals across 
the plasma membrane to cytoplasmic effectors, enabling the cell to respond to 
environmental cues. The signal is initiated by ligand binding to the orthosteric 
binding site (a binding pocket inside the helix bundle in the case of Class A 
GPCRs). Binding of the ligand induces substantial conformational changes in both 
the transmembrane helix bundle and the intracellular domain. Recent crystal 
structures of ligand-bound rhodopsin, β2 adrenergic receptor and A2A adenosine 
receptor have revealed that these changes are conserved among Class A GPCRs 
(Rasmussen et al., 2011, Standfuss et al., 2011, Xu et al., 2011). Stabilisation of 
this active conformation enables translocation and binding of cytoplasmic 
effector proteins to the receptor’s intracellular domain, which in turn regulates 
intracellular signalling cascades. 
1.2.3 Classical G protein-mediated signalling 
GPCR signalling is now known to be a complex network, influenced by many 
different components and feeding into a multitude of effector pathways. 
However, the superfamily takes its name from the first of these effectors to be 
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described – the heterotrimeric G proteins. This family of guanine nucleotide-
binding proteins are the major cytoplasmic signalling effectors of most GPCRs. 
They consist of α, β and γ subunits, which form a heterotrimeric complex in the 
inactive, guanosine diphosphate (GDP)-bound state. The complex is tethered to 
the plasma membrane by lipid modifications on the α and γ subunits (Vögler et 
al., 2008). Upon ligand binding to the GPCR and stabilisation of its active 
conformation, the Gα subunit binds to the receptor’s intracellular domain. In the 
case of Class A GPCRs, Gα binds to the cytoplasmic ends of transmembrane 
helices 5 and 6 (Rasmussen et al., 2011, Standfuss et al., 2011, Xu et al., 2011). 
This causes a conformational change in the Gα subunit which promotes GDP/GTP 
exchange, thus activating the G protein and allowing the Gα subunit to 
dissociate from both the βγ dimer and the receptor (Figure 1-1 A) (Chung et al., 
2011). The active Gα and Gβγ subunits can then regulate various second 
messengers until the intrinsic GTPase activity of the Gα subunit hydrolyses GTP 
to GDP (Higashijima et al., 1987, Sprang et al., 2007). This allows reassociation 
of the inactive heterotrimer and terminates the signal. The GTPase activity of 
Gα can be accelerated by a family of GTPase activating proteins called 
regulators of G protein signalling (RGS), which mediate rapid termination of the 
signal (Woodard et al., 2015). G proteins can continue to be activated and 
inactivated via this GDP/GTP cycle until either ligand dissociation returns the 
GPCR to its inactive conformation, or desensitisation mechanisms preclude 
further Gα binding. 
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Figure 1-1 GPCR signalling (A) Upon ligand binding, Gα binds to the GPCR, promoting 
GDP/GTP exchange and allowing dissociation of the Gα and Gβγ subunits and G protein-
dependent signalling. (B) G protein-coupled receptor kinases phosphorylate the agonist-occupied 
GPCR. (C) Recruitment of β-arrestin to the phosphorylated GPCR sterically hinders further G 
protein activation. (D) β-arrestin recruits proteins that initiate clathrin-mediated internalisation. (E) 
β-arrestin can also act as a scaffold to recruit proteins involved in G protein-independent signalling. 
The G protein family contains multiple α, β and γ isoforms, each of which has a 
specific tissue distribution and downstream signalling profile (Wettschureck and 
Offermanns, 2005). G proteins can interact with multiple GPCRs and GPCRs can 
interact with multiple Gα family members. Thus, the availability of the GPCR, its 
interacting G protein subunits and their cytoplasmic effector proteins all 
contribute to the signalling outcome in response to a stimulus in any given cell. 
The Gα proteins can be split into several sub-families, each of which has a 
characteristic signalling profile. 
1.2.3.1 The Gαs sub-family 
Gα ‘stimulatory’ (Gαs) subunits are ubiquitously expressed, and transduce their 
signals by increasing intracellular levels of the second messenger cAMP. Active 
Gαs diffuses within the plasma membrane and binds to and activates the 
transmembrane enzyme adenylate cyclase, which converts adenosine 
triphosphate (ATP) into cAMP. cAMP has diverse cellular effects depending on 
the cell type in question, including the activation of glycogenolysis and lipolysis, 
hormone release, smooth muscle relaxation and neuronal activation (Sutherland, 
1972, Wettschureck and Offermanns, 2005). These effects are mediated by 
cAMP-dependent proteins, such as cAMP-dependent protein kinase (PKA) and 
exchange proteins activated by cAMP (EPACs). 
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1.2.3.2 The Gαi/o sub-family 
The Gα ‘inhibitory’ (Gαi/o) sub-family has eight members, which exert their 
effects by decreasing intracellular cAMP and by regulating a variety of ion 
channels. Gαi1, Gαi2 and Gαi3 are the most abundant in most tissues and are 
widely distributed. They decrease cAMP by inhibiting various isoforms of 
adenylate cyclase. Other Gαi/o members have restricted expression, such as Gαo 
in neurons and Gαz in neurons and platelets. It is thought that these primarily 
mediate their effects indirectly through the release of their βγ subunits 
(Wettschureck and Offermanns, 2005). Because of their role in decreasing cAMP, 
the cellular effects of Gαi/o proteins are largely antagonistic to those of Gαs. 
1.2.3.3 The Gαq/11 sub-family 
Like the Gαi/o sub-family, the Gαq/11 sub-family includes both ubiquitous and 
tissue-specific members. Gαq and Gα11 are ubiquitously expressed, whereas Gα14 
is restricted to kidney, lung and spleen and Gα16 is expressed only in 
hematopoietic cells (Wettschureck and Offermanns, 2005). All of these 
transduce their signals by recruiting and activating phospholipase C-β, which 
catalyses the breakdown of phosphatidylinositol 4,5-bisphosphate into inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (Wettschureck and 
Offermanns, 2005, Litosch, 2016). IP3 mediates the release of intracellular 
calcium and DAG activates protein kinase C (PKC). Gαq/11 can also activate RhoA 
via p63RhoGEF (Litosch, 2016). These multiple effectors perform a range of 
signalling functions, with outcomes such as smooth muscle contraction, cellular 
hypertrophy and synaptic transmission (Wettschureck and Offermanns, 2005). 
1.2.3.4 The Gα12/13 sub-family 
Gα12 and Gα13 are both ubiquitously expressed, but frequently couple to GPCRs 
that also activate other Gα subunits. Since specific inhibitors of Gα12/13 are not 
available, their precise signalling roles have been difficult to define. The best-
characterised role of Gα12 and Gα13 is their RhoA-mediated effects on the actin 
cytoskeleton. Gα12/13 binds to and activates a panel of four Rho guanine 
nucleotide exchange factors (RhoGEFs), which promote RhoA GDP/GTP exchange 
(Siehler, 2009). RhoA activates a number of downstream pathways that lead to 
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changes in cell shape, polarity and adhesion, cell migration and cellular 
hypertrophy (Worzfeld et al., 2008, Siehler, 2009). 
1.2.3.5 Gβγ signalling 
In addition to signalling via the four Gα sub-families, GPCRs can also signal 
through the Gβγ complex, which often complements the Gα-mediated response. 
Following GPCR-mediated dissociation of the Gα subunit, Gβγ is free to regulate 
a number of its own targets, including the G protein-regulated inward rectifier 
K+ channel, phospholipase C-β and adenylate cyclase (Clapham and Neer, 1997). 
Because Gαi subunits are the most highly expressed Gα subunit in most tissues, 
Gβγ complexes released from Gαi-containing heterotrimers are thought to be 
primarily responsible for Gβγ-mediated signalling (Wettschureck and 
Offermanns, 2005). 
1.2.4 GPCR desensitisation 
GPCRs have a range of mechanisms for desensitisation, that is, a decline in the 
magnitude of the response as a result of continued or repeated stimulation. 
These mechanisms enable highly regulated termination of the agonist-induced 
response, and are carried out by cytoplasmic proteins which act on the ICLs and 
C-terminal tail of the receptor (Lohse, 1993, Tobin et al., 2008). Thus, 
desensitisation mechanisms are dependent on both the GPCR amino acid 
sequence and the expression of various cytoplasmic mediators.  
1.2.4.1 Heterologous desensitisation by effector kinases 
Heterologous desensitisation concerns the desensitisation of receptors by 
effector kinases. Because this is independent of agonist occupancy and is not 
receptor-specific, it can occur as a result of ligand binding to a receptor other 
than the one that is ultimately desensitised. Both PKA and PKC can 
phosphorylate certain receptors on serine and threonine residues at consensus 
sites in the ICLs and C-terminal tail, which disrupts the G protein binding site 
and thus uncouples the receptor from the G protein-mediated response (Lohse, 
1993, Tobin, 2008). 
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1.2.4.2 Homologous desensitisation by arrestins 
Homologous desensitisation is the desensitisation of agonist-occupied, activated 
GPCRs, and occurs more rapidly than heterologous desensitisation  (Lohse, 
1993). G protein-coupled receptor kinases (GRKs) phosphorylate the ICLs and 
C-terminal tails of agonist-bound GPCRs at serine and threonine residues distinct 
from those phosphorylated by effector kinases (Figure 1-1 B) (Seibold et al., 
2000). Unlike in heterologous desensitisation, phosphorylation by GRKs alone is 
not sufficient to uncouple the receptor from the G protein (Benovic et al., 
1987). Instead, GRK-mediated phosphorylation leads to the recruitment and 
binding of the adaptor protein arrestin to the GPCR, which mediates the 
desensitisation by sterically hindering binding of the Gα subunit (Gimenez et al., 
2012). 
The arrestins are a family of four proteins: visual arrestin and cone arrestin, 
which are expressed only in the retina; and β-arrestins 1 and 2, which are 
ubiquitously expressed and thus are responsible for homologous desensitisation 
of most non-visual GPCRs (Luttrell and Lefkowitz, 2002). Since the β-arrestin and 
Gα binding interfaces overlap, the immediate consequence of β-arrestin binding 
to the GPCR is steric hindrance of further Gα-GDP binding to the agonist-
occupied receptor (Figure 1-1 C) (Szczepek et al., 2014). This rapidly terminates 
the activation of G protein-dependent signalling (Benovic et al., 1987, Lohse, 
1993). 
A secondary desensitising role of β-arrestin is to initiate clathrin-mediated 
internalisation of an agonist-occupied receptor (Figure 1-1 D). Receptor-bound 
β-arrestin recruits adaptor protein 2 complex (AP2) and clathrin to the plasma 
membrane to initiate the formation of clathrin-coated pits (Goodman et al., 
1996, Laporte et al., 1999). This leads to internalisation of the agonist-occupied 
receptor. There are two potential modes of β-arrestin-mediated internalisation. 
Depending on the GPCR involved, the β-arrestin either dissociates prior to 
endocytosis, or remains in complex with the receptor and co-localises to the 
endosome (Zhang et al., 1999). This is determined at least in part by the GRK-
mediated phosphorylation of serine and threonine residues in the C-terminal tail 
(Gimenez et al., 2012). Both sorting signals in the receptor intracellular domain 
and the stability of the interaction with β-arrestin determine the fate of the 
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endocytosed receptor – it can either be recycled back to the plasma membrane 
or targeted for degradation by ubiquitination (Marchese and Trejo, 2013). For 
receptors that dissociate from β-arrestin prior to endocytosis, the receptor can 
resume G protein-dependent signalling in a spatially compartmentalised manner 
(Calebiro et al., 2009, Tsvetanova and von Zastrow, 2014). However, very recent 
reports suggest that this may also be possible for β-arrestin-bound internalised 
GPCRs, giving rise to sustained G protein signalling from within the endosomal 
compartment (Thomsen et al., 2016). These features of the internalisation cycle 
provide additional spatiotemporal regulation of the G protein-dependent 
response. 
1.2.4.3 G protein-independent signalling 
In addition to its role in desensitisation, β-arrestin has recently come to be 
recognised as an important mediator of signalling in its own right. -arrestin can 
be recruited to agonist-occupied GPCRs at the plasma membrane independently 
of G protein activation, where it can act as a scaffold for cytoplasmic signalling 
proteins (Figure 1-1 E) (Wei et al., 2003, Shenoy et al., 2006). GPCR-bound 
β-arrestin has been shown to bind and activate members of several important 
pathways including the Src-family kinases, extracellular signal-regulated kinase 
(ERK) and c-jun N-terminal kinase (JNK) mitogen-activated protein kinases and 
phosphodiesterases (Luttrell et al., 1999, McDonald et al., 2000, Houslay and 
Baillie, 2005, Shenoy et al., 2006, DeWire et al., 2007). This β-arrestin-mediated 
signalling is slower-onset and more sustained than G protein-dependent 
responses, adding further temporal regulation and heterogeneity to GPCR 
signalling (Shenoy et al., 2006). β-arrestin-mediated signalling has been shown 
to have physiological relevance in vivo in a number of contexts, including 
development, the central nervous system and the cardiovascular system (Luttrell 
and Gesty-Palmer, 2010). It is therefore an important consideration in drug 
discovery, both as a specific target and as a mediator of undesirable on-target 
effects. 
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1.2.5 The phosphorylation barcode and tissue-specific GPCR 
signalling 
Out of many possible signalling fates that might result from a ligand binding to a 
GPCR, how is one specific outcome selected? Much of the signal specificity 
described above is conferred by phosphorylation of the GPCR by several 
different kinases, but primarily the GRK family. There is an emerging paradigm 
that this phosphorylation pattern or ‘barcode’ can affect cellular responses to 
receptor activation, with different kinases differentially promoting G protein- 
versus β-arrestin-mediated signalling, or favouring desensitisation or 
internalisation of the receptor (Innamorati et al., 1998, Ren et al., 2005, Nobles 
et al., 2011). The potential phosphorylation pattern of the GPCR intracellular 
domain is defined by the presence of phospho-acceptor residues in the GPCR 
sequence, but also depends on the expression of the relevant GRKs or other 
kinases. This reasoning has led to a theory of cell type-specific signalling, 
whereby the kinases expressed in a particular cell type determine the specificity 
of the GPCR signalling profile (Tobin et al., 2008, Liggett, 2011). Cell type-
specific GRK activity has been demonstrated in vivo for therapeutically relevant 
GPCRs such as the dopamine and muscarinic receptors (Walker et al., 2004, 
Gurevich et al., 2016).  This shows that GPCRs have the potential to perform 
distinct functions in different tissues or cell types, or in different physiological 
and pathophysiological settings. Once again, developing an understanding of how 
this applies to individual GPCRs will be beneficial in utilising them as drug 
targets. 
1.2.6 Ligand-specific GPCR signalling 
In addition to the GPCR sequence and the available kinases and signalling 
mediators, one fundamental factor influencing signal specificity remains: the 
ligand. Certain ligands bind in such a way as to stabilise a receptor conformation 
that selectively activates a particular signalling pathway – so-called biased 
ligands. Ligand-specific receptor conformations can favour a particular G protein 
coupling specificity, promote β-arrestin-mediated signalling, or determine how 
rapidly a receptor is internalised or recycled (Maudsley et al., 2005). Biased 
ligands of GPCRs have great potential in drug discovery in terms of increasing 
the specificity of responses and reducing on-target side effects caused by 
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unwanted activation of deleterious pathways (Whalen et al., 2011). To this end, 
biased ligands are being pursued as therapeutics for a range of applications, 
most promisingly G protein-biased agonists of the μ-opioid receptor as 
analgesics, as well as β-arrestin-biased agonists of the angiotensin II receptor as 
heart failure treatments (DeWire et al., 2013, Luttrell et al., 2015). Ligand-
specific signalling, especially G protein versus β-arrestin bias, has been shown to 
be linked to receptor phosphorylation, such that different ligand-receptor 
conformations favour phosphorylation by different GRKs to determine the 
signalling response (Wisler et al., 2007, Nobles et al., 2011). Understanding how 
therapeutically relevant GPCRs are phosphorylated and how this contributes to 
downstream signalling will be key to harnessing the power of this ‘functional 
selectivity’ for drug discovery applications. 
1.3 GPCRs in cardiovascular function and disease 
1.3.1 Cardiovascular disease 
As in all physiological systems, GPCR signalling plays major roles in both normal 
and aberrant cardiovascular function, and, just as GPCRs are extremely 
important drug targets in general (as discussed in section 1.1.2), they are 
commonly targeted in the treatment of cardiovascular disease (CVD). 
According to the World Health Organization, CVD is now the leading cause of 
death worldwide, being the primary cause for an estimated 17.5 million deaths 
annually (www.who.int/cardiovascular_diseases). The term CVD encompasses a 
group of diseases affecting the heart and circulation, including arterial disease, 
heart failure, heart attack and stroke. These diseases are usually associated with 
hypertension (high blood pressure) and/or atherosclerosis (a build-up of fatty 
deposits in the arteries that increases the risk of blood clots). The effects of CVD 
are often accompanied by damage to end organs including the heart, blood 
vessels, kidney and brain, which can manifest as injury, scarring or impaired 
function of the affected tissue. 
The causes of CVD are complex and multifactorial and involve multiple signalling 
networks. Although many pharmacological treatments for CVD exist, it 
nonetheless remains a significant global disease burden. There is therefore a 
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continuous need to improve our understanding of cardiovascular pathophysiology 
in order to develop novel therapeutics. 
1.3.2 GPCR signalling in the cardiovascular system and CVD 
Many different GPCRs have overlapping roles in the neural, hormonal and 
biochemical regulation of both cardiac and vascular function, as well as in the 
interconnected systems that influence these, such as the CNS, the renal system 
and various endocrine glands. The adrenergic system and the renin-angiotensin 
system are the two major regulators of cardiovascular function, and components 
of these comprise the major CVD drug targets, although many other GPCRs – 
including muscarinic, adenosine, endothelin, apelin and vasopressin receptors, 
to name but a few – also play meaningful roles. 
1.3.2.1 The adrenergic receptors 
Sympathetic input to the cardiovascular system occurs via the actions of 
adrenaline and noradrenaline at members of the adrenergic receptor (AR) 
family, consisting of three α1-ARs, three α2-ARs and three β-ARs (Philipp and 
Hein, 2004). In the heart, the β-ARs (mostly the β1-AR) regulate heart rate and 
cardiac contractility through Gαs-mediated increases in cAMP (Philipp and Hein, 
2004, Lymperopoulos et al., 2013). This leads to PKA-mediated [Ca2+]i release, 
which stimulates cardiac muscle contraction through well-characterised 
mechanisms (Bers, 2008). The α2-ARs have an indirect effect on cardiac function 
by inhibiting norepinephrine release from cardiac sympathetic nerve terminals 
through their activation of Gαi/o (Philipp and Hein, 2004, Lymperopoulos et al., 
2013). 
Not only do ARs have actions in cardiac muscle, they also regulate vascular 
smooth muscle contraction and thus directly impact blood pressure. In vascular 
smooth muscle cells, norepinephrine and epinephrine have antagonistic effects 
through α- and β-ARs, respectively (Rohrer and Kobilka, 1998). Norepinephrine 
binds α1- and α2-ARs and causes smooth muscle contraction via Gαq/11- and Gαi/o-
mediated [Ca2+]i release, which causes vasoconstriction and thus raises blood 
pressure. Conversely, epinephrine binds β2-ARs and stimulates Gαs-mediated 
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smooth muscle relaxation and vasodilation, which reduces blood pressure 
(Rohrer and Kobilka, 1998). 
The ARs are subject to GRK-mediated phosphorylation and internalisation, and 
can also transactivate other receptors or signalling pathways in a GRK- and 
β-arrestin-dependent manner (Harris et al., 2008, Capote et al., 2015). The 
upregulation of certain GRKs in the heart and the resultant desensitisation and 
downregulation of the β1-AR is a major pathological mechanism in heart failure 
(Ungerer et al., 1993). This exemplifies how important the ‘phosphorylation 
barcode’ (discussed in section 1.2.5) can be in cardiovascular pathophysiology, 
and how it might be targeted in the treatment of CVD. 
1.3.2.2 Receptors for angiotensin II and the renin-angiotensin system 
Angiotensin II (Ang II) is a peptide ligand that has a great many effects on 
cardiovascular, endocrine and renal function, the combined outcome of which is 
increased blood pressure. Its release is controlled by the renin-angiotensin 
system, a hormonal axis responsible for blood pressure homeostasis. The 
activating stimulus for the pathway is hypotension sensed by the juxtaglomerular 
cells in the kidney, which respond by initiating an enzymatic cascade through 
release of the peptidase renin (Davis and Freeman, 1976). Renin cleaves the 
precursor angiotensinogen into angiotensin I, which can then be converted into 
the active signalling peptide angiotensin II by angiotensin converting enzyme 
(ACE) (Te Riet et al., 2015). 
Ang II has immediate cardiovascular effects through the angiotensin II type 1 
receptor (AT1R) expressed on the vascular smooth muscle cells of resistance 
arteries. Both Gαq/11-mediated [Ca2+]i release and Gα12/13-mediated myosin 
phosphatase inhibition contribute to contraction of the smooth muscle, resulting 
in vasoconstriction (Wynne et al., 2009). Ang II also has acute actions both 
directly on the kidney and on endocrine tissues to stimulate aldosterone and 
anti-diuretic hormone secretion, which have the combined effect of increasing 
water reuptake by the kidneys and thus increasing blood volume and therefore 
blood pressure (Te Riet et al., 2015). 
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As well as acutely raising blood pressure through these mechanisms, Ang II also 
regulates cell growth and morphology in a number of cardiovascular cell types, 
promoting hypertrophy and remodelling in both the heart and the vasculature 
via several G protein-dependent and -independent pathways (Mehta and 
Griendling, 2007). In particular, it has been shown to stimulate proliferation, 
migration and hypertrophy of vascular smooth muscle cells (Ruiz-Ortega et al., 
2001), and to contribute to cardiac hypertrophy and fibrosis through direct 
effects on cardiomyocytes and cardiac fibroblasts (Capote et al., 2015). Thus, 
Ang II and the AT1R have profound effects on the cardiovascular system, and 
unsurprisingly are often implicated in the development and progression of CVD. 
1.3.2.3 GPCR biased signalling in the cardiovascular system 
A novel and exciting development in GPCR drug discovery in all therapeutic 
areas is the discovery of biased agonists – ligands that can selectively activate 
signalling through a particular pathway (discussed in section 1.2.6). Biased 
agonists of GPCRs involved in cardiovascular regulation have already shown 
immense potential in the treatment of CVD. β blockers (β-AR antagonists) are a 
class of drugs historically used to treat hypertension and ischemic heart disease. 
However, a subset of these, including the third-generation drug carvedilol, have 
been found to have superior survival effects in chronic heart failure (Poole-
Wilson et al., 2003). On closer inspection in vitro, it was found that this subset 
of β blockers are actually β-arrestin-biased agonists that promote β-arrestin-
mediated ERK phosphorylation and thus induce specific signalling outcomes in 
the heart that have cardioprotective effects (Noma et al., 2007, Wisler et al., 
2007). Conversely, GRK2-mediated phosphorylation of β2-AR has been shown to 
bias the receptor towards Gαi/o signalling, which exacerbates pressure overload-
induced pathological remodelling in mice (Zhu et al., 2012). 
The AT1R is also a promising target for biased agonists. The β-arrestin-biased 
agonist TRV120027 has been shown to improve cardiac function but also actively 
reduce blood pressure independently of the pressor response to angiotensin II in 
rats (Violin et al., 2010). This dual effect is not achieved with traditional AT1R 
antagonists or ACE inhibitors, and so in this case the biased agonist has a unique 
therapeutic impact (Violin et al., 2010). TRV120027 entered Phase II clinical 
trials in 2011, but has recently been discontinued due to a lack of efficacy 
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(Soergel et al., 2013, Felker et al., 2015). Nonetheless, biased agonists of the 
AT1R remain a promising strategy for the treatment of heart failure.  
The evident therapeutic potential of biased ligands in CVD highlights a need to 
investigate the signalling mechanisms of poorly characterised GPCRs that have 
potential as CVD targets. The power of biased ligands can only be exploited by 
developing a detailed understanding of how such receptors achieve their signal 
specificity, through mechanisms such as post-translational modification and 
interactions with cytoplasmic signalling mediators. 
1.4 G protein-coupled receptor 35 
G protein-coupled receptor 35 (GPR35) is a poorly characterised orphan GPCR, 
which nonetheless has potential therapeutic value based on its association with 
a range of diseases, including cardiovascular disease (Divorty et al., 2015). 
Despite being discovered nearly two decades ago, its endogenous ligand and 
physiological function remain undefined. However, with several proposed 
endogenous ligands and a range of high-potency surrogate ligands now available, 
studies into GPR35 pharmacology and function are beginning to shed more light 
on its therapeutic potential (Divorty et al., 2015, Mackenzie and Milligan, 2015). 
1.4.1 Discovery and basic characteristics 
GPR35 was originally identified in a genomic DNA homology screen, in which it 
was amplified from human genomic DNA using degenerate primers for GPR1 
(O'Dowd et al., 1998). In this first report, a single open reading frame was found 
to encode a protein of 309 amino acids, which showed highest identity with 
lysophosphatidic acid (LPA) receptor 4 (also known as P2Y9/GPR23) (32%), the 
hydroxycarboxylic acid receptor HM74 (30%) and several members of the 
purinergic  P2Y receptor family (29%). This study mapped the novel GPR35 gene 
to human chromosome 2q37.3. 
A subsequent study identified two splice variants of GPR35 in a cDNA screen of 
human gastric cancer tissue: the previously-identified short isoform GPR35a and 
a multi-exon variant, GPR35b, which has a 31 amino acid N-terminal extension 
(Okumura et al., 2004). Although this study found enrichment of GPR35b in 
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gastric cancer samples, the functional significance of this long variant is still 
unclear. GPR35b has only ever been detected in humans; mouse and rat GPR35 
are 307 and 306 amino acids in length, respectively, and both share 72% identity 
with human GPR35a and 85% identity with each other (Figure 1-2) (Taniguchi et 
al., 2006). GPR35a and GPR35b appear to share similar pharmacological 
properties, with agonists displaying similar potency at the two isoforms in both G 
protein- and β-arrestin-based assays (Guo et al., 2008, MacKenzie et al., 2014). 
The N-terminal extension on GPR35b does not appear to affect expression or 
trafficking, as both isoforms have similar subcellular localisation (Guo et al., 
2008). For these reasons, the large majority of studies on GPR35, including those 
described in this thesis, have used the GPR35a isoform. 
GPR35 is in the δ group of Class A Rhodopsin family of GPCRs, and is 
phylogenetically grouped into the purin receptor cluster (Fredriksson et al., 
2003). Its closest relatives are the aforementioned LPA4 and HM74, along with 
hydroxycarboxylic acid receptor HCA1/GPR81, the succinate receptor 
SUCNR1/GPR91, LPA6/P2Y5, and the putative lysophosphatidylinositol receptor 
GPR55 (Fredriksson et al., 2003). The basic structure of GPR35 is the same as 
most Class A GPCRs, comprising seven transmembrane helices, a relatively short 
N-terminal domain and a cytosolic helix 8 preceding a short C-terminal tail 
(Figure 1-2). The amino acid sequence of the transmembrane helices is highly 
conserved between the human and rodent orthologues, whereas the ECLs, ICLs 
and C-terminal tail are more variable (Figure 1-2). 
The GPR35 gene is relatively polymorphic, with non-synonymous, coding region 
single nucleotide polymorphisms (SNPs) leading to seven natural variants of the 
protein in humans (Figure 1-2). Of these, only the V76M variant (minor allele 
frequency 0.02) has a significant effect on ligand binding (MacKenzie et al., 
2014). Notably, the T108M and S294R variants have been associated with disease 
(discussed in section 1.4.6), although the mechanistic significance of these 
associations is unknown (Sun et al., 2008, Ellinghaus et al., 2013). 
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Figure 1-2 Species alignment of human GPR35a with mouse and rat GPR35 showing notable 
features Human, rat and mouse sequences were aligned using Jalview Online. Conserved 
residues are marked with an asterix. Transmembrane regions are shown in blue, Helix 8 in green 
and the C-terminal tail in yellow. Residues essential for ligand binding (Y3.32, R3.36, R4.60, 
L/R4.62 and R/Q6.58) are highlighted in red. Single nucleotide polymorphisms of the human 
orthologue (A25T, V29I, V76M, T108M, R125S, T253M and S294R) are highlighted in pink. 
1.4.2 Proposed endogenous ligands of GPR35 
Over the years, several endogenous molecules have been found to have agonist 
activity at GPR35, a number of which are summarised below (Figure 1-3 and 
Table 1-2). Some reports have attempted to designate these as the endogenous 
ligands, but they have each been rejected for various reasons (discussed below) 
and the receptor is still officially classified as an orphan by the International 
Union of Basic and Clinical Pharmacology (Davenport et al., 2013). 
21 
 
 
Figure 1-3 Structures of proposed endogenous ligands of GPR35 (DHICA = 5,6-
dihydroxyindole-2-carboxylic acid.) 
1.4.2.1 Kynurenic acid 
The first endogenously occurring molecule reported to have agonist activity at 
GPR35 was kynurenic acid, a product of tryptophan metabolism with signalling 
functions that mostly occur in the central and peripheral nervous systems (Stone 
and Darlington, 2002). Kynurenic acid is well characterised as a competitive 
antagonist of all three ionotropic glutamate receptors, with potency in the high 
micromolar range (Schwarcz et al., 2012). However, it also has actions at a 
number of other targets, including agonism at GPR35 (Wang et al., 2006, Zhao et 
al., 2010, Jenkins et al., 2011, Deng et al., 2012, Berlinguer-Palmini et al., 
2013). Wang et al. were the first to report this activity, demonstrating kynurenic 
acid-induced activation of Gαi/o and internalisation of GPR35 in cells 
overexpressing the receptor, with mid to low micromolar-range potency at the 
human, mouse and rat orthologues (Wang et al., 2006). The pharmacological 
action of this ligand at GPR35 was subsequently confirmed by other groups, but 
with wide variations in potency between 40 and 200 µM depending on the assay 
system used (Zhao et al., 2010, Jenkins et al., 2011, Deng et al., 2012, 
Berlinguer-Palmini et al., 2013). 
The reported micromolar potency at rat GPR35 is consistent with the 
concentration of kynurenic acid present in rat small intestine, where GPR35 is 
most highly expressed (Wang et al., 2006, Kuc et al., 2008). However, the 
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potency at the human orthologue has been found in some studies to be in excess 
of 100 μM (Jenkins et al., 2011, Deng et al., 2012). Based on these findings, the 
concentration of kynurenic acid required for GPR35 activation in humans 
exceeds physiological levels (Forrest et al., 2002). However, since the potency 
of kynurenic acid at human GPR35 is comparable to that at glutamate receptors, 
its effects in the nervous system might be attributable to GPR35 in the specific 
regions where its expression has been observed (discussed in section 1.4.6.4). 
Due to the conflicting nature of the current findings, kynurenic acid is yet to be 
officially designated as the endogenous ligand for GPR35, despite being widely 
referred to as such in the literature (Davenport et al., 2013). 
Table 1-2 Proposed endogenous ligands of GPR35 
Endogenous 
agonist 
G protein 
pathway 
β-arrestin 
recruitment? 
EC50 
(human) 
Efficacy 
(human) 
Reference 
Kynurenic acid Gαi/o Yes 40–>200 μM Partial (Wang et al., 2006) 
LPA Gαq/11 No Not reported Unknown (Oka et al., 2010) 
DHICA Unknown Yes 22–25 μM Partial (Deng et al., 2012) 
Reverse T3 Unknown No 5–100 μM Full (Deng et al., 2012) 
CXCL17 Gαq/11 Unknown nM range Unknown 
(Maravillas-Montero 
et al., 2015) 
EC50 range is estimated from results of all reported assays. Efficacy describes maximal response 
compared with reference agonist zaprinast. (LPA = lysophosphatidic acid; DHICA = 5,6-
dihydroxyindole-2-carboxylic acid.) 
1.4.2.2 Lysophosphatidic acid 
In a screen for endogenous ligands of GPR35 based on its homology with 
lysophospholipid and purinergic receptors, Oka et al. identified three derivatives 
of LPA as agonists of GPR35 (Oka et al., 2010). In this study, 2-arachidonoyl LPA, 
2-linoleoyl LPA and 2-oleoyl LPA induced increases in [Ca2+]i to a greater extent 
in human embryonic kidney (HEK) cells stably expressing GPR35 than in HEK cells 
expressing endogenous levels of LPA receptors. GPR35 overexpression also 
enhanced 2-oleoyl LPA-induced RhoA activation and ERK phosphorylation. These 
findings suggest a Gαq/11-mediated signalling profile, which is consistent with 
that of the existing LPA receptors, although GPR35 coupling to Gαq/11 has never 
been directly demonstrated (Choi et al., 2010). This could be indicative of ligand 
bias at GPR35, since other agonists have been shown to promote coupling to 
other G proteins and β-arrestin (Jenkins et al., 2010, Jenkins et al., 2011, Guo 
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et al., 2008, Ohshiro et al., 2008). LPA was found in two separate studies not to 
induce β-arrestin recruitment to GPR35, a response that is robust and 
reproducible for the majority of other GPR35 agonists (Southern et al., 2013, 
Zhao et al., 2010). This would suggest a unique mechanism of action for LPA 
compared with kynurenic acid and synthetic GPR35 agonists. However, since no 
antagonists were available at the time of this study, the specific contribution of 
GPR35 could not be verified, and has not been reported on since. In addition, 
LPA is known to exert its physiological actions through a well-characterised 
family of LPA receptors, and so it is unlikely that LPA could have specific GPR35-
mediated effects (Choi et al., 2010). 
1.4.2.3 Tyrosine metabolites 
In a label-free dynamic mass redistribution (DMR) screen of the endogenously 
GPR35-expressing HT-29 human colon adenocarcinoma cell line, Deng et al. 
identified several tyrosine derivatives as potent agonists of GPR35 (Deng et al., 
2011). This led to the screening of a panel of endogenously-produced tyrosine 
metabolites in the hope of identifying an endogenous ligand for GPR35 (Deng et 
al., 2012). Again using DMR in the HT-29 cell line, this screen identified the 
melanin biosynthesis intermediate 5,6-dihydroxyindole-2-carboxylic acid (DHICA) 
and the thyroid hormone synthesis intermediate 3,3,5-triiodothyronine (reverse 
T3) as GPR35 agonists with low micromolar-range potency. These agonists were 
susceptible to antagonism by the competitive GPR35 antagonist CID-2745687 and 
also promoted GPR35 internalisation, which verified GPR35 as the target 
(Heynen-Genel et al., 2011, Deng et al., 2012). However, only DHICA was able to 
induce β-arrestin recruitment with comparable potency in a fluorescence 
resonance energy transfer-based assay, which again might suggest that reverse 
T3 is a biased agonist (Deng et al., 2012). Unfortunately, as with kynurenic acid, 
these ligands do not appear to be present in vivo at concentrations that could 
activate GPR35 based on in vitro estimations of potency. Circulating levels of 
reverse T3 are in the low nanomolar range and do not reach the micromolar 
concentrations required to activate GPR35, although the levels have been shown 
to increase under pathophysiological conditions, including during heart failure 
(Peeters et al., 2005, Hamilton et al., 1990). More evidence is required to assess 
this potential ligand-receptor pairing. 
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1.4.2.4 CXCL17 
The most recently proposed endogenous ligand for GPR35 is the orphan 
chemokine CXCL17. Maravillas-Montero et al. reported that CXCL17 was able to 
induce dose-dependent [Ca2+]i release in pro-B cells and HEK cells transfected 
with GPR35 (Maravillas-Montero et al., 2015). These effects were observed at 
nanomolar concentrations, suggesting CXCL17 to be significantly more potent 
than other endogenous agonists. However, as with LPA, the effect on [Ca2+]i 
suggests Gαq/11 coupling, which is uncharacteristic of GPR35. These findings were 
also not validated with the use of a GPR35 antagonist, so it is difficult to assess 
the specific contribution of GPR35 to changes in [Ca2+]i. Although these findings 
are not sufficient to designate GPR35 as the CXCL17 receptor, existing reports of 
GPR35 expression and function in leukocytes (discussed in section 1.4.6.3) (Yang 
et al., 2010, Fallarini et al., 2010, Barth et al., 2009) suggest that a potential 
role for GPR35 as a chemokine receptor deserves further investigation. 
1.4.3 Synthetic ligands of GPR35 
In spite of uncertainty surrounding the ‘true’ endogenous ligand of GPR35, 
screening efforts have yielded a number of synthetic surrogate ligands with 
different pharmacological properties. These have proven useful as tool 
compounds and have facilitated studies into GPR35 pharmacology and function 
(Divorty et al., 2015). The available panel of synthetic ligands have a range of 
potencies and efficacies and vary in species selectivity and mode of action 
(Table 1-3), and so can be used to address a wide variety of questions provided 
their pharmacological properties are taken into account when interpreting 
results. 
1.4.3.1 Synthetic agonists of GPR35 
The structures and properties of a selection of relevant synthetic GPR35 agonists 
are summarised below (Figure 1-4 and Table 1-3). One of the first synthetic 
GPR35 agonists to be discovered was the cGMP-specific phosphodiesterase type 5 
(PDE5) inhibitor, zaprinast (Taniguchi et al., 2006). It acts with moderate 
potency but elicits a robust and high efficacy response in vitro, and is therefore 
often used as a reference ligand against which other agonists are assessed. 
However, like many of the agonists described since, zaprinast displays significant 
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selectivity for the rat orthologue, with a 50-fold greater EC50 at the human 
receptor (Taniguchi et al., 2006, Milligan, 2011). The anti-asthma drugs 
cromolyn disodium and dicumarol show lower potency than zaprinast, but are 
equipotent at the rat and human orthologues (Jenkins et al., 2010). This shows 
that the apparent species orthologue selectivity of most GPR35 agonists does not 
apply to all ligands, and may in fact be exploited to probe the intricacies of 
ligand binding at this receptor (discussed in section 1.4.4) (Yang et al., 2010, 
Jenkins et al., 2010). 
 
Figure 1-4 Structures of selected synthetic agonists of GPR35 
Besides zaprinast, several other agonists with high potency at human GPR35 
have been reported. Pamoic acid was identified as a partial but potent agonist in 
two independent screens of the Prestwick Chemical Library®, with an EC50 of 50–
80 nM at human GPR35 in β-arrestin recruitment assays (Zhao et al., 2010, 
Jenkins et al., 2010). However, pamoic acid is highly selective for the human 
orthologue, with negligible potency at mouse and rat GPR35 (Jenkins et al., 
2012). Neetoo-Isseljee et al. described a high potency, human-selective agonist, 
“compound 1”, that at the rodent orthologues acted as a partial agonist in 
β-arrestin recruitment assays, but as a full agonist with markedly higher potency 
in G protein activation assays (Neetoo-Isseljee et al., 2013). Conversely, the 
anti-allergic drug doxantrazole is a partial agonist at human GPR35, but a full 
agonist at rat GPR35 (MacKenzie et al., 2014). These examples demonstrate that 
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the pharmacology of GPR35 is complex, with different agonist-occupied 
conformations capable of eliciting distinct signalling outcomes. 
Recently, the anti-inflammatory mast cell stabiliser amlexanox was identified as 
a potent partial agonist at human GPR35, which prompted a screen of other 
mast cell stabilisers that led to the identification of lodoxamide and bufrolin as 
high potency, full agonists at both rat and human GPR35 (Southern et al., 2013, 
MacKenzie et al., 2014). These agonists will all serve as useful tools in the study 
of GPR35 signalling and function. 
Table 1-3 Selected synthetic agonists of GPR35 
Synthetic 
agonist 
EC50 
(human) 
EC50 
(mouse) 
EC50  
(rat) 
Efficacy Notes Reference 
Zaprinast 2–8 μM 1 μM 100 nM Full PDE5 inhibitor 
(Jenkins et al., 
2010, Jenkins et 
al., 2012) 
Pamoic acid 30–50 nM Inactive > 100 μM Partial 
DNA pol. β 
inhibitor 
(Jenkins et al., 
2012, Zhao et al., 
2010) 
Compound 1 26 nM 17 μM 8 μM 
Full (human) 
Partial (rodent) 
β-arr-biased 
at human 
(Neetoo-Isseljee et 
al., 2013) 
Doxantrazole 3.4 μM Untested 300 nM 
Partial (human) 
Full (rat) 
Mast cell 
stabiliser 
(MacKenzie et al., 
2014) 
Amlexanox 
(Aphthasol®) 
4 μM Untested 23 nM Partial 
TBK1/IKK-ε 
inhibitor 
(MacKenzie et al., 
2014, Southern et 
al., 2013) 
Lodoxamide 
(Alomide®) 
4 nM Untested 13 nM Full 
Commercial 
anti-allergic 
(MacKenzie et al., 
2014) 
EC50 values are those obtained in BRET-based β-arrestin recruitment assays. Nanomolar-range 
EC50 values are highlighted in grey to show orthologue selectivity. (PDE5 = phosphodiesterase 5; 
TBK1 = TANK-binding kinase 1; IKK-ε = inhibitor of NFκB kinase ε.) 
1.4.3.2 Synthetic antagonists of GPR35 
Selective competitive antagonists are essential to verify the specificity of GPCR-
mediated responses. Two potent antagonists of GPR35, ML-145 and CID-2745687, 
have been reported (summarised in Figure 1-5 and Table 1-4) (Zhao et al., 2010, 
Heynen-Genel et al., 2010, Heynen-Genel et al., 2011). These are both selective 
for GPR35 over the closely-related receptor GPR55, and exhibit inverse agonist 
activity at human GPR35 (Heynen-Genel et al., 2010, Heynen-Genel et al., 2011, 
Jenkins et al., 2012). Interestingly, both antagonists act competitively with 
zaprinast and cromolyn disodium, but CID-2745687 appears to act non-
competitively with pamoic acid, suggesting both that the partial agonist pamoic 
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acid may have a different binding mode, and that the two antagonists have 
distinct modes of action (Jenkins et al., 2012). 
 
Figure 1-5 Structures of synthetic antagonists of GPR35 
Despite good potency at human GPR35, both antagonists display significant 
species selectivity, inhibiting β-arrestin recruitment only at the human receptor 
and not at the rat or mouse orthologues (Jenkins et al., 2012). Therefore, 
although these compounds will be useful in studying human GPR35 in vitro, they 
cannot be utilised to probe GPR35 function in rodent in vivo disease models. No 
equipotent alternatives are currently available, which presents a significant 
challenge in investigating the function of this receptor. 
Table 1-4 Synthetic antagonists of GPR35 
Antagonist 
IC50 
(human) 
Notes Reference 
ML-145 27 nM 
Competitive 
antagonist 
(Heynen-Genel et al., 
2010, Jenkins et al., 
2012) 
CID-2745687 200 nM 
Non-competitive 
with pamoic acid 
(Heynen-Genel et al., 
2011, Jenkins et al., 
2012) 
IC50 values are those obtained against zaprinast EC80 in BRET-based β-arrestin recruitment 
assays. 
1.4.4 GPR35 ligand binding and species selectivity 
The orthosteric ligand binding site of most Class A receptors consists of a pocket 
within the transmembrane bundle, with the most conserved ligand-contacting 
residues residing in transmembrane helices 3, 6 and 7 (Venkatakrishnan et al., 
2013). The evidence to date suggests that GPR35 ligand binding is typical of 
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Class A GPCRs, with several important interacting residues in TM3, TM4, TM6 and 
TM7 identified by mutagenesis studies (Figure 1-2) (Jenkins et al., 2011, 
MacKenzie et al., 2014). Since most GPR35 ligands contain a carboxylate group 
or a carboxylate bioisostere (Figure 1-3, Figure 1-4 and Figure 1-5), it is likely 
that positively-charged residues in the binding pocket are important in ligand 
binding.  An arginine at position 3.36 (using Ballesteros and Weinstein 
nomenclature1 (Ballesteros and Weinstein, 1995)) (R3.36) is conserved among 
several GPCRs related to GPR35 that have small, acidic ligands (Liu et al., 2009). 
Alanine substitution of this residue or a tyrosine one turn of the helix towards 
the extracellular side (Y3.32) eliminates ligand binding at both human and rat 
GPR35 (Figure 1-2) (Jenkins et al., 2011). Studies using species swap mutations 
that exchange non-conserved residues between the rat and human orthologues 
identified some additional important features of ligand binding (MacKenzie et 
al., 2014). Specifically, R6.58 in human GPR35 and R4.60 in both orthologues 
were identified as essential residues in ligand binding, which were confirmed to 
interact with ligand in homology model docking studies. Furthermore, a non-
conserved residue at position 4.62 (leucine in human GPR35, arginine in rat) was 
identified which, when swapped between the human and rat orthologues, was 
sufficient to reverse the species selectivity of zaprinast. This residue is therefore 
highly likely to be involved in binding of the equipotent agonists, an observation 
that could prove useful in the search for further equipotent ligands. 
1.4.5 GPR35 signalling 
Insights into ligand binding and the increasing availability of synthetic tool 
compounds have aided studies into the downstream signalling and functional 
consequences of GPR35 activation. Elucidating the signalling pathways 
influenced by the receptor and the cellular outcomes of GPR35 activity will be 
vital in understanding its physiological function. Several GPCR signalling 
mediators have been shown to be regulated by GPR35 in vitro, and studies in 
physiological systems have provided insight into the pathways and responses that 
                                         
1 Ballesteros and Weinstein nomenclature is a system of numbering whereby the most conserved 
residue in a helix ‘x’ is given the value x.50 (e.g. 3.50 for helix 3) and residues decrease in value 
towards the N-terminus and increase in value towards the C-terminus (e.g. one residue towards 
the N-terminus is 3.49 and one residue towards the C-terminus is 3.51). 
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could potentially be manipulated through pharmacological targeting of this 
receptor (summarised in Figure 1-6). 
 
Figure 1-6 Current model of GPR35 signalling GPR35 has been shown to couple to Gαi/o, Gα13 
and β-arrestin. Signalling pathways and physiological outcomes associated with GPR35 activity are 
summarised. 
In terms of classical G protein-mediated signalling, investigating poorly 
characterised GPCRs can be challenging due to the fact that most assays 
measure the signalling outcome of a single G protein family. A common solution 
to this problem is the use of chimeric G proteins, where the GPCR-coupling 
portion (i.e. the C-terminal tail) of various G proteins are fused with the 
signalling portion of a G protein with an easy-to-measure signalling output, such 
as Gαq , whose activity can easily be monitored by measuring accumulation of IP1 
(a metabolite of IP3) or [Ca2+]i mobilisation (Kostenis et al., 2005). Despite being 
a slightly crude and indirect method, chimeric G proteins are valuable as a 
starting point to guide studies into GPCR-G protein interactions. This technique 
has enabled the identification of a number of Gα subunits that can couple to 
GPR35 with varying efficacy and in a context-dependent manner. 
1.4.5.1 GPR35 coupling to Gαi/o proteins 
Early reports of GPR35 signalling designated it as a Gαi/o-coupled receptor. Wang 
et al. used chimeric G proteins to demonstrate that in Chinese hamster ovary 
cells heterologously expressing human GPR35 and transfected with Gαi/Gαq or 
Gαo/Gαq chimeras, kynurenic acid elicited Gαq-associated signalling (Wang et al., 
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2006). They also showed that kynurenic acid-induced [35S]-GTPγS binding in 
these cells was sensitive to Bordetella pertussis toxin (PTx), which ADP-
ribosylates and specifically inhibits Gαi/o family G proteins (Wang et al., 2006). 
Furthermore, in Chinese hamster ovary cells overexpressing rat GPR35, both 
kynurenic acid and zaprinast treatment inhibited forskolin-induced cAMP 
production, indicating activation of Gαi/o protein (Ohshiro et al., 2008). 
Similarly, Guo et al. reported PTx-sensitive effects on N-type calcium channels 
in rat neurons heterologously expressing human GPR35, and Zhao et al. reported 
PTx-sensitive ERK phosphorylation by both zaprinast and pamoic acid in U2OS 
osteosarcoma cells stably expressing human GPR35 (Guo et al., 2008, Zhao et 
al., 2010). Together, these findings demonstrate that a number of Gαi/o-
associated signalling outcomes in a range of cell types occur in response to 
GPR35 stimulation, and these effects are sensitive to specific inhibition of Gαi/o 
proteins. 
1.4.5.2 GPR35 coupling to Gα12/13 proteins 
As well as a role for Gαi/o signalling in GPR35-mediated responses, more recent 
reports have demonstrated Gα13 coupling to GPR35. Using a conformational 
active-state-sensing GTP-Gα13 antibody, Jenkins et al. observed zaprinast-
induced activation of Gα13 in HEK cells transfected with either human or rat 
GPR35 (Jenkins et al., 2011). The same study also demonstrated zaprinast-
induced [Ca2+]i release in these cells when co-transfected with a Gα13/Gαq 
chimera, an effect that was specific for Gα13 over the other subfamily member 
Gα12. Gα13 and Gα12 have very similar but subtly different roles within the cell. Of 
the four RhoGEF proteins that are effectors for this G protein family, leukemia-
associated RhoGEF (LARG) and lymphoid blast crisis (Lbc)-RhoGEF can be 
activated by both Gα12 and Gα13, whereas p115-RhoGEF and PDZ-RhoGEF can 
only be activated by Gα13 (Siehler, 2009). This results in slightly different 
signalling profiles, though the differences between the two subfamily members 
are not well defined (Siehler, 2009). It is of note, however, that homozygous 
inactivation of Gα13 is embryonically lethal due to defects in vascular 
development, whereas Gα12 knockout mice are viable and lack apparent defects 
(Gu et al., 2002, Offermanns et al., 1997). A Gα13-specific signalling profile is 
unusual among GPCRs, but interestingly is a feature of the orphan receptor 
GPR55, which is phylogenetically similar to GPR35 (Ryberg et al., 2007). This 
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potentially suggests similar signalling roles for these two receptors, but their 
functional relationship is yet to be properly investigated (Zhao and Abood, 
2013). 
1.4.5.3 Recruitment of -arrestin to GPR35 
In addition to eliciting G protein-mediated responses, GPR35 has been shown to 
directly recruit -arrestin-2 following agonist stimulation (Jenkins et al., 2010). 
All of the synthetic agonists, as well as the endogenous agonists kynurenic acid 
and DHICA, induce recruitment of -arrestin-2 to GPR35 (Table 1-2 and Table 
1-3). This is followed by agonist-dependent internalisation of both the receptor 
and -arrestin, which is indicative of a strong interaction between GPR35 and 
-arrestin that is likely driven by phosphorylation of the receptor (see section 
1.2.4.2) (Jenkins et al., 2012, Zhao et al., 2010). 
While -arrestin-mediated internalisation is clearly important in regulating the 
GPR35/G protein signalling axis, -arrestin-mediated signalling has not yet been 
reported for GPR35. GPR35 stimulation can lead to phosphorylation of ERK, but 
this is PTx-sensitive and thus is assumed to be mediated by Gαi/o proteins. 
However, given the diversity of physiological processes seemingly influenced by 
GPR35 (discussed in section 1.4.6), an understanding of G protein- and 
-arrestin-regulated processes may be key to elucidating this receptor’s 
functions in different cellular contexts and harnessing its therapeutic potential. 
1.4.6 Physiological function of GPR35 
Amid uncertainty regarding the endogenous ligand of GPR35 and following the 
development of insights into its cellular signalling profile, this orphan receptor’s 
physiological function and importance remain poorly understood. In recent 
years, however, GPR35 has been suggested to have roles in a range of 
physiological and pathophysiological settings. Its association with several diverse 
disease areas hints at potentially far-reaching therapeutic value. It is therefore 
of significant interest to investigate the physiological functions of this receptor, 
both in health and disease, in order to evaluate its potential as a novel 
therapeutic target. 
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1.4.6.1 GPR35 expression profile 
Expression of GPR35 mRNA has been detected in a number of diverse tissues in 
both rodent and human studies. In the study that first cloned GPR35 from human 
genomic DNA, tissue distribution of GPR35/Gpr35 mRNA was investigated by 
performing Northern blot analysis on a range of human and rat tissues including 
various parts of the brain and digestive tract (O'Dowd et al., 1998). Although no 
data were shown, the authors reported that Gpr35 mRNA was only detected in 
rat small intestine, and could not be detected in any of the human tissues 
tested. This is likely due to quite low expression levels of GPCRs in general and 
of GPR35 in particular. However, since this initial study, technical advancements 
have enabled much more sensitive methods for detection of mRNA. Using 
quantitative real-time polymerase chain reaction (qRT-PCR), Wang et al. 
amplified GPR35/Gpr35 mRNA from lung, stomach, small intestine, colon and 
spleen in both human and mouse tissues, and also detected GPR35 in human 
peripheral lymphocytes (Wang et al., 2006). In a mouse tissue array, in situ 
hybridisation with Gpr35 mRNA probes revealed expression throughout the lower 
digestive tract, including duodenum, jejunum, ileum, cecum, colon and rectum 
(Wang et al., 2006). Taniguchi et al. used qRT-PCR in rat tissues to confirm high 
expression levels in lung, stomach, small intestine and colon, as previously 
reported, but also detected high levels in skeletal muscle, dorsal root ganglion 
(DRG) and uterus, and lower levels in spinal cord, heart, liver, bladder, whole 
brain and cerebrum (Taniguchi et al., 2006). Several other groups have 
confirmed expression in rat spinal cord and DRG and additionally reported 
expression in mouse astrocytes (Ohshiro et al., 2008, Cosi et al., 2011, 
Berlinguer-Palmini et al., 2013). GPR35 mRNA has also been detected in various 
human immune cells, including mast cells, basophils, eosinophils and invariant 
natural killer-like T cells (Yang et al., 2010, Fallarini et al., 2010). Recently, 
GPR35 mRNA was found to be expressed in a number of human vascular cell 
types, including human saphenous vein smooth muscle cells, human saphenous 
vein endothelial cells and human umbilical cord endothelial cells (McCallum et 
al., 2015). The collective evidence suggests expression and therefore possible 
roles for GPR35 in four key physiological systems: the gastrointestinal system, 
the immune system, the nervous system and the cardiovascular system. 
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1.4.6.2 GPR35 in gastrointestinal disease 
Since GPR35 is expressed most highly in the gastrointestinal tract, this would be 
an obvious starting point in the search for a physiological function for GPR35. A 
genome-wide association study (GWAS) for early-onset inflammatory bowel 
disease (IBD), including Crohn’s disease and ulcerative colitis, identified a GPR35 
SNP associated with ulcerative colitis (Imielinski et al., 2009). The rs4676410 
SNP is located upstream of the open reading frame and so does not alter the 
coding sequence, but this SNP was also not associated with any change in GPR35 
expression level in IBD patients when compared with genetically related healthy 
controls. However, in a linkage disequilibrium analysis, rs4676410 was associated 
with the CAPN10, KIF1A and RNPEPL1 genes (Imielinski et al., 2009). CAPN10, 
which encodes the calcium-regulated intracellular cysteine protease calpain 10, 
was found to be significantly downregulated in individuals with ulcerative colitis, 
and is therefore likely to be the disease-related gene in the linkage 
disequilibrium block (Imielinski et al., 2009). 
A more recent study investigating genetic risk factors in the chronic cholestatic 
liver disease, primary sclerosing cholangitis (PSC), has provided further evidence 
of a possible role for GPR35 in IBD (Ellinghaus et al., 2013). Since most patients 
with PSC have concurrent ulcerative colitis and these two conditions appear to 
have shared genetic susceptibility factors, the study performed an integrated 
analysis of GWAS’s for both diseases (Bergquist et al., 2008).  Two GPR35 SNPs 
were found to have a significant association with PSC, one of which was the 
upstream intron variant previously identified in the IBD GWAS (Imielinski et al., 
2009). The other SNP encodes a threonine to methionine substitution in helix 3 
(Figure 1-2) with a minor allele frequency of 0.15. Based on the expression of 
GPR35 in both the liver and gastrointestinal tract, and the presence of kynurenic 
acid both in bile and the gut, the authors of this report speculated that GPR35 
may have a role in the regulation of inflammation in the biliary and 
gastrointestinal tracts. However, all the existing evidence for a role for GPR35 in 
gut inflammation is from genetic association studies. This is yet to be examined 
experimentally, and so no firm conclusions can currently be drawn regarding the 
role of this receptor in gut homeostasis and disease. 
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1.4.6.3 GPR35 in immunity and inflammation 
As in the gastrointestinal system, the relatively high expression of GPR35 in 
various types of immune cell suggests a possible role in the immune system. 
GPR35 has been implicated in inflammation in several studies, though it remains 
unclear whether its effects are pro- or anti-inflammatory. GPR35 is suggested to 
have anti-inflammatory effects through its possible role as a ‘metabolite-
sensing’ receptor for endogenous kynurenic acid (discussed in section 1.4.2.1). 
Kynurenic acid is produced via the kynurenine pathway in the small intestine 
following consumption of tryptophan-rich foods such as red meat, fish and eggs 
(Thorburn et al., 2014, Stone and Darlington, 2002). The kynurenine pathway is 
activated under inflammatory conditions, and kynurenic acid levels are elevated 
during inflammatory disease (Larkin et al., 2016, Forrest et al., 2002). In the 
study by Wang et al., kynurenic acid was found to inhibit lipopolysaccharide 
(LPS)-induced release of tumour necrosis factor- from human peripheral blood 
mononuclear cells and purified peripheral blood monocytes, which was proposed 
to be mediated by agonism of GPR35 (Wang et al., 2006). This was also 
demonstrated in vivo in a mouse model of LPS-induced endotoxic shock (Moroni 
et al., 2012). Additionally, Kuc et al. have reported that kynurenine can be 
converted into kynurenic acid by Escherichia coli, which may provide a link 
between the gut microbiota and GPR35-mediated effects on gut inflammation 
(Kuc et al., 2008, Thorburn et al., 2014). 
A conflicting study found that kynurenic acid treatment induced arrest of 
monocytes and neutrophils onto intracellular adhesion molecule 1-expressing 
monolayers of vascular endothelial cells (Barth et al., 2009). This was sensitive 
both to PTx, suggesting Gi/o involvement, and to GPR35 knockdown by short 
hairpin RNA (Barth et al., 2009). This report suggests a role for GPR35 in 
leukocyte infiltration, a pro-inflammatory process. However, the effect on 
leukocyte arrest was observed at nanomolar concentrations of kynurenic acid, 
which is far lower than the potency range at GPR35 reported in overexpression 
systems (Wang et al., 2006, Zhao et al., 2010, Jenkins et al., 2011, Deng et al., 
2012). More direct evidence that these effects are mediated by GPR35 and not 
through other receptors modulated by kynurenic acid is required to clarify this 
discrepancy. Additional support for a pro-inflammatory role for GPR35 comes 
from its effects on invariant natural killer-like T cells, which are involved in 
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dendritic cell maturation and protect against autoimmunity. Treatment with 
either kynurenic acid or zaprinast was shown to reduce interleukin-4 release by 
these cells in a dose-dependent and PTx-sensitive manner (Fallarini 2010). 
However, in this study, the agonists had no effect on the level of interferon-γ, 
which tends to increase as interleukin-4 decreases, and vice versa, in a manner 
that reflects Th1/Th2 cell polarisation (Paludan, 1998). It is therefore difficult 
to interpret this finding in terms of its physiological significance to pro-/anti-
inflammatory signalling. 
Considering these studies demonstrating kynurenic acid-induced effects on 
inflammation, it is noteworthy that several synthetic agonists of GPR35 are 
known anti-inflammatory agents. Yang et al. reported the anti-allergic and anti-
asthma drugs cromolyn disodium and nedocromyl sodium to be moderately 
potent agonists of GPR35, and also demonstrated upregulation of GPR35 in 
response to challenge with IgE antibodies (Yang et al., 2010). An independent 
study reported potency of several related anti-allergic mast cell stabilisers at 
GPR35 (Table 1-3) (MacKenzie et al., 2014). These findings suggest a possible 
role for GPR35 in the attenuation of IgE-mediated inflammation and allergy, 
though this has not been followed up to date. 
An additional link between GPR35 and the immune system is the suggestion that 
GPR35 might be a chemokine receptor for CXCL17 (discussed in section 1.4.2.4) 
(Maravillas-Montero et al., 2015). CXCL17 is a mucosal macrophage 
chemoattractant that is upregulated in idiopathic pulmonary fibrosis (Burkhardt 
2012). Lung tissue from CXCL17 knockout mice was shown to have significantly 
reduced expression of GPR35, along with several macrophage markers, 
compared with lung tissue from wild type mice (Maravillas-Montero et al., 2015). 
The authors of this report concluded that CXCL17 is required to recruit GPR35-
expressing macrophages to the lungs, where they may play a role in pulmonary 
inflammation. However, this is an isolated report and further investigation is 
required to determine whether GPR35 is indeed involved in chemoattraction. 
1.4.6.4 GPR35 in the nervous system and nociception 
A role for GPR35 in the central nervous system has been investigated following 
reports of its expression in rat spinal cord and DRG neurons (Ohshiro et al., 2008, 
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Cosi et al., 2011). Kynurenic acid and zaprinast were shown to have 
PTx-sensitive effects on forskolin-induced cAMP generation in both rat DRG 
neurons and mouse glial cells endogenously expressing GPR35, (Ohshiro et al., 
2008, Cosi et al., 2011). Furthermore, administration of either kynurenine or 
zaprinast had anti-nociceptive effects in a mouse ‘writhing test’ pain model, 
significantly reducing the number of writhes by a maximum of 58% and 54%, 
respectively (Cosi et al., 2011). This in vivo finding has recently been 
recapitulated in a rat pain withdrawal model (Resta et al., 2016). This study also 
demonstrated that kynurenic acid and zaprinast can counteract prostaglandin-E2-
induced hyperalgesia by inhibiting its cAMP-mediated effect on neuronal 
excitability, which is regulated by hyperpolarisation-activated cyclic nucleotide-
gated channels (Resta et al., 2016). These findings highlight the Gαi/o-coupled 
GPR35 pathway as a potential therapeutic target in the treatment of pain, 
though it remains to be seen whether these promising findings will translate into 
humans. 
A further potential function of GPR35 in the nervous system is to attenuate 
excitatory post-synaptic currents in the central nervous system. Berlinguer-
Palmini et al. detected GPR35 expression in mouse cortical astrocytes, and 
demonstrated that kynurenic acid can inhibit forskolin-mediated cAMP 
production (Berlinguer-Palmini et al., 2013). This effect was sensitive both to 
the GPR35 antagonist CID-2745687 and to RNA interference-mediated GPR35 
knockdown. The inhibitory capacity of the antagonist should be interpreted with 
caution, however, considering that a previous study found it to be practically 
inactive at the rodent orthologues (Jenkins et al., 2012). Berlinguer-Palmini et 
al. also reported that kynurenic acid and zaprinast altered calcium waves in 
mouse astrocytes and reduced evoked excitatory post-synaptic currents in rat 
hippocampal neurons (Berlinguer-Palmini et al., 2013). As kynurenic acid is also 
an agonist of N-methyl-D-aspartate and α7-nicotinic receptors, the investigators 
showed that the kynurenic acid-mediated effects on both calcium waves and 
synaptic currents were insensitive to antagonists of these receptors. This 
suggests that these effects are indeed mediated by agonism of GPR35, although, 
once again, these findings are yet to be validated in human cells. Translation 
into human models is now required to determine the potential of GPR35 as a 
target in analgesia or in the prevention of excitotoxic damage. 
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1.4.6.5 GPR35 in the cardiovascular system 
Although GPR35 is expressed more highly in other tissues, several studies have 
highlighted roles for GPR35 in the heart and vasculature. The first report to 
suggest a link between GPR35 and CVD described a GWAS that aimed to identify 
novel risk genes for coronary artery disease in a population of hypertensive 
individuals (Sun et al., 2008). This study identified an association between a 
GPR35 SNP and coronary artery calcification, a risk factor in coronary artery 
disease. The SNP, which has a minor allele frequency of 0.48, encodes a serine 
to arginine substitution in the receptor C-terminal tail (Figure 1-2), a region 
known to be important in binding cytoplasmic mediator proteins (Szczepek et 
al., 2014). Since phosphorylation of the C-terminal tail is known to influence the 
specificity of the downstream response to GPCR activation, and the SNP affects 
a potential phospho-acceptor serine residue, it is tempting to speculate that it 
may alter the selectivity of G protein- versus β-arrestin-mediated responses to 
GPR35. However, in a more recent study, the S294R substitution had no effect 
on either cell surface expression or ligand potency in a β-arrestin recruitment 
assay (MacKenzie et al., 2014). The mechanism by which this SNP could alter 
receptor function and contribute to disease therefore remains unclear. 
Further evidence of GPR35 contributing to CVD was found in a study 
investigating myocardial gene expression in twelve patients with chronic heart 
failure (Min et al., 2010). In this microarray analysis, GPR35 expression was 
found to be upregulated in the myocardial tissue of these patients compared 
with healthy controls, suggesting that although GPR35 is not highly expressed in 
the heart under basal conditions, it is induced at some point during the 
development of disease. The same study found that adenovirus-mediated 
overexpression of GPR35 in primary rat cardiomyocytes resulted in cellular 
hypertrophy, which is a feature of the pathological cardiac hypertrophy that 
leads to heart failure. Follow-up analysis in a global GPR35 knockout mouse 
revealed a significant 37.5 mmHg increase in systolic blood pressure compared 
with the wild type background strain, strongly suggesting that GPR35 has an 
important role in blood pressure regulation (Min et al., 2010). 
A subsequent investigation of GPR35 expression in cardiomyocytes found both 
mRNA and cell surface protein levels to increase in response to hypoxia and 
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hypoxia-inducible factor 1 activation (Ronkainen et al., 2014). As hypoxia is a 
feature of most cardiac pathologies, this provides a possible rationale for the 
apparently broad involvement of GPR35 in cardiovascular disease. The same 
study found that GPR35 expression is induced in the heart tissue of experimental 
mouse models of myocardial infarction and pathological hypertrophy, and this 
induction precedes cardiac remodelling and heart failure. However, in this 
study, overexpression of GPR35 in mouse cardiomyocytes led to membrane 
ruffling and formation of retraction fibres, but no change in cell size. This 
conflicts with the previous finding in rat cardiomyocytes (Min et al., 2010), 
suggesting possible species variation in the specific cellular effects of GPR35 
overexpression. Since overexpression alone was sufficient to initiate 
cardiomyocyte remodelling in both cases, these effects may be due either to a 
constitutive signalling capacity of GPR35 or the presence of a GPR35 agonist in 
the extracellular environment. Once again, however, the lack of antagonists 
with efficacy at the rodent orthologues has hindered a more detailed 
understanding of these findings. 
In addition to an apparent role in regulating cell size and shape in 
cardiomyocytes, GPR35 has been reported to have effects in vascular cells. 
McCallum et al. demonstrated that GPR35 is expressed in vascular smooth 
muscle and endothelial cells, and that GPR35 agonists can induce both actin 
fibre reorganisation and migration in vascular smooth muscle cells (McCallum et 
al., 2015). These effects were blocked by the antagonists CID-2745687 and 
ML-145, and also by inhibitors of members of the RhoA signalling pathway, 
indicating that endogenous GPR35 mediates its effects on vascular cells through 
its coupling to G13, as previously demonstrated in GPR35-overexpressing HEK293 
cells (Jenkins et al., 2011). These findings suggest a potential role for GPR35 in 
the regulation of vascular remodelling, which is an important element of 
pathological processes such as intimal hyperplasia, restenosis and vein graft 
failure. 
1.5 GPR35 as a potential therapeutic target in CVD 
The evidence reported to date indicates broad functions of GPR35 in various 
tissues and physiological systems. The emerging roles of GPR35 in the 
cardiovascular system implicate it as a novel contributor to cardiovascular 
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dysfunction and a potential therapeutic target in CVD (Divorty et al., 2015). 
Importantly, CVD is one of the areas in which research into orphan GPCRs has 
revealed previously unknown transmitter systems and novel therapeutic 
opportunities (Maguire and Davenport, 2005). Investigating the role of GPR35 in 
cardiovascular regulation could therefore yield similar novel insights. 
1.5.1 Gα12/13-mediated signalling in CVD 
GPR35 is known to couple to both Gαi/o and Gα13 (see section 1.4.5) (Wang et 
al., 2006, Jenkins et al., 2011). However, all of the direct experimental 
evidence of a role for GPR35 in the cardiovascular system revolves around its 
ability to regulate cell size and shape (discussed in section 1.4.6.5), which 
strongly suggests that its cardiovascular functions are mediated primarily by Gα13 
(Ronkainen et al., 2014, McCallum et al., 2015). Furthermore, McCallum et al. 
demonstrated that its effects on vascular smooth muscle cell morphology are 
inhibited by disrupting the RhoA pathway (McCallum et al., 2015). Although 
Gα12/13 signalling is still relatively poorly understood compared with the other G 
protein subfamilies, its primary effects seem to be mediated by its activation of 
RhoA and its effector Rho-associated kinase (ROCK), which phosphorylates a 
number of targets involved in shape change and migration (Worzfeld et al., 
2008). 
While many Gα12/13-coupled receptors can also couple to Gαq/11, Gα12/13 effectors 
have been shown to have important Gαq/11-independent roles in cardiovascular 
physiology and pathophysiology. Studies in smooth muscle-specific Gα12/13 
knockout mice have shown that while Gα12 and Gα13 are not required for basal 
maintenance of vascular tone, they and their RhoGEF target LARG are required 
for the development of salt-induced hypertension (Wirth et al., 2008). This 
appears to be due to direct effects on vascular contractility, as expression of 
dominant-negative forms of Gα12/13 has been shown to inhibit vascular smooth 
muscle cell contraction in response to endothelin-1 (Gohla et al., 2000). In 
addition to direct effects on vascular smooth muscle contraction, Gα13 has been 
implicated in pathological remodelling of the heart. A study in inducible 
cardiomyocyte-specific Gα12 and Gα13 knockout mice identified a Gα13-specific 
role in pressure overload-induced cardiac remodelling and the subsequent 
development of heart failure, which was mediated by RhoA/myocardin-related 
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transcription factor (Takefuji et al., 2012). These findings suggest that Gα13-
coupled GPCRs that are expressed in the cardiovascular system (especially those 
that are upregulated in cardiovascular tissues during disease, as GPR35 is) are 
potential therapeutic targets in CVD, particularly in hypertension and heart 
failure. 
1.5.2 GPR35 as a potential therapeutic target in hypertension 
As discussed in section 1.4.6.5, GPR35 has been associated with adverse 
coronary artery remodelling in hypertensive human subjects (Sun et al., 2008), 
and its deficiency reportedly has a significant impact on blood pressure in 
knockout mice (Min et al., 2010). These reports implicate GPR35 in the 
pathogenesis of hypertension, though it is uncertain whether loss, gain or 
alteration of receptor function is to blame. 
1.5.2.1 Causes of hypertension 
Hypertension occurs in over a third of adults worldwide, and is a major risk 
factor for cardiovascular morbidity and mortality (Campbell et al., 2016). If left 
untreated, hypertension leads to a range of secondary diseases including 
coronary artery disease, heart failure, renal failure and stroke, and contributed 
to an estimated 10.3 million deaths globally in 2013 (Chobanian et al., 2003, 
Campbell et al., 2016).  It is defined as a systolic blood pressure greater than 
140 mmHg with a diastolic blood pressure greater than 90 mmHg (Williams et 
al., 2004). The causes of hypertension are multifarious and complex, with 
lifestyle, genetic susceptibility factors and various diseases and medications all 
contributing to its development and progression (Williams et al., 2004). On the 
molecular level, things are no simpler. There are many molecular and cellular 
mechanisms involved in the pathogenesis of hypertension, including altered 
vasoreactivity, excessive production of vasoactive hormones, and endothelial 
dysfunction resulting from oxidative stress or chronic inflammation (Daiber et 
al., 2016, Grassi et al., 2015, Harris et al., 2008).  
1.5.2.2 Current treatments for hypertension and their limitations 
Due to the multitude of interacting factors, it is challenging to resolve 
hypertension by eliminating its primary cause. Instead, management relies on a 
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combination of lifestyle alterations and pharmacological intervention with one 
or more of several classes of drug (Williams et al., 2004). First-line treatments 
include ACE inhibitors, AT1R antagonists, β blockers, calcium channel blockers 
and diuretics, and various combinations thereof (Williams et al., 2004). ACE 
inhibitors and AT1R antagonists block elevated activity of the renin-angiotensin 
system, whereas β blockers attenuate the hypertensive effects of excessive 
adrenergic stimulation. Calcium channel blockers and diuretics are less specific 
approaches, which reduce the sensitivity of vascular smooth muscle cells to 
vasoconstrictors or decrease blood volume by inhibiting water reabsorption, 
respectively. Most patients require a combination of drugs from at least two of 
these four classes to appreciably reduce blood pressure (Williams et al., 2004). 
However, about a quarter of patients fail to respond at all to this treatment 
strategy, and are classed as having ‘treatment-resistant’ or ‘uncontrolled’ 
hypertension (Calhoun et al., 2008, Eirin et al., 2016). While alternative 
therapeutic strategies are emerging, the identification of novel pharmacological 
targets can only be beneficial in combating this type of hypertension. This is 
especially relevant for poorly-characterised potential targets like GPR35, the 
study of which may reveal novel signalling systems whose contributions are 
currently underappreciated. 
1.5.3 GPR35 as a potential therapeutic target in heart failure 
Some of the strongest evidence for a pathophysiological role for GPR35 comes 
from studies in both humans and mice that demonstrate upregulation of GPR35 
in the heart during heart failure (discussed in section 1.4.6.5) (Min et al., 2010, 
Ronkainen et al., 2014). However, whether the induction of GPR35 is an 
adaptive response or contributes to pathogenesis in these contexts is unclear. 
Since heterologous overexpression of GPR35 in rat cardiomyocytes has been 
shown to promote either cytoskeletal rearrangements or hypertrophy (Min et al., 
2010, Ronkainen et al., 2014), it is possible that GPR35 is part of the 
pathological signalling involved in the progression of cardiac hypertrophy to 
heart failure, and could therefore constitute a therapeutic target. 
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1.5.3.1 Causes of pathological cardiac remodelling 
Heart failure is the end-point of progressive and debilitating alterations in the 
heart’s size, shape and function in response to stress or injury, leading to 
impaired contractile function and reduced blood flow (Bisping et al., 2014). 
Pathological remodelling of the heart can be triggered by many different 
stressors, such as chronic hypertension, myocardial infarction, or inflammation, 
and can be exacerbated by both lifestyle and genetic factors (Bisping et al., 
2014). 
Cardiac hypertrophy and increased contractility is initially an adaptive response 
to cardiovascular stress that progresses to pathological remodelling in response 
to persistent overload (Burchfield et al., 2013). Pressure overload resulting from 
excessive afterload – as a consequence of hypertension, for example – leads to 
concentric hypertrophy, where cardiomyocytes increase in width leading to wall 
thickening and reduced chamber area (Kehat et al., 2011). Concentric 
hypertrophy is a compensatory mechanism and allows the heart to maintain 
normal function (Cohn et al., 2000). On the other hand, volume overload or 
myocardial infarction leads to eccentric hypertrophy, where cardiomyocytes 
elongate without increasing in width (Kehat et al., 2011). This leads to wall 
thinning and dilation of the ventricles, which is detrimental to function (Cohn et 
al., 2000).  Concentric hypertrophy progresses to eccentric hypertrophy, and this 
transition, along with increased collagen deposition and ventricular stiffening, 
marks the progression to maladaptive remodelling and failure to pump 
adequately (Cohn et al., 2000). 
In molecular terms, pathological cardiac remodelling is driven by pro-apoptotic, 
pro-hypertrophic and pro-fibrotic signalling, directed largely by the adrenergic 
and angiotensin receptor systems but also by other GPCRs, receptor tyrosine 
kinases, inflammatory mediators and mechanical stimuli (Bisping et al., 2014, 
Capote et al., 2015). The effector pathways involved include the PKC, 
Ca2+/Calmodulin, RhoA/ROCK and mitogen-activated protein kinase pathways, 
all of which are potential clinical targets (van Berlo et al., 2013, Bisping et al., 
2014). 
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1.5.3.2 Current treatments for heart failure and their limitations 
In similarity to hypertension (which is the single biggest risk factor for heart 
failure), the primary drug interventions for adverse cardiac remodelling and 
prevention of heart failure are usually β blockers, ACE inhibitors or AT1R 
antagonists, along with mineralocorticoid receptor antagonists, which target the 
aldosterone-mediated actions of the renin-angiotensin system (Hunt et al., 
2009). These are effective both in controlling hypertension and therefore 
minimising this risk factor, and in actively inhibiting or even reversing 
hypertrophy and fibrosis (Xie et al., 2013). Advanced heart failure may also be 
treated with implantable devices including cardioverter-defibrillators and 
ventricular assist devices (Hunt et al., 2009). However, heart failure remains a 
significant cause of death worldwide, indicating that current treatments are not 
sufficient in the long term (Hunt et al., 2009). This is probably due to the 
multitude of signalling pathways and cell types involved in the pathogenesis of 
the disease, and so understanding the different mechanisms that lead to adverse 
remodelling of the heart is still a necessity. Elucidating the role of GPR35 in this 
process therefore has therapeutic relevance. 
1.6 Aims and objectives 
Recent findings of both human and animal studies contribute towards an 
emerging link between GPR35 and CVD (Sun et al., 2008, Min et al., 2010, 
Ronkainen et al., 2014, McCallum et al., 2015). This link appears to have 
justification at the biochemical and cellular levels in terms of G protein coupling 
and the possible signalling pathways involved, and brings us closer to assigning a 
function to the orphan receptor, although its precise role in disease remains 
unclear. Given the historical success of GPCRs (including orphan GPCRs) as drug 
targets, the link between GPR35 and CVD makes it a potential therapeutic target 
in diseases such as hypertension and its associated pathological cardiac 
remodelling and heart failure. The treatment of these diseases remains a global 
health challenge, and so there is a need to identify novel mechanisms and 
therapeutic targets. This thesis aims to address this need by characterising 
GPR35 signalling and its role in the cardiovascular system, to investigate the 
hypothesis that GPR35 is a potential therapeutic target in CVD. To this end, the 
work presented in this thesis is based on three objectives: 
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1. Investigate GPR35 signalling in vitro 
Determining the specific downstream consequences of GPR35 activation is 
necessary to place it into context as a signalling mediator in the 
cardiovascular system. Elucidating the signalling pathways activated by 
GPR35 and how these are regulated, for example by investigating the 
contributions of G protein, β-arrestin and receptor phosphorylation, will be 
valuable in assessing how GPR35 signalling might be targeted using emerging 
therapeutic strategies such as the use of biased agonists to increase the 
specificity of drug responses. 
Hypothesis: GPR35 activates signalling pathways in vitro that are 
consistent with a role in regulation of the cardiovascular system. 
2. Examine the role of GPR35 in the cardiovascular system by assessing 
the cardiovascular phenotype of a GPR35 knockout mouse 
Studies in knockout animals have been very valuable in linking orphan 
receptors to disease phenotypes. Although GPR35 has been linked with CVD, 
and a knockout mouse has been briefly reported on, the consequences of 
GPR35 deficiency on cardiovascular function are yet to be examined in 
detail. This has been addressed through a study into the basal cardiovascular 
phenotype of a GPR35 knockout mouse. 
Hypothesis: GPR35 is essential for normal cardiovascular function in the 
mouse. 
3. Determine the contribution of GPR35 to cardiovascular pathophysiology 
using rodent models of CVD 
To assess the potential of GPR35 as a therapeutic target, it is necessary to 
investigate its function in the context of cardiovascular dysfunction. This has 
been addressed using rodent models of CVD, including a study of 
hypertension in the knockout mouse and an agonist study in an inbred rat 
model of hypertension and end-organ damage. 
Hypotheses: GPR35 is essential for the development of Ang II-induced 
hypertension in the mouse; and pharmacological agonism of GPR35 
exacerbates cardiovascular disease in the stroke-prone spontaneously 
hypertensive rat.
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Chapter 2 Materials and Methods 
2.1 Pharmacological reagents 
- Amlexanox (2-Amino-7-(1-methylethyl)-5-oxo-5H- [1]Benzopyrano[2,3-
b]pyridine-3-carboxylic acid): Tocris Bioscience. 
- CID-2745687 (1-(2,4- Difluorophenyl)-5-[[2-[[(1,1- 
dimethylehyl)amino]thioxomethyl]hydrazinylidene]methyl]-1H-pyrazole-4-
carboxylic acid methyl ester): Tocris Bioscience. 
- Doxantrazole (3-(1H-tetrazol-5-yl)-9H-thioxanthen-9-one 10,10-dioxide 
monohydrate): Sigma-Aldrich 
- Lodoxamide (2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic 
acid): synthesised in collaboration with MRCT (London, UK). 
- ML-145 (-Hydroxy-4-[4-(5Z)-5-[(E)-2-methyl-3-phenylprop-2- enylidene]-4-
oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid): 
Tocris Bioscience. 
- Pamoic acid (1, 1′-Methylene-bis(2-hydroxy-3-naphthoic acid)): 
Sigma-Aldrich. 
- Zaprinast (2-(2-Propyloxyphenyl)-8-azapurin-6-one): Tocris Bioscience. 
All pharmacological agents were dissolved in dimethyl sulfoxide (DMSO) at 
stock concentrations of 1–100 mM depending on solubility. 
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2.2 Buffers and solutions 
- Competent bacteria solution 1: 30 mM CH3CO2K, 10 mM RbCl2, 10 mM 
CaCl2, 50 mM MnCl2, 15% (v/v) glycerol, pH 5.8 with acetic acid 
- Competent bacteria solution 2: 10 mM 3-morpholinopropane-1-sulfonic 
acid (MOPS), 10 mM RbCl2, 75 mM CaCl2, 15% (v/v) glycerol, pH 6.5 with 
HCl 
- DMEM-HEPES: 1x Dulbecco’s modified Eagle’s medium (DMEM) High 
Glucose, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), pH 7.4 
- DNA loading buffer (6x): 0.4 mg/mL sucrose, 0.25% (w/v) bromophenol 
blue 
- Hank’s balanced salt solution (HBSS): 137 mM NaCl, 5.3 mM KCl, 0.34 mM 
Na2HPO4, 0.44 mM KH2PO4, 4 mM NaHCO3, 1.26 mM CaCl2, 0.5 mM MgCl2, 
0.4 mM MgSO4, pH 7.3 
- HEPES microscope buffer: 130 mM NaCl, 5 mM KCl, 20 mM HEPES, 10 mM 
glucose, 1 μM MgCl2, 1 μM CaCl2, pH 7.2 
- Krebs/HEPES buffer (phospholabelling): 118 mM NaCl, 1.3 mM CaCl2, 4.3 
mM KCl, 1.17 MgSO4, 4.17 mM NaHCO3, 11.7 mM glucose, 10 mM HEPES, 
pH 7.4 
- Laemmli buffer (2x): 60 mM Tris, 80 mM sodium dodecyl sulphate (SDS), 
50 mM dithiothreitol, 10% (v/v) glycerol, 0.25% (w/v) bromophenol blue 
- Luria-Bertani (LB) agar: 10 g/L tryptone, 5 g/L yeast extract, 10 g/L 
NaCl, 15 g/L agar, pH 7 
- Luria-Bertani (LB) broth: 10 g/L tryptone, 5 g/L yeast extract, 10 g/L 
NaCl, pH 7 
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- Lysis buffer (phospholabelling): 20 mM Tris (pH 7.4), 150 mM NaCl, 3 mM 
ethylenediaminetetraacetic acid (EDTA), 1% (v/v) NP-40, 0.5% (w/v) 
sodium deoxycholate 
- Phosphate-buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 1.8 mM 
KH2PO4, 10 mM Na2HPO4, pH 7.4 
- Physiological salt solution (PSS): 118.3 mM NaCl, 4.7 mM KCl, 1.2 mM 
MgSO4, 25 mM NaHCO3, 1.19 mM KH2PO4, 11.7 mM glucose, 2.5 mM CaCl2, 
bubbled with O2 15 min 
- Physiological salt solution high potassium (KPSS): 120 mM KCl, 1.2 mM 
MgSO4, 25 mM NaHCO3, 1.19 mM KH2PO4, 11.7 mM glucose, 2.5 mM CaCl2, 
bubbled with O2 15 min 
- Radioimmunoprecipitation assay (RIPA) buffer: 50 mM HEPES (pH 7.4), 
150 mM NaCl, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 
0.1% (w/v) SDS, 10 mM NaF, 5 mM EDTA, 10 mM Na2HPO4, 5% (v/v) 
ethylene glycol, pH 7.3 
- Transfer buffer: 200 mM glycine, 25 mM Tris, 20% (v/v) methanol 
- Tris-acetate-EDTA (TAE) buffer: 40 mM Tris, 1 mM EDTA (pH 8), 20 mM 
acetic acid 
- Tris-buffered saline (TBS): 20 mM Tris, 150 mM NaCl, 3 mM EDTA, pH 7.4 
- Tris-EDTA (TE) buffer: 10 mM Tris, 0.1 mM EDTA, pH 7.4  
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2.3 Molecular biology and cloning 
2.3.1 Preparation of competent bacteria 
To prepare competent bacteria for chemical transformation, XL1-Blue 
competent bacteria were streaked onto LB agar and grown overnight at 37°C. A 
single colony was inoculated into 5 mL LB broth and grown overnight at 37°C, 
then subcultured into 100 mL LB broth and grown at 37°C until reaching an 
optical density at 550 nm of 0.48. The culture was chilled on ice for 5 min and 
two 50 mL aliquots were subjected to centrifugation at 1750 x g for 10 min at 
4°C. Each pellet was resuspended in 20 mL solution 1, then chilled on ice for 
5 min and subjected to centrifugation as before. Each pellet was resuspended in 
2 mL solution 2 and chilled on ice for 15 min. The resulting XL1-Blue competent 
bacteria were aliquoted and stored at − 80°C. 
2.3.2 Chemical transformation 
XL1-Blue competent bacteria were transformed with plasmid DNA using chemical 
transformation. 100–500 ng plasmid DNA was added to 50 μL competent bacteria 
in pre-chilled microcentrifuge tubes and incubated on ice for 20 min. Samples 
were heat-shocked for 90 sec at 42°C, then incubated on ice for 2 min. Next, 
450 μL LB broth was added and samples were incubated with shaking for 60 min 
at 37°C, before plating 100–250 μL onto LB agar containing 50 μg/mL ampicillin. 
Plates were incubated overnight at 37°C. 
2.3.3 Purification of plasmid DNA 
2.3.3.1 Miniprep purification 
Microgram quantities of plasmid DNA were purified using the Wizard® Plus SV 
Minipreps DNA Purification System (Promega) as per the manufacturer’s 
instructions. Briefly, 3–5 mL overnight culture was subjected to centrifugation at 
10,000 x g for 5 min. The bacterial pellet was resuspended in kit buffer and 
lysed by the addition of SDS-containing lysis solution. Lysates were incubated 
with alkaline phosphatase for 5 min at room temperature, then neutralised by 
the addition of a neutralising buffer. The resulting solution was applied to a spin 
column and subjected to centrifugation at 16,000 x g for 1 min to allow the DNA 
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to bind the column. The flow-through was discarded and the column washed 
twice, centrifuging at 16,000 x g for 1 min each time. DNA was eluted in 50–
100 μL nuclease-free water into a sterile microcentrifuge tube and stored at 
− 20°C. 
2.3.3.2 Maxiprep purification 
Milligram quantities of plasmid DNA were purified using the QIAGEN® Plasmid 
Maxi Kit as per the manufacturer’s instructions. Briefly, 200–500 mL overnight 
culture was subjected to centrifugation at 3000 x g for 30 min at 4°C. The 
bacterial pellet was resuspended in pre-chilled resuspension buffer and lysed by 
the addition of lysis buffer. Lysate was incubated for 5 min at room 
temperature, then neutralised by the addition of pre-chilled neutralisation 
buffer and incubated on ice for 20 min. The resulting solution was subjected to 
centrifugation at 3000 x g for 15 min at 4°C. A QIAGEN-tip 100 column was 
equilibrated with 15 mL equilibration buffer, and the lysate supernatant applied 
and allowed to pass through the column by gravity flow. The flow-through was 
discarded and the column was washed twice with wash buffer. DNA was eluted 
in 15 mL elution buffer and precipitated by adding 10.5 mL isopropanol, then 
subjected to centrifugation at 3000 x g for 30 min. The pellet was air-dried, 
desalted by washing with 2 mL 70% (v/v) ethanol, transferred to a sterile 
microcentrifuge tube and subjected to centrifugation at 16,000 x g for 15 min. 
The pellet containing purified DNA was air-dried, then dissolved in 0.5–1 mL 
nuclease-free water. 
2.3.3.3 Ethanol precipitation 
Prior to using maxiprep-purified plasmid vectors for cloning, DNA was further 
purified using ethanol precipitation to remove residual contaminants such as 
excess salt. Two volumes of 100% ethanol and 0.1 volumes of 3 M sodium acetate 
(pH 5.2) were added to the DNA, and the mixture incubated at – 80°C for 
30 min. The precipitated DNA was subjected to centrifugation at 16,000 x g for 
15 min. The pellet was desalted by washing with 100 μL 70% (v/v) ethanol and 
subjected to centrifugation as before. The pellet containing purified DNA was 
air-dried, then dissolved in the original volume of nuclease-free water. 
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2.3.3.4 Determination of DNA concentration 
Plasmid DNA concentration was determined by measuring absorbance at 260 nm 
of a 1:100 dilution using a spectrophotometer. DNA purity was assessed using the 
A260/A280 ratio, with a ratio between 1.7 and 2.0 considered pure. 
2.3.4 Polymerase chain reaction (PCR) 
PCR was used to introduce restriction sites or epitope tags and to amplify 
specific DNA fragments. Reactions of 50 μL were set up in sterile 500 μL PCR 
tubes with the following components: 
- 1 x Colourless GoTaq® Buffer (Promega) 
- 0.8 mM deoxyribonucleotides (dNTPs) (0.2 mM each deoxyadenosine 
triphosphate, deoxycytidine triphosphate, deoxyguanosine triphosphate 
and deoxythymidine triphosphate) (Promega) 
- 0.5 μM each forward and reverse primers 
- 100 ng template DNA 
- 5 units GoTaq® DNA Polymerase (Promega) 
Reaction mixtures were subjected to thermal cycling using the following 
conditions: 
1. Preheating  95°C  2 min 
2. Denaturing  95°C  30 sec 
3. Annealing  50–60°C* 30 sec 
4. Extension  72°C  2 min 
5. Repeat steps 2–4 (x 29) 
6. Final extension 72°C  10 min 
7. Hold   4°C  ∞ 
*Depending on melting temperature (Tm) of primers. 
2.3.5 PCR Purification 
PCR products were purified using the QIAquick® PCR Purification Kit (QIAGEN) as 
per the manufacturer’s instructions. Briefly, PCR product was diluted in five 
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volumes of binding buffer, applied to a QIAquick spin column and subjected to 
centrifugation at 16,000 x g for 1 min. The flow-through was discarded and the 
column washed once, centrifuging as before. The flow-through was discarded 
and the column subjected to centrifugation once more to remove residual 
ethanol. DNA was eluted in 50 μL nuclease-free water into a sterile 
microcentrifuge tube, allowing the water to stand on the column for 1 min 
before centrifuging. 
2.3.6 Restriction endonuclease digestion 
Digestion by restriction endonuclease enzymes was used to generate sticky-end 
DNA fragments for ligation. pcDNA3.1(+), pcDNA3.1/Hygro(+) or pcDNA5/FRT/TO 
plasmid vectors and relevant insert fragments were digested overnight at 37°C 
in 50–100 μL digests containing the following components: 
- 1 x CutSmart® Buffer (New England Biolabs) 
- 10–50 μg vector DNA or 50 μL PCR product 
- 1–10 units (depending on manufacturer’s recommendation for supercoiled 
plasmid DNA) High Fidelity (HF®) restriction endonucleases (New England 
Biolabs) 
 
2.3.7 Agarose gel electrophoresis 
DNA insert and vector fragments were separated by agarose gel electrophoresis. 
Gels were prepared by dissolving 1% (w/v) agarose and 1 x SYBR® Safe DNA stain 
(Life Technologies) in TAE buffer. Once set, gels were immersed in TAE buffer 
and samples were prepared by adding 1 x DNA loading buffer before loading 5–
50 μL/well onto the gel. Samples were subjected to electrophoresis at 125 V for 
20–30 min. The size and concentration of the DNA fragments were estimated by 
running 5 μL HyperladderTM 1kb (Bioline) alongside the samples. 
2.3.8 Gel extraction 
After gel electrophoresis, DNA insert and vector fragments were extracted from 
the gel using the QIAquick Gel Extraction Kit (QIAGEN) as per the manufacturer’s 
instructions. Briefly, bands were visualised using ultraviolet light and excised 
from the gel with a razor blade. Gel pieces were put into sterile microcentrifuge 
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tubes and weighed. Three gel volumes of solubilisation buffer was added and the 
gel pieces dissolved by incubating at 50°C for 10 min, vortexing every 2–3 min. 
One gel volume of isopropanol was added, and the resulting solution was applied 
to a QIAquick spin column and subjected to centrifugation at 16,000 x g for 
1 min. The flow-through was discarded and the column washed once, repeating 
the cenntrifugation step. The flow-through was discarded and the column 
subjected to centrifugation once more to remove residual ethanol. DNA was 
eluted in 30–50 μL nuclease-free water into a sterile microcentrifuge tube, 
allowing the water to stand on the column for 1 min before centrifuging. 
2.3.9 DNA dephosphorylation 
To remove 5’ phosphate groups from digested vector fragments and thus 
minimise re-ligation of empty vector, vector fragments were treated with 
Antarctic Phosphatase (New England Biolabs). 1 unit of Antarctic Phosphatase 
was added per μg of vector, along with 0.1 volumes of 10 x Antarctic 
Phosphatase Reaction Buffer. Samples were incubated for 30 min at 37°C, then 
the enzyme was inactivated by incubating at 65°C for 5 min. 
2.3.10 DNA ligation 
Ligation of DNA sticky ends was carried out to produce recombinant plasmid 
DNA. Insert and vector fragments were added at molar ratios of 1:3, 1:1 and 3:1 
to 20 μL ligation reactions containing the following components: 
- 1 x T4 DNA Ligase Reaction Buffer (New England Biolabs) 
- 100 ng vector DNA   
- X ng insert DNA 
- 400 units (1 μL) T4 DNA Ligase (New England Biolabs) 
Ligation reactions were incubated overnight at 16°C and 5 μL of ligated product 
was transformed into XL1-Blue competent bacteria as described in section 2.3.2. 
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2.3.11 Site-directed mutagenesis 
Point mutations were introduced into DNA sequences using the Stratagene 
QuikChange® system. Mutagenic primer pairs containing the desired base 
substitution(s) with a Tm ≥78°C were designed using the formula: 
Tm = 81.5 + 0.41(%GC) − 675/n − % mismatch 
(n = primer length in base pairs.) 
 
To amplify mutagenised plasmid DNA, 50 μL reactions were set up in sterile 
500 μL PCR tubes with the following components: 
- 1 x Pfu Turbo Reaction Buffer (Agilent Technologies) 
- 0.8 mM dNTPs 
- 1 μM each forward and reverse primers 
- 20 ng template DNA 
- 2.5 units Pfu Turbo DNA Polymerase (Agilent Technologies) 
Reaction mixtures were subjected to thermal cycling using the following 
conditions: 
1. Preheating  95°C  30 sec 
2. Denaturing  95°C  30 sec 
3. Annealing  55°C  1 min 
4. Extension  72°C  10 min 
5. Repeat steps 2–4 (x 17) 
6. Hold   4°C  ∞ 
Methylated parental template DNA was digested using DpnI restriction enzyme 
by adding 10 units of DpnI (Promega) directly to the PCR product and incubating 
for 2 hours at 37°C. Following incubation, 1 μL digested PCR product was 
transformed into XL1-Blue competent bacteria as described in section 2.3.2. 
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2.3.12 DNA sequencing 
Cloning and mutagenesis products were sequenced to verify that the correct 
changes had been introduced. DNA sequencing was performed by DNA 
Sequencing & Services (MRC I PPU, College of Life Sciences, University of 
Dundee, Scotland, www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 
chemistry on an Applied Biosystems model 3730 automated capillary DNA 
sequencer. DNA sequences were assessed using Chromas software and NCBI Basic 
Local Alignment Search Tool (BLAST) (www.blast.ncbi.nlm.nih.gov). 
2.3.13 Generation of hemagglutinin (HA)-tagged GPR35 
constructs 
Human (hGPR35), rat (rGPR35) and mouse (mGPR35) GPR35 constructs with 
N-terminal FLAG epitope tags (amino acid sequence DYKDDDDK) and C-terminal 
enhanced yellow fluorescent protein (eYFP) tags (FLAG-hGPR35-eYFP, FLAG-
rGPR35-eYFP, and FLAG-mGPR35-eYFP) in pcDNA3.1(+) (Jenkins et al., 2010, 
Jenkins et al., 2012) were used as PCR templates. An HA tag (amino acid 
sequence YPYDVPDYA) was introduced to the C-terminus and restriction sites 
introduced to both 5’ and 3’ termini by PCR using the following primers 
(restriction sites are underlined): 
HindIII hGPR35 Forward: 
5’ GATCAAGCTTGCCACCATGAATGGCACCTACAACACCTGT 3’ 
hGPR35-HA BamHI Reverse: 
5’ TATTGGATCCTTAAGCGTAATCTGGAACATCGTATGGGTAGGCGAGGGTCACGCACAG 3’ 
KpnI rGPR35 Forward: 
5’ GCGCGGTACCGCCACCATGAACAATACAAATTGTAGCATCCTCCC 3’ 
rGPR35-HA BamHI Reverse: 
5’ GCGCGGTACCGCCACCATGAACAATACAAATTGTAGCATCCTCCC 3’ 
HindIII mGPR35 Forward: 
5’ GCGCAAGCTTGCCACCATGAATAGTACAACCTGTAACAGCACC 3’ 
mGPR35-HA BamHI Reverse: 
5’ TACTGGATCCTTAAGCGTAATCTGGAACATCGTATGGGTAGGTGAGGCTCAGGATCTGGG 3’ 
PCR products were cloned into pcDNA5/FRT/TO for subsequent use in the 
Flp-InTM T-RExTM system. 
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2.3.14 Generation of GPR35 phospho-acceptor site mutant 
constructs 
Phospho-acceptor serine and threonine residues in the GPR35 C-terminal tail 
were mutated to alanine in order to preclude phosphorylation. FLAG-hGPR35-
eYFP, FLAG-rGPR35-eYFP and FLAG-mGPR35-eYFP in pcDNA3.1(+) or hGPR35-HA 
and mGPR35-HA in pcDNA5/FRT/TO were used as templates for site-directed 
mutagenesis. S/T to A substitutions were introduced using a series of mutagenic 
primers as detailed in Table 2-1, Table 2-2 and Table 2-3. For multiple mutations 
spread across >10 bp, site-directed mutagenesis was carried out sequentially 
using multiple primer pairs. Phosphorylation-deficient mutants (PDMs) of 
hGPR35, rGPR35 and mGPR35 with all of the C-terminal tail S/T residues 
mutated were generated in this manner. 
2.3.15 Generation of phosphorylation-deficient hGPR35 
intramolecular BRET sensor constructs 
An intramolecular bioluminescence resonance energy transfer (BRET) sensor 
construct was generated in order to test the capacity of phosphorylation-
deficient GPR35 to couple to Gα13. FLAG-hGPR35(PDM)-eYFP in pcDNA3.1(+) was 
used as a PCR template. HindIII and KpnI restriction sites were introduced to the 
5’ and 3’ termini of the FLAG-hGPR35 open reading frame using the following 
primers (restriction sites are underlined): 
HindIII FLAG Forward: 
5’ ACTTAAGCTTGCCACCATGGATTACAAGGATGACG 3’ 
hGPR35 T307A KpnI Reverse: 
5’ TAATGGTACCGGCGAGGGCCACGCACAG 3’ 
The PCR product was inserted upstream of an intramolecular BRET sensor 
construct in pcDNA5/FRT/TO, consisting of mCitrine linked to NanoLuc® 
luciferase by an ER/K α-helical linker and fused with the C-terminal 27 amino 
acids of Gα13 (mCitrine-ER/K-NanoLuc-Gα13) or the same construct with no 
peptide (mCitrine-ER/K-NanoLuc-NP). 
56 
 
Table 2-1 hGPR35 mutagenic primers 
Primer sequence (5' to 3') Template Mutation For/Rev 
CCAGGAGGCGGCTGCACTGGCCGTG hGPR35 S287A For 
CACGGCCAGTGCAGCCGCCTCCTGG hGPR35 S287A Rev 
CCGTGGCTCCCGCTGCTAAGGCCC hGPR35 S294A For 
GGGCCTTAGCAGCGGGAGCCACGG hGPR35 S294A Rev 
GGCCCACAAAGCCCAGGACGCTCTGTGCGTG hGPR35 S300A/S303A For 
CACGCACAGAGCGTCCTGGGCTTTGTGGGCC hGPR35 S300A/S303A Rev 
GGCCCACAAAGCCCAGGACTCTC hGPR35 S300A For 
GAGAGTCCTGGGCTTTGTGGGCC hGPR35 S300A Rev 
CAAAAGCCAGGACGCTCTGTGCGTG hGPR35 S303A For 
CACGCACAGAGCGTCCTGGCTTTTG hGPR35 S303A Rev 
CTGTGCGTGGCCCTCGCCGCG hGPR35-eYFP T307A For 
CGCGGCGAGGGCCACGCACAG hGPR35-eYFP T307A Rev 
CTGTGCGTGGCCCTCGCCTACCC hGPR35-HA T307A For 
GGGTAGGCGAGGGCCACGCACAG hGPR35-HA T307A Rev 
Mutagenic primer pairs used to introduce Ser/Thr to Ala substitutions to hGPR35 constructs. Altered codons are underlined. For = forward; Rev = reverse; eYFP = 
enhanced yellow fluorescent protein; HA = haemagglutinin  
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Table 2-2 mGPR35 mutagenic primers 
Primer sequence (5' to 3') Template Mutation Rev 
CCAGGAAGCGGCCAAGCCAGCCACG mGPR35 S286A For 
CGTGGCTGGCTTGGCCGCTTCCTGG mGPR35 S286A Rev 
TCCAAGCCAGCCACGGCTGCCAACACACCCC mGPR35 S291A/S292A For 
GGGGTGTGTTGGCAGCCGTGGCTGGCTTGGA mGPR35 S291A/S292A Rev 
CCCCACAAGGCCCAAGATGCCCAGATCCTGAGC mGPR35 S298A/S301A For 
GCTCAGGATCTGGGCATCTTGGGCCTTGTGGGG mGPR35 S298A/S301A Rev 
CCCAGATCCTGGCCCTCGCCTGCGGCCGCATGG mGPR35-eYFP S305A/T307A For 
CCATGCGGCCGCAGGCGAGGGCCAGGATCTGGG mGPR35-eYFP S305A/T307A Rev 
CCAAGCCAGCCGCGGCTGCCAACACACC mGPR35-eYFP (S291A/S292A) T290A For 
GGTGTGTTGGCAGCCGCGGCTGGCTTGG mGPR35-eYFP (S291A/S292A) T290A Rev 
CCGCGGCTGCCAACGCACCCCACAAGAGC mGPR35-eYFP (T290A/S291A/S292A) T294A For 
GCTCTTGTGGGGTGCGTTGGCAGCCGCGG mGPR35-eYFP (T290A/S291A/S292A) T294A Rev 
CCCAGATCCTGGCCCTCGCCTACCCATACGATGTTCC mGPR35-HA/rGPR35-HA S305A/T307A For 
GGAACATCGTATGGGTAGGCGAGGGCCAGGATCTGGG mGPR35-HA/rGPR35-HA S305A/T307A Rev 
Mutagenic primer pairs used to introduce Ser/Thr to Ala substitutions to mGPR35 constructs. Altered codons are underlined. For = forward; Rev = reverse; eYFP = 
enhanced yellow fluorescent protein; HA = haemagglutinin   
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Table 2-3 rGPR35 mutagenic primers 
Primer sequence (5' to 3') Template Mutation For/Rev 
CCAGGATGCGGCCTTGCGGGCC rGPR35 S285A For 
GGCCCGCAAGGCCGCATCCTGG rGPR35 S285A Rev 
CCTTGCGGGCCGCAGCCTCTAGC rGPR35 T289A For 
GCTAGAGGCTGCGGCCCGCAAGG rGPR35 T289A Rev 
GCCGCAGCCGCTGCCGCACCCCACAAGAGCC rGPR35 S291A/S292A/T293A For 
GGCTCTTGTGGGGTGCGGCAGCGGCTGCGGC rGPR35 S291A/S292A/T293A Rev 
CCCCACAAGGCCCAAGATGCTCAGAGCCTGAGCC rGPR35 S297A/T300A For 
GGCTCAGGCTCTGAGCATCTTGGGCCTTGTGGGG rGPR35 S297A/T300A Rev 
CCAAGATACTCAGGCCCTGGCCCTCGCCAGCGGCCGC rGPR35-eYFP S302A/S304A/T306A For 
GCGGCCGCTGGCGAGGGCCAGGGCCTGAGTATCTTGG rGPR35-eYFP S302A/S304A/T306A Rev 
GCGGGCCGCAGCCGCTGCCGCACCCCACAAGGCCC rGPR35-eYFP (T289A/S297A) S291A/S292A/T293A For 
GGGCCTTGTGGGGTGCGGCAGCGGCTGCGGCCCGC rGPR35-eYFP (T289A/S297A) S291A/S292A/T293A Rev 
CCCAAGATGCTCAGGCCCTGGCCCTCGCCAGCGGCCGC rGPR35-eYFP (S289A/S301A) S302A/S304A/T306A For 
GCGGCCGCTGGCGAGGGCCAGGGCCTGAGCATCTTGGG rGPR35-eYFP (S289A/S301A) S302A/S304A/T306A Rev 
Mutagenic primer pairs used to introduce Ser/Thr to Ala substitutions to rGPR35 constructs. Altered codons are underlined. For = forward; Rev = reverse; eYFP = 
enhanced yellow fluorescent protein; HA = haemagglutinin   
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2.4 Mammalian cell culture 
2.4.1 Maintenance of mammalian cell lines 
2.4.1.1 HEK293T cells 
Human embryonic kidney 293 cells transformed with large T-antigen (HEK293T 
cells) were maintained in Dulbecco’s Modified Eagle’s Medium supplemented 
with 10% (v/v) heat-inactivated foetal calf serum (FCS), 2 mM L-glutamine., 
100 units/mL penicillin and 100 μg/mL streptomycin at 37°C and 5% CO2 in a 
humidified atmosphere. 
2.4.1.2 Flp-In T-REx-293 cells 
Flp-In T-REx HEK293 cells (Life Technologies) were maintained in Dulbecco’s 
Modified Eagle’s Medium High Glucose without Sodium Pyruvate supplemented 
with 10% (v/v) heat-inactivated FCS, 100 units/mL penicillin, 100 μg/mL 
streptomycin and 10 μg/mL blasticidin at 37°C and 5% CO2 in a humidified 
atmosphere. 
2.4.1.3 Cryopreservation 
Cell lines were cryopreserved for long-term storage in liquid nitrogen. Confluent 
cells were detached by incubating with trypsin-EDTA and subjected to 
centrifugation at 500 x g for 5 min. The pellet was resuspended in 2-3 mL FCS + 
10% (v/v) DMSO and 1 mL aliquots frozen at − 80°C before transferring to liquid 
nitrogen storage. Cryopreserved cells were revived by thawing rapidly in a 37°C 
water bath and transferring to 10 mL pre-warmed culture medium in a flask. 
Medium was changed after 8-16 hours to remove DMSO. 
2.4.2 Transient transfection of cell lines 
2.4.2.1 Polyethyleimine (PEI) 
PEI transient transfection was used as the default method of transient 
transfection. For a 10 cm2 culture dish, 5 μg of DNA was diluted in 250 μL 
150 mM NaCl and mixed 1:1 with 250 μL 150 mM NaCl containing 30 μg PEI.  The 
mixture was vortexed for 10 sec and incubated for 10 min at room temperature 
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before adding dropwise to the dish. This procedure was scaled down for 6-well 
plates. Cells were incubated with the PEI overnight at 37°C, then transfection 
medium was replaced with fresh culture medium. Cells were incubated for a 
further 24–48 hours before using in assays. 
2.4.2.2 Lipofectamine® 
For applications where PEI transfection negatively affected cell morphology and 
assay reliability, cells were transiently transfected using Lipofectamine (Life 
Technologies) as per the manufacturer’s instructions. For a 6-well plate, 0.5–
2.5 μg DNA was diluted in 100 μL Opti-MEM® and mixed 1:1 with 100 μL 
Opti-MEM containing 5 μL Lipofectamine reagent. The mixture was incubated for 
5 min at room temperature before adding dropwise to the well. Cells were 
incubated with the Lipofectamine for 4–5 hours, then transfection medium was 
replaced with fresh culture medium or induction medium. Cells were incubated 
for a further 24–48 hours before using in assays. 
2.4.3 Stable transfection of cell lines 
2.4.3.1 Flp-In T-REx doxycyline-inducible 293 cells 
GPR35-HA and GPR35 intramolecular BRET sensors were stably transfected into 
HEK293 cells using the Flp-In T-REx system. The pcDNA5/FRT/TO vector 
containing the relevant cDNA was transfected into Flp-In T-REx-293 parental 
cells using the FRT stable integration site. Cells were co-transfected with the 
relevant cDNA/pcDNA5/FRT/TO construct and the pOG44 Flp recombinase vector 
in a 1:8 ratio using PEI. After 48 hours, cells were subcultured 1:10 and 1:30, 
and 24 hours later medium was changed to maintenance medium plus 10 µg/mL 
blasticidin and 200 µg/mL hygromycin to select for stable transfectants. Medium 
was changed every three days until individual colonies were visible by eye (10–14 
days).  Cells were then detached by incubating with trypsin-EDTA and pooled to 
give polyclonal cell lines which were maintained in blasticidin/hygromycin 
selection medium. When required, expression of the integrated gene was 
induced by addition of 100 ng/mL doxycycline (Dox) for 18-24 h. 
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2.4.3.2 CRISPR-modified HEK293T cells 
Clustered regularly interspaced short palindromic repeats (CRISPR)-modified 
HEK293T cell lines with β-arrestin-1/2 or Gα12/13 knocked out (Arr KO and G12/13 
KO, respectively) and the equivalent parental cell line were obtained from Asuka 
Inoue (Tohoku University, Japan). Stable cell lines constitutively expressing 
FLAG-hGPR35-eYFP or FLAG-hGPR35(PDM)-eYFP were generated in order to 
assess β-arrestin- and Gα12/13-mediated responses. Cells were transfected with 
the relevant cDNA in pcDNA3.1/Hygro(+) using PEI as described in section 
2.4.2.1. After 48 hours, cells were subcultured 1:500, 1:1000 and 1:2000, and 24 
hours later medium was changed to maintenance medium plus 200 μg/mL 
hygromycin to select for stable transfectants. Medium was changed every three 
days until individual colonies were visible by eye (10–14 days).  Individual 
colonies were picked into 24-well plates and scaled up to give monoclonal cell 
lines which were maintained in hygromycin selection medium. 
2.5 Assessing receptor expression 
2.5.1 Immunocytochemistry 
Immunocytochemistry was used to assess receptor expression and subcellular 
localisation. Cells were seeded at 3 x 105 cells/well on poly-D-lysine-coated 
22 mm round coverslips in 6-well plates and incubated overnight at 37°C. Cells 
were washed twice in PBS and fixed with 3.7% (w/v) paraformaldehyde (PFA) in 
PBS for 10 min at room temperature. Fixed cells were washed 3 x 5 min in PBS 
and blocked with 3% (w/v) non-fat milk in PBS or blocked and permeabilised with 
3% (w/v) non-fat milk and 0.15% (v/v) Triton-X100 in PBS for 10 min at room 
temperature. Cells were then incubated with primary antibody (rat anti-HA High 
Affinity (Roche) 1:100 dilution) in 3% (w/v) non-fat milk for 1 hour at room 
temperature, washed 3 x 5 min in PBS, then incubated with secondary antibody 
(Alexa Fluor® 594-goat anti-rat IgG (Molecular Probes) 1:500 dilution) in 
3% (w/v) non-fat milk for 1 hour at room temperature. Cells were washed 
3 x 5 min in PBS and coverslips were mounted onto glass slides using Immu-
MountTM (Fisher Scientific). Images were taken using a Nikon Eclipse TE2000 
epifluorescence microscope with Coolsnap HQ camera using the rhodamine filter 
and x40 oil immersion objective. 
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2.5.2 Cell surface enzyme-linked immunosorbent assay (ELISA) 
Cell surface expression of receptors was quantified by live-cell ELISA. Cells were 
seeded at 6 x 104 cells/well in poly-D-lysine-coated clear 96-well plates and 
incubated overnight at 37°C. Cells were incubated with primary antibody (mouse 
monoclonal anti-FLAG M2 (Sigma-Aldrich) 1:1000) in culture medium for 30 min 
at 37°C, then washed once with DMEM-HEPES and incubated with secondary 
antibody (Horseradish peroxidase (HRP)-sheep anti-mouse IgG (GE Healthcare) 
1:5000) and 10 μg/mL Hoechst 33342 in culture medium for 30 min at 37°C 
protected from light. Cells were then washed twice with warmed (37°C) PBS. 
During the second wash, the Hoechst 33342 signal (excitation 355 nm, emission 
460 nm) was read on a POLARStar® Omega (BMG Labtech). Finally, PBS was 
removed and 100 μL/well room temperature TMB substrate was added. The 
plate was incubated for 5 min at room temperature protected from light, then 
the absorbance at 620 nm was read on a POLARStar Omega. Absorbance was 
corrected for cell number by dividing by the Hoechst 33342 signal. 
2.6 Pharmacological and functional assays 
2.6.1 [32P] phospholabelling assay 
Flp-In T-REx-293 GPR35-HA cells were seeded in 6-well plates at 2 x 105 
cells/well and incubated overnight at 37°C. GPR35-HA expression was induced 
by adding 100 ng/mL doxycycline and incubating overnight at 37°C. Cells were 
washed three times with Krebs/HEPES buffer without phosphate and incubated 
in this buffer plus 100 μCi/mL [32P]-orthophosphate for 90 min at 37°C. Cells 
were pre-treated with antagonist for 5 min where stated, then stimulated for 5 
min with vehicle only (DMSO) or agonist and immediately lysed by addition of 
750 μL/well lysis buffer containing cOmpleteTM EDTA-free Protease Inhibitor 
Cocktail (Roche) and PhosSTOPTM Phosphatase Inhibitor Cocktail (Roche). Lysates 
were incubated on ice for 5 min, then cleared by centrifugation at 20,000 x g for 
20 min at 4°C. GPR35-HA was immunoprecipitated from the cleared lysates using 
anti-HA affinity matrix (Roche). Lysates were incubated with 50 μL affinity 
matrix suspension with rotation for 2 h at 4°C. Immunoprecipitate was collected 
by centrifuging at 1000 x g for 1 min and washed 3 x with lysis buffer, subjecting 
to centrifugation and aspirating supernatant after each wash. GPR35-HA was 
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eluted from the matrix by adding 50 μL Laemmli buffer, vortexing and 
incubating at 65°C for 10 min. Immunoprecipitates were separated by SDS-PAGE 
on 10% Bis-Tris acrylamide gels, which were dried and exposed to X-ray film 
overnight at − 80°C. A small amount of each sample was run in parallel on a 
separate gel, then transferred to PVDF membrane and immunoblotted for 
GPR35-HA. Bands were quantified by densitometry using ImageJ software. 
2.6.2 β-arrestin recruitment BRET assay 
A BRET-based β-arrestin recruitment assay was used to assess the effect of 
C-terminal tail mutations on β-arrestin coupling. HEK293T cells were seeded in 
10 cm2 dishes and transiently co-transfected with wild type or mutant 
FLAG-GPR35-eYFP and β-arrestin-2 fused with Renilla luciferase (β-arrestin-2-
RLuc) in a 4:1 ratio using PEI, as described in section 2.4.2.1. Control cells were 
transfected with β-arrestin-2-RLuc only. After 24 hours, cells were detached by 
incubating with trypsin-EDTA and seeded at 6 x 104 cells/well in poly-D-lysine-
coated white 96-well plates, then incubated overnight at 37°C. Cells were 
washed once with pre-warmed (37°C) HBSS and incubated in HBSS for 30–60 min 
at 37°C. During incubation, the eYFP signal (excitation 485 nm, emission 
520 nm) was read on a PHERAstar® FS (BMG Labtech) to estimate relative 
receptor expression. The RLuc substrate coelenterazine-h (Promega) was added 
to a final concentration of 5 μM and the plate incubated for 10 min at 37°C 
protected from light. Agonist was added at the relevant concentrations in 
triplicate and the plate incubated for a further 5 min at 37°C, then the 
emissions at 475 nm and 535 nm were read on a PHERAstar FS. Since 
coelenterazine h luminesces at 475 nm and eYFP is excited at 475 nm and emits 
at 535 nm, net BRET values were obtained by dividing the emission at 535 nm by 
the emission at 475 nm and subtracting the 535 nm/475 nm ratio for cells 
expressing only the β-arrestin-2-RLuc donor (the basal BRET): 
Net BRET = (em535 nm/em475 nm) – (em535 nm/em475 nm (RLuc only)) 
2.6.3 Gα13 intramolecular BRET sensor assay 
An assay using the Gα13 intramolecular BRET sensor described in section 1.1.1 
was used to assess the effect of C-terminal mutations on Gα13 recruitment. 
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Flp-In T-REx-293 cells stably transfected with the relevant GPR35 sensor were 
seeded at 6 x 104 cells/well in poly-D-lysine-coated white 96-well plates and 
incubated for 6 hours at 37°C before adding 100 ng/mL doxycycline and 
incubating overnight at 37°C to induce GPR35 sensor expression. Cells were 
washed once with pre-warmed (37°C) HBSS and incubated in HBSS for 30–60 min 
at 37°C. During incubation, the mCitrine signal (excitation 485 nm, emission 
520 nm) was read on a PHERAstar FS to estimate receptor expression. The 
NanoLuc substrate Nano-Glo® (Promega) was added to a final dilution of 1:800 
and the plate incubated for 10 min at 37°C protected from light. Agonist was 
added at the relevant concentrations in triplicate and the plate incubated for a 
further 5 min at 37°C, then the emissions at 455 nm and 530 nm were read on a 
CLARIOstar® (BMG Labtech). Since NanoGlo luminesces at 455 nm and mCitrine 
is excited at 455 nm and emits at 530 nm, BRET Ratio values were obtained by 
dividing the emission at 530 nm by the emission at 455 nm: 
BRET Ratio = (em530 nm/em455 nm) 
2.6.4 Receptor internalisation 
2.6.4.1 Qualitative receptor internalisation 
Receptor internalisation was qualitatively examined using live-cell confocal 
microscopy. Cells were seeded at 0.5–1 x 105 cells/well on poly-D-lysine-coated 
30 mm round coverslips in 6-well plates and incubated for at least 48 hours at 
37°C to recover normal morphology after seeding. For transient transfection, 
cells were transfected using Lipofectamine, as described in section 2.4.2.2, 24 
hours after seeding. Cells were washed once with HBSS and coverslips were 
placed in a microscope chamber containing HBSS. eYFP images were taken 
before treatment and at 15 min intervals following addition of agonist. Images 
were acquired on a ZEISS Axio Observer.Z1 microscope fitted with a spinning disk 
structured illumination Viva Tome, using narrow band 490/20 nm excitation and 
536/40 nm emission and a 63x oil-immersion Plan-Apochromat objective, and 
captured on an Axiocam MRm charge-coupled device camera. Images were 
optically sectioned using AxioVision software (ZEISS). 
65 
 
2.6.4.2 ArrayScan quantitative internalisation assay 
Receptor internalisation was quantitatively assessed using ArrayScan high 
content analysis. Cells were seeded at 4 x 104 cells/well in poly-D-lysine coated 
black-walled, clear-bottomed 96-well plates and incubated overnight at 37°C. 
Culture medium was replaced with serum-free medium containing agonist 
concentrations in triplicate. Cells were incubated with agonist for 45 min, then 
washed once with PBS and fixed with 3.7% (w/v) paraformaldehyde for 1 hour at 
room temperature. Fixed cells were washed three times with PBS, then stained 
with 10 μg/mL Hoechst 33342 for 30 min at room temperature protected from 
light. Cells were washed 3x with PBS before acquiring eYFP and DAPI images 
using a Cellomics ArrayScan II high content imager. Internalisation was 
quantified using an algorithm designed to identify the number of individual 
‘endosomal recycling compartments’ in the eYFP channel, which was normalised 
against cell number using the Hoechst 33342 signal in the DAPI channel. 
2.6.5 Actin cytoskeleton staining 
To assess GPR35-mediated effects on actin cytoskeletal rearrangement, F-actin 
was stained with tetramethylrhodamine B isothiocyanate (TRITC)-labelled 
phalloidin. Cells were seeded at 0.5–1 x 105 cells/well on poly-D-lysine-coated 
22 mm round coverslips in 6-well plates and incubated for at least 48 hours at 
37°C to recover normal morphology after seeding. Cells were treated with 
agonist/antagonist, then washed twice with PBS and fixed with 3.7% (w/v) 
paraformaldehyde for 20 min at room temperature. Fixed cells were washed 
twice with PBS, permeabilised with 0.1% (v/v) Triton X-100 in PBS for 20 min at 
room temperature and blocked with 0.5% (w/v) bovine serum albumin (BSA) in 
PBS for 1 hour at 37°C. Cells were washed twice with PBS and stained with 
5 μg/mL phalloidin-TRITC (Sigma-Aldrich) in PBS for 1 hour at room temperature 
protected from light. Cells were washed three times with PBS and coverslips 
were mounted onto glass slides using Immu-Mount (Fisher Scientific). Images 
were acquired on a ZEISS Axio Observer.Z1 microscope fitted with a spinning disk 
structured illumination Viva Tome, using a 40x oil-immersion Plan-Apochromat 
objective. Emission at 610 nm was imaged using an Axiocam MRm charge-
coupled device camera. Images were optically sectioned using AxioVision 
software (ZEISS). 
66 
 
2.7 Immunoblotting 
2.7.1 Sample preparation 
2.7.1.1 Whole-cell lysates 
Cells were seeded in 6-well plates and cultured until confluent, then stimulated 
with the relevant ligand(s). To lyse, cells were washed twice with ice-cold PBS 
and immediately lysed with 200 μL/well RIPA buffer containing cOmpleteTM 
EDTA-free Protease Inhibitor Cocktail (Roche) (and PhosSTOPTM Phosphatase 
Inhibitor Cocktail (Roche) if immunoblotting for phosphoproteins). Lysates were 
passed 5x through a 25 gauge needle, rotated at 4°C for 30 min and then 
subjected to centrifugation at 20,000 x g for 10 min at 4°C to remove debris. 
2.7.1.2 Membrane and cytosolic fractions 
Cells were seeded in 10 cm dishes and cultured until confluent. Cells were 
washed once with ice-cold PBS and detached by scraping into 2–3 mL ice-cold 
PBS, then subjected to centrifugation at 1750 x g for 5 min at 4°C. Cell pellets 
were incubated at – 80°C for at least 30 min. Thawed pellets were resuspended 
in 1 mL TE buffer containing cOmpleteTM EDTA-free Protease Inhibitor Cocktail 
(Roche) and homogenised by passing 50 x in a Dounce homogeniser and passing 
5 x through a 25 gauge needle. Homogenate was subjected to centrifugation at 
500 x g for 5 min at 4°C to remove cell debris. Supernatants were carefully 
collected and subjected to centrifugation at 100,000 x g for 60 min at 4°C. For 
cytosolic fractions, supernatant was collected. For membrane fractions, 
membrane pellets were resuspended in 400 μL TE buffer containing protease 
inhibitors and passed 5x through a 25 gauge needle. 
2.7.1.3 Determination of protein concentration 
Protein concentrations of samples for immunoblotting were determined by 
bicinchoninic assay (BCA), using a standard curve of 0.2–2 μg/μL BSA. 10 μL of 
sample or standard was added to a clear 96-well plate. Proteoquant BCA 
Reagent B (Expedeon) was diluted 1:50 in Proteoquant BCA Reagent A 
(Expedeon) and 200 μL/well added to the samples. The plate was incubated at 
37°C for 15 min before reading the absorbance at 562 nm on a POLARStar Omega 
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(BMG Labtech). Sample concentrations were interpolated from the standard 
curve. Samples were diluted to 1 μg/μL, then aliquoted and stored at − 20°C. 
2.7.2 SDS-PAGE and protein transfer 
Protein samples were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Samples were denatured by adding 2 x Laemmli 
buffer and incubating at 65°C for 10 min. 10–30 μg protein/well was loaded onto 
BOLT® 4–12% Bis-Tris Plus Gels (Life Technologies) or NuPAGE® Novex® 4–12% 
Bis-Tris Gels (Life Technologies). Gels were run in NuPAGE® MOPS SDS Running 
Buffer (Life Technologies) at 200 V for 30–50 min. Proteins were transferred from 
the gel onto nitrocellulose membrane using a wet transfer system. Proteins were 
transferred in transfer buffer at 35 V for 90 min. 
2.7.3 Probing and detection 
2.7.3.1 Probing for chemiluminescent detection (GPR35-HA) 
GPR35-HA was detected using chemiluminescence. Membranes were blocked in 
5% (w/v) BSA for 1 hour at room temperature or overnight at 4°C, then 
incubated for 1 hour at room temperature with rat anti-HA High Affinity (Roche) 
at 1:1000 dilution in TBS with 0.5% (v/v) NP-40, 10% (v/v) goat serum and 
5% (w/v) BSA. Membranes were washed 5 x 5 min in TBS with 0.5% (v/v) NP-40, 
then incubated for 1 hour at room temperature with HRP-goat anti-rat IgG 
(Sigma-Aldrich) at 1:5000 dilution in the same buffer. Membranes were washed 
5 x 5 min in TBS with 0.5% (v/v) NP-40, and bands were detected using 
Immobilon Western Chemiluminescent HRP Substrate (Millipore). 
2.7.3.2 Probing for fluorescent detection 
All other proteins were detected using fluorescent detection on a LI-COR® 
Odyssey system. Antibodies used are detailed in Table 2-4. Membranes were 
blocked in LI-COR Blocking Buffer (PBS) (or (TBS) for phosphoproteins) for 1 hour 
at room temperature, then incubated with primary antibody in blocking buffer 
with 0.2% (v/v) Tween-20 overnight at 4°C. Membranes were washed 5 x 5 min 
with PBS or TBS with 0.1% (v/v) Tween-20, then incubated with IRDye® 
fluorescently labelled secondary antibody in blocking buffer with 0.2% (v/v) 
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Tween-20 for 1 hour at room temperature protected from light. Membranes 
were washed 5 x 5 min with PBS or TBS with 0.1% (v/v) Tween-20, then imaged 
on a LI-COR Odyssey using the 700 nm and 800 nm channels. 
Table 2-4 Antibodies used in immunofluorescent immunoblotting 
Antibody Supplier Dilution 
Primary antibodies 
Anti-HA High Affinity (rat) Roche 1:1000 
Monoclonal anti-FLAG M2 (mouse) Sigma-Aldrich 1:1000 
Gα12 Antibody (S-20) (rabbit) Santa Cruz Biotechnology 1:1000 
Gα13 Antibody (A-20) (rabbit) Santa Cruz Biotechnology 1:1000 
β-arrestin-1 (D8O3J) rabbit mAb Cell Signaling Technology 1:1000 
β-arrestin-2 (CD16D9) rabbit mAb Cell Signaling Technology 1:1000 
Anti-β-tubulin mouse monoclonal Sigma-Aldrich 1:500 
Secondary antibodies 
IRDye 800CW Goat anti-Rat IgG* LI-COR 1:10000 
IRDye 680RD Goat anti-Mouse IgG* LI-COR 1:15000 
IRDye 800CW Donkey anti-Rabbit IgG* LI-COR 1:10000 
IRDye 680RD Donkey anti-Rabbit IgG* LI-COR 1:10000 
*When multiplexing, IRDye 800CW was used to detect the lower abundance protein i.e. G protein 
or β-arrestin and IRDye 680RD was used to detect the loading control. 
2.8 Mass spectrometry 
2.8.1 Sample preparation 
Flp-In T-REx-293 GPR35-HA cells were seeded in 10 x T150 flasks and grown until 
confluent, then GPR35-HA expression was induced by adding 100 ng/mL 
doxycycline and incubating overnight at 37°C. Cells were washed once with 
Krebs/HEPES buffer containing 1.18 μM KH2PO4 , and incubated in this buffer for 
90 min at 37°C. After stimulating with 100 μM zaprinast for 5 min at 37°C, the 
cells were harvested in 1 mL/flask PBS containing 1 mM EDTA. Cells were 
subjected to centrifugation at 1000 x g for 5 min and the cell pellet was 
resuspended in 10 mL TE buffer containing cOmplete EDTA-free Protease 
Inhibitor Cocktail (Roche) and PhosSTOPTM Phosphatase Inhibitor Cocktail 
(Roche). Cells were homogenised by sonication and the homogenate subjected to 
centrifugation at 40,000 x g at 4°C. The membrane pellet was solubilised in 5 mL 
TBS containing 1% (v/v) NP-40 plus protease and phosphatase inhibitor cocktails 
and incubated on ice for 1 hour. After centrifugation at 20,000 x g for 20 min at 
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4°C, the supernatant was diluted 1:1 in TBS, and GPR35-HA was 
immunoprecipitated using anti-HA affinity matrix (Roche). The sample was 
incubated with 100 μL affinity matrix suspension with rotation overnight at 4°C. 
After extensive washing with TBS containing 0.5% (v/v) NP-40 followed by a final 
wash with TBS containing 500 mM NaCl, GPR35-HA was eluted from the matrix by 
adding 100 μL Laemmli buffer. The sample was resolved by SDS-PAGE on 10% Bis-
Tris acrylamide gels. Gels were exposed to X-ray film overnight at − 80°C. 
GPR35-HA bands were excised by overlaying the exposed film, and the gel pieces 
were washed 3 x 15 min with 100 mM triethylammonium bicarbonate (TEAB). 
Disulfide bonds were reduced and alkylated by incubation with 10 mM DTT in 50 
mm TEAB at 60°C for 30 min followed by 100 mM iodoacetamide in 50 mm TEAB 
at room temperature for 30 min protected from light. Gel slices were 
dehydrated by washing 3 x 15 min in 50 mM TEAB with 50% (v/v) acetonitrile and 
1 x 15 min in 100% acetonitrile, then resuspended in 50 mM TEAB with 10% (v/v) 
acetonitrile and incubated overnight at 37°C with 1 μg sequencing grade trypsin. 
The resulting tryptic peptides were extracted by vortexing three times with 
50 mM TEAB with 50% (v/v) acetonitrile and pooling the washes. Peptides were 
dried and resuspended in 30 μL 0.1% (v/v) trifluoroacetic acid and the pH 
adjusted to <2 with 1% (v/v) trifluoroacetic acid. 
2.8.2 Mass spectrometry 
Mass spectrometry was carried out by Dr. Andrew Bottrill at the University of 
Leicester Proteomics Facility. Samples were analysed as described previously 
(Butcher et al., 2014). LC-MS/MS was carried out using an LTQ Orbitrap mass 
spectrometer (Thermo Fisher Scientific). A reverse-phase trapping column 
(0.3 mm inner diameter x 1 mm) containing 5 μm C18 300 Å Acclaim PepMap 
medium (Dionex) was loaded with the tryptic peptides at high flow rate. 
Peptides were eluted through a reverse phase capillary column (75 μm inner 
diameter x 150 mm) containing Symmetry C18 100 Å medium (Waters) that was 
self-packed using a high pressure packing device (Proxeon Biosystems) (Butcher 
et al., 2014). 
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2.8.3 Mass spectrometry data analysis 
Spectra were searched against the UniProtKB/Swiss-Prot database using Mascot 
software (Matrix Science Ltd.) with peptide tolerance set to 5 ppm and the 
MS/MS tolerance set to 0.6 Da. Fixed modifications were set as 
carbamidomethylcysteine with variable modifications of phosphoserine, 
phosphothreonine, phosphotyrosine, and oxidized methionine. The enzyme was 
set to trypsin/Pro, and up to two missed cleavages were allowed. Spectra of 
phosphorylated peptides were manually inspected to verify phosphorylated 
residues using Scaffold software (Proteome Software). 
2.9 Experimental animals 
2.9.1 Maintenance of experimental animals 
Animals were housed under 12 hour light/dark cycles (0700–1900 light, 1900–
0700 dark) at ambient temperature and were maintained on normal chow (Rat 
and Mouse No. 1 maintenance diet, Special Diet Services). All animals used for 
experimental procedures were adult males. All procedures were conducted in 
accordance with the Animals (Scientific Procedures) Act 1986 under project 
licence 60/4286, held by Dr. Delyth Graham (University of Glasgow). 
2.9.2 GPR35 knockout (KO) mouse 
2.9.2.1 Breeding 
A colony of GPR35 KO mice was established at the University of Glasgow in 2014. 
Animals were obtained from the Genomics Institute of the Novartis Research 
Foundation, San Diego. An inbred colony of homozygous (HO) KO animals was 
maintained to supply female HO KO breeders. F1 hemizygous (HE) offspring were 
generated by breeding HO KO females with C57BL/6 males (Charles River). HO 
wild type (WT) and KO littermates (F2 offspring) were generated by breeding F1 
HE males with F1 HE females. All experimental procedures were carried out on 
male F2 HO littermates. 
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2.9.2.2 Genotyping 
Genotypes were determined by end-point PCR on genomic DNA extracted from 
ear notches. DNA was extracted using the DNeasy® Blood and Tissue Kit 
(QIAGEN) as per the manufacturer’s instructions. Briefly, tissue was digested 
with proteinase K overnight at 56°C, lysed by the addition of lysis buffer and 
passed through a DNeasy Mini spin column by centrifuging at 6000 x g for 1 min. 
The column was washed once with a guanidine hydrochloride-containing buffer 
and once with an ethanol-containing buffer. DNA was eluted in 50 μL 
nuclease-free water. Fragments of wild type mGPR35 and the knockout 
construct were amplified by PCR using the following primers: 
mGPR35 Forward: 
5’ ATCGCATGCACCAGTGGACAGAGAC 3’ 
Neo Forward: 
5’ GACGAGTTCTTCTGAGGGGATCGATC 3’ 
mGPR35 Reverse: 
5’ GGTCCACAGCAATGGCAGTGACCAG 3’ 
 
20 μL PCR reactions were set up using the following components: 
 
- 1 x HotStarTaq® PCR Buffer (QIAGEN) (contains 1.5 mM MgCl2) 
- 2 mM MgCl2 (3.5 mM total) 
- 1.6 mM (0.4 mM each) dNTP mix 
- 0.3 μM each primer 
- 50 ng genomic DNA 
- 2.5 units HotStarTaq DNA Polymerase (QIAGEN) 
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Reaction mixtures were subjected to thermal cycling using the following 
conditions: 
1. Preheating  94°C  15 min 
2. Denaturing  94°C  30 sec 
3. Annealing  60°C  30 sec 
4. Extension  72°C  45 sec 
5. Repeat steps 2–4 (x 34) 
6. Final extension 72°C  5 min 
7. Hold   4°C  ∞ 
The presence of the WT and KO PCR products was assessed by agarose gel 
electrophoresis (section 2.3.7). 
2.9.3 Stroke-prone spontaneously hypertensive rat (SHRSP) 
An inbred colony of SHRSP, originally obtained from the Department of Anatomy 
and Cell Biology at the University of Michigan, has been maintained in-house at 
the University of Glasgow since 1991 (Dominiczak et al., 1993). 
2.10 In vivo procedures 
2.10.1 Experimental design 
Group numbers for blood pressure measurements were based on historical 
systolic blood pressure recordings in male SHRSP rats of 196.6 ± 10.2 (standard 
deviation) mmHg. For 80% power and α = 0.05, 8 animals per group were 
required to detect a biologically meaningful difference of 15 mmHg. For the Ang 
II infusion model, the blood pressure difference was expected to be 
approximately 20 mmHg and so the group size was reduced to 6. Animals were 
randomly allocated into treatment groups by an independent observer and the 
experimenter was blinded to treatments until after analysis was performed. If 
telemetry readings were outside of the physiological blood pressure range (due 
to technical error such as displacement of the probe) at any time over the 
duration of the study period, the entire dataset for that animal was excluded 
prior to unblinding. 
73 
 
2.10.2 Surgical procedures 
Recovery surgery was carried out under aseptic conditions, and animals were 
anaesthetised with 1 L/min 2.5% isoflurane and 1.5 L/min medical O2 throughout 
the procedure. Fur was removed from the incision area using clippers, and the 
skin was sterilised with Betadine povidone-iodine solution or Vetasept 
chlorhexidine solution. Following recovery surgery, animals were weighed and 
recovered in a 32°C hot box until fully conscious, and monitored daily by 
weighing to assess post-operative health. 
2.10.3 Blood pressure monitoring by telemetry 
2.10.3.1 Telemetry probe implantation in the mouse 
PhysioTel® PA-C10 pressure transmitters (DSI) were surgically implanted into 12–
13-week old mice, with the transmitter positioned subcutaneously on the right 
shoulder and the catheter inserted into the left carotid artery, as previously 
described (Huetteman and Bogie, 2009). The transmitters were calibrated to 
verify accuracy to within 3 mmHg before implantation. With the animal in a 
prone position, a 10 mm incision was made on the right shoulder and a 
subcutaneous pocket made towards the flank by blunt dissection. The 
transmitter was positioned in the pocket and the animal placed in a supine 
position to make the second incision. A vertical 15 mm midline incision was 
made in the neck, and a Luer-Lock needle was used to tunnel the catheter under 
the skin towards the incision. The remainder of the procedure was performed 
under 16x magnification. The mandibular glands were separated to expose the 
trachea, and the left carotid artery was isolated by blunt dissection. The artery 
was permanently ligated with 5-0 Mersilk suture (Ethicon) at the bifurcation of 
the internal and external branches. The suture was retracted towards the head 
of the mouse, and a second length of suture was placed approximately 10 mm 
below the first and retracted towards the tail to occlude blood flow. A third 
suture was positioned between the first and second and tied loosely, to be 
secured around the catheter after insertion. A 30-gauge needle was bent to 
approximately 100° with the bevel facing up, and used to puncture the ventral 
wall of the artery. Right-angled forceps were used to lift the wall at the 
puncture site in order to insert the catheter. Once inserted, the middle suture 
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was tightened around the artery and catheter, and the tension on the caudal 
suture was released to allow advancement of the catheter towards the 
transverse aorta. The caudal suture was tied around the artery and catheter, 
and finally the cranial suture was released and used to tie a final knot around 
the catheter at the point of ligation. Both incisions were sutured using 4-0 
coated Vicryl absorbable suture (Ethicon) and the animal administered with 
analgesic (5 mg/kg carprofen) by subcutaneous injection. 
2.10.3.2 Telemetry probe implantation in the rat 
PhysioTel PA-C40 pressure transmitters (DSI) were surgically implanted into 8–
9-week old rats, with the transmitter positioned intraperitoneally and the 
catheter inserted into the abdominal aorta, as previously described (Huetteman 
and Bogie, 2009). The transmitters were calibrated to verify accuracy to within 
3 mmHg before implantation. A vertical 30 mm midline incision was made in the 
abdomen, and the intestines positioned outside the peritoneum on sterile, PBS-
soaked gauze. The remainder of the procedure was performed under 10x 
magnification. A length of 5-0 Mersilk suture was positioned under the aorta 
approximately 20 mm above the common iliac bifurcation, and retracted 
towards the head to occlude blood flow. A 30-gauge needle was bent to 
approximately 100° with the bevel facing up, and used to puncture the ventral 
wall of the artery. Right-angled forceps were used to lift the wall at the 
puncture site in order to insert the catheter and advance it towards the heart. 
The insertion site was sealed using hemostatic gauze and Vetbond tissue 
adhesive. The intestines were replaced into the peritoneum and the transmitter 
was secured by suturing to the abdominal wall whilst closing the muscle layer 
using non-absorbable 4-0 Ethilon suture (Ethicon). The skin was sutured with 4-0 
coated Vicryl, and the animal was administered with analgesic (5 mg/kg 
carprofen) by subcutaneous injection. 
2.10.3.3 Data recording and analysis 
Following a 7-day recovery period, transmitters were remotely switched on and 
measurements of systolic blood pressure, diastolic blood pressure, heart rate 
and activity (an arbitrary measure of locomotion) were recorded using the 
Dataquest IV Telemetry System (DSI). Measurements were recorded every 5 min 
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for the duration of the study. These were used to calculate daily and nightly 
means based on the 12-hour light/dark cycle in order to show diurnal variation, 
or converted into 24-hour means. 
2.10.4 Blood pressure monitoring by tail cuff plethysmography 
Non-invasive tail cuff plethysmography was used to measure systolic blood 
pressure in 6–8-week old SHRSP. Rats were trained by taking several mock 
measurements before commencing the study. Rats were placed at 30°C for 
15 min prior to the procedure, and the procedure was carried out on a heat mat 
to encourage vasodilation. Rats were restrained by hand to minimise distress, 
and an inflatable cuff with a built-in piezoceramic transducer was positioned at 
the base of the tail. Approximately 10 readings were taken in each session. 
Outlying readings were discarded and the mean of the remaining readings was 
taken. 
2.10.5 Echocardiography 
M-mode echocardiography was used to assess cardiac function in mice, as 
described by Ram et al. (Ram et al., 2011). M-mode echocardiographic images 
were obtained using a Siemens Acuson Sequoia 512 ultrasound unit with an 18LS 
probe set at a frequency of 14 MHz. Animals were anaesthetised with 1 L/min 
1.5% isoflurane and 1.5 L/min medical O2 throughout the procedure. Animals 
were placed in a supine position on a heat mat and fur was removed from the 
chest area using clippers. Ultrasound gel was applied to the probe and M-mode 
images obtained on the longitudinal axis just above the papillary muscle. Left 
ventricular dimensions during systole and diastole were measured using ImageJ 
software, as shown in Figure 2-1. Measurements were taken from nine separate 
cardiac cycles over three different images. Fractional shortening (FS), end 
systolic volume (ESV), end diastolic volume (EDV) and ejection fraction (EF) 
were calculated using the following equations: 
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FS (%) = ((LVEDD – LVESD)/LVEDD) x 100 
ESV (mL) = (7/(2.4 + LVESD)) x LVESD3 
EDV (mL) = (7/(2.4 + LVEDD)) x LVEDD3 
EF (%) = ((EDV – ESV)/EDV) x 100 
Where LVEDD = left ventricular end diastolic dimension and LVESD = left 
ventricular end systolic dimension. ESV and EDV were derived using the 
Teichholz method (Teichholz et al., 1976). 
 
Figure 2-1 Measuring LV dimensions using M-mode echocardiography (A) Longitudinal 
B-mode image showing visible heart regions (LV = left ventricle; LA = left atrium; Ao = aorta; PM = 
papillary muscle) and the axis used to generate 1-dimensional M-mode images. (B) M-mode image 
showing dimensions measured (IVSd = intraventricular septum in diastole; IVSs = intraventricular 
septum in systole; LVEDD = left ventricular end diastolic dimension; LVESD = left ventricular end 
systolic dimension; LVFWd = left ventricular free wall in diastole; LVFWs = left ventricular free wall 
in systole.) 
2.10.6 Subcutaneous infusion of Ang II 
Ang II was administered by subcutaneous infusion using ALZET® micro-osmotic 
pumps (Model 1002, Charles River). Treatment commenced at 13–14 weeks of 
age (seven days after telemetry implantation) and continued for two weeks until 
sacrifice. Angiotensin II human (Sigma-Aldrich) was dissolved in water and 
sterilised by passing through a 0.2 μm filter. Pumps were filled with the 
appropriate concentration of Ang II to deliver a dose of 400 ng/kg/min 
(24 μg/kg/hour) at a flow rate of 0.25 μL/hour. After filling as per the 
manufacturer’s instructions, pumps were primed in sterile saline overnight at 
37°C. Pumps were subcutaneously implanted on the left flank (the opposite side 
to telemetry apparatus) under aseptic conditions. A 10 mm incision was made 
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below the left shoulder and a large subcutaneous pocket made towards the flank 
by blunt dissection. The pump was inserted into the pocket, then the incision 
was sutured with 4-0 coated Vicryl and the animal administered with analgesic 
(5 mg/kg carprofen) by subcutaneous injection. 
2.10.7 Oral administration of amlexanox 
Amlexanox was dissolved in DMSO to a stock concentration of 20 mM. Daily 
dosing commenced at six weeks of age and continued for six weeks until 
sacrifice. Treated animals received a daily dose of 2.5 mg/kg/day in highly 
palatable egg custard baby food. Control animals received an equivalent volume 
of DMSO in egg custard baby food. 
2.11 Wire myography 
2.11.1 Isolation and mounting 
Aortas and mesenteric arteries were isolated from experimental animals for use 
in wire myography. Aortas and mesenteries were collected at sacrifice under 
terminal anaesthesia and placed immediately into ice-cold PSS. Fat and 
connective tissue was removed and 2 mm lengths of vessel were dissected in PSS 
under a dissecting microscope. For mesenteric arteries, only second or third 
order vessels with a diameter <200 μm were used. Vessels were mounted onto 
40 μm (aortas) or 25 μm (mesenteric arteries) wires on a four-channel multi 
myograph system (DMT), as originally described by Mulvany and Halpern 
(Mulvany and Halpern, 1977). Following mounting, vessels were equilibrated in 
PSS at 37°C for 30 min. 
2.11.2 Normalisation 
The transmural pressure of mesenteric arteries was normalised using Laplace’s 
law (T = ri x P, where T = wall tension, ri = internal radius and P = transmural 
pressure), using successive stretches of the vessel to create a standard curve of 
internal circumference against wall tension. The internal circumference was 
adjusted to 90% of that required to produce a transmural pressure of 100 mmHg 
or 13.3 kPa, thereby putting the vessel under passive, but not active, tension 
(Angus and Wright, 2000). Aortas were not normalised, but placed under a fixed 
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tension of 1 g (9.81 mN). Following the normalisation process, vessels were 
allowed to equilibrate at 37°C for a further 60 min. 
2.11.3 Wake-up protocol 
To stimulate maximal contraction, vessels were subjected to a K+-mediated 
‘wake-up’ protocol prior to stimulating with the chosen ligand. After draining 
the PSS, KPSS was added to the bath and wall tension recorded for at least 1 min 
before washing three times with PSS and allowing to return to baseline tension, 
then repeating the process. Following wake-up, vessels were equilibrated in PSS 
at 37°C for 30 min. 
2.11.4 Data recording and analysis 
After normalisation and wake-up, vessels were treated with the appropriate 
ligands by adding cumulatively to the bath, allowing the wall tension to plateau 
for 2−3 min between each addition. Wall tension was recorded in mN using 
LabChart software (ADInstruments). Traces were analysed using LabChart Reader 
software (ADInstruments), using the maximum peak or minimum trough after 
each addition and subtracting the mean baseline reading to obtain change in 
force (ΔF) in mN. For mesenteric arteries, change in active effective pressure 
(AEP) was calculated using the following equation: 
ΔAEP (kPa) = (ΔF/w) / (ID1/2) x 100 
Where F = force (mN), w = wall length (mm) and ID1 = working internal diameter 
after normalisation (μm). For aortas, contraction was plotted as percentage of 
the maximum response to K+. 
2.12 Histology 
2.12.1 Fixation 
Tissues were harvested at sacrifice under terminal anaesthesia and placed 
immediately into 10% (v/v) formalin for 24 hours. Rat tissues were sliced 
transversely after 24 hours and placed back into 10% formalin for a further 
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24 hours. Following fixation, tissues were washed in PBS and stored in 50% (v/v) 
ethanol at 4°C until use. 
2.12.2 Paraffin embedding and sectioning 
Tissues were processed for paraffin embedding using a ShandonTM ExcelsiorTM 
tissue processor (Thermo Scientific), then embedded in paraffin wax. All tissues 
were embedded on the transverse axis. 3–5 μm sections were cut on a 
microtome and baked onto silane-treated microscope slides at 50°C overnight. 
2.12.3 Deparaffinisation and dehydration 
Prior to staining, sections were deparaffinised in Histoclear for 2 x 7 min, then 
rehydrated by incubating for 7 min each in 100% ethanol, 95% (v/v) ethanol and 
70% (v/v) ethanol. 
2.12.4 Wheat-germ agglutinin (WGA) staining 
WGA was used to stain sialic acid and N-acetylglucosaminyl residues in 
cardiomyocyte cell membranes in order to measure cardiomyocyte hypertrophy 
(Huet and Garrido, 1972). Following deparaffinisation and dehydration, 5 μM 
heart (left ventricle + septum) sections were washed in running tap water for 
5 min. Antigen retrieval was performed by microwaving in pre-heated 10 mM 
sodium citrate solution (pH 6) with 0.1% (v/v) Tween-20 for 10 min. Following 
antigen retrieval, sections were cooled to room temperature before blocking in 
1% (v/v) goat serum + 5% (w/v) BSA for 1 hour at room temperature. Sections 
were then incubated with 10 μg/mL WGA conjugated to Alexa Fluor 555 
(Molecular Probes) (diluted in blocking solution) for 1 hour at room temperature 
protected from light. Sections were washed for 2 x 5 min in PBS protected from 
light, then mounted with ProLong® Gold anti-fade reagent with DAPI (Molecular 
Probes) and dried overnight at room temperature before imaging. DAPI and 
Alexa Fluor 555 images were taken with a x40 objective on an Olympus BX40 
microscope using a QImaging QICAM Fast 1394 camera. The experimenter was 
blinded to treatment groups during imaging and analysis. Four fields of view 
showing cardiomyocytes in transverse orientation were taken from each section. 
Cardiomyocyte width (the longest axis of a transversely-orientated 
cardiomyocyte) was measured using ImageJ software. Approximately 50 cells 
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from each field of view were measured, using a grid system to minimise bias, 
meaning a mean cardiomyocyte width for each animal was calculated from >200 
measurements. 
2.12.5 Picro-sirius red staining 
Picro-sirius red was used to stain collagen fibres in heart and kidney tissue as a 
measure of cardiac and renal fibrosis. Following deparaffinisation and 
dehydration, 3 μm heart (left ventricle + septum) and kidney sections were 
incubated for 5 min in distilled water. Nuclei were stained by incubating in 
Weigert’s hematoxylin (Sigma-Aldrich) for 10 min, then sections were washed in 
running tap water for 10 min. Sections were stained with picro-sirius red (0.1% 
(w/v) sirius red in saturated picric acid solution (both Sigma-Aldrich)) for 90 min. 
Sections were washed 2 x 3 min in acidified water (0.01 N HCl), then vigorously 
shaken to remove water before dehydrating in 100% ethanol for 3 min. Sections 
were cleared in Histoclear for 2 x 7 min, mounted in DPX mountant and dried 
overnight at room temperature. Images were taken with a x40 objective on an 
Olympus BX41 microscope using a QImaging Go-3 camera. The experimenter was 
blinded to treatment groups during imaging and analysis. For hearts, six fields of 
view were taken. For kidneys, eight fields of view (four interstitial and four 
perivascular) were taken. Fibrosis was quantified by measuring the proportion of 
red pixels using Image-Pro Plus software (Media Cybernetics). 
2.12.6 Hematoxylin and eosin (H&E) staining 
Hematoxylin and eosin was used to stain nuclei and cytoplasm in order to 
visualise the gross morphology of blood vessels. Following deparaffinisation and 
dehydration, 5 μm aorta or carotid artery sections were incubated for 5 min in 
distilled water. Sections were stained with Harris hematoxylin (CellPath) for 
2 min, then washed in running tap water for 5 min. Sections were incubated in 
70% (v/v) ethanol for 1 min, then stained with Eosin Y (CellPath) for 3 min. 
Sections were washed in 95% (v/v) ethanol for 2 x 30 sec, then dehydrated in 
100% ethanol for 2 x 5 min. Sections were cleared in Histoclear for 2 x 5 min, 
mounted in DPX mountant and dried overnight at room temperature. Images 
showing the whole vessel were taken with a x4 (aortas) or x10 (carotid arteries) 
objective on an Olympus BX41 microscope using a QImaging Go-3 camera. The 
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experimenter was blinded to treatment groups during imaging and analysis. 
Total and lumen areas were measured using ImageJ software and used to 
calculate medial area (total area − lumen area) and wall-to-lumen ratio (total 
area − lumen area/lumen area). 
2.13 Gene expression analysis 
2.13.1 Tissue harvest and lysis 
2.13.1.1 Heart and kidney tissue lysis 
Animal tissues were snap frozen in liquid nitrogen at sacrifice and stored at 
− 80°C. To lyse, 30–50 mg of tissue was transferred to an RNase-free 
microcentrifuge tube along with 700 μL QIAzol® (QIAGEN) and two 3 mm 
tungsten carbide beads. Tissues were homogenised for 2 x 1 min in a QIAGEN 
TissueLyser. 
2.13.1.2 Aorta tissue lysis 
The entire thoracic aorta was snap frozen in liquid nitrogen at sacrifice and 
stored at − 80°C. For disruption, the aorta was cooled in liquid nitrogen and 
crushed to a fine powder using a mortar and pestle cooled on dry ice. The 
resulting powder was lysed by the addition of QIAGEN RTL buffer containing 1% 
(v/v) β-mercaptoethanol, and homogenised using a QIAshredder spin column 
(QIAGEN) by applying to the column and subjecting to centrifugation at 
16,000 x g for 2 min. 
2.13.2 RNA extraction 
2.13.2.1 RNA extraction from heart and kidney tissue 
RNA extraction was performed immediately following tissue lysis using the 
miRNeasy® Mini Kit (QIAGEN) as per the manufacturer’s instructions. Briefly, 
homogenate was mixed with chloroform and subjected to centrifugation at 
12,000 x g for 15 min at 4°C. The aqueous phase containing RNA was collected 
and mixed with 100% ethanol, then applied to an RNeasy Mini spin column and 
subjected to centrifugation at 8000 x g for 15 sec at room temperature. The 
flow-through was discarded and the column was washed with guanidine-
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containing stringent wash buffer. On-column DNA digestion was performed using 
the RNase-free DNase Set (QIAGEN) as per the manufacturer’s instructions. The 
column was then washed again with stringent wash buffer, then washed twice 
with mild wash buffer, centrifuging for 2 min after the final wash to remove 
residual ethanol. RNA was eluted in 30 μL nuclease-free water. 
2.13.2.2 RNA extraction from aorta tissue 
RNA extraction was performed immediately following tissue lysis using the 
RNeasy Fibrous Tissue Mini Kit (QIAGEN) as per the manufacturer’s instructions. 
Briefly, homogenate was incubated with proteinase K (supplied in kit at unknown 
concentration) at 55°C for 10 min and cleared by centrifugation at 10 000 x g for 
3 min. The supernatant was applied to an RNeasy Mini spin column and 
subjected to DNase digestion and washing as detailed in section 2.13.2.1. 
2.13.2.3 Determination of RNA concentration 
RNA concentration was determined by measuring absorbance at 260 nm using a 
NanoDrop spectrophotometer. RNA purity was assessed using the A230/A260 and 
A260/A280 ratios, with ratios of 2–2.2 considered pure. RNA was stored at – 80°C 
until use. 
2.13.3 Reverse Transcription (RT) 
1 μg of RNA was reverse transcribed to cDNA using TaqMan® Reverse 
Transcription Reagents (Life Technologies). 20 μL reactions were set up in 
96-well PCR plates using the following components: 
- 1 x RT Buffer  
- 5.5 mM MgCl2 
- 2 mM (0.5 mM each) dNTP mix 
- 2.5 μM Random hexamers 
- 8 units RNase Inhibitor 
- 25 units MultiScribeTM RT 
- 200–1000 ng RNA 
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Reaction mixtures were incubated in a thermal cycler using the following 
conditions: 
1. Annealing  25°C  10 min 
2. Extension  48°C  30 min 
3. Inactivation  95°C  5 min 
4. 4°C  ∞ 
cDNA was stored at − 20°C until use. 
2.13.4 Quantitative Real-Time PCR (qRT-PCR) 
qRT-PCR was performed using Applied Biosystems TaqMan® Gene Expression 
Assays (Life Technologies) containing a pair of unlabelled PCR primers and a 
TaqMan probe which binds downstream of the forward primer and carries a 
fluorescent label on the 5’ end and a minor groove binder and non-fluorescent 
quencher on the 3’ end. The assays used are detailed in Table 2-5. 10 μL 
reactions were set up in triplicate in 384-well MicroAmp® Optical PCR plates 
(Life Technologies) using the following components: 
- 1 x TaqMan Universal Master Mix II, no UNG (Life Technologies) 
- 1 x TaqMan Assay 
- 100 ng cDNA (2 μL RT product) 
Table 2-5 Taqman gene expression assays 
Gene Assay Label 
Gpr35 Mm01973686_s1 FAM 
Agtr1a Mm00616371_m1 FAM 
Ppib Mm00478295_m1 FAM 
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Plates were read on a QuantStudioTM Flex Real-Time PCR System (Thermo Fisher 
Scientific) using the fluorescence channel appropriate to the probe. Reaction 
mixtures were subjected to thermal cycling using the following conditions: 
1. Preheating  95°C  10 min 
2. Denaturing  95°C  15 sec 
3. Annealing  60°C  1 min 
4. Repeat steps 2–3 (x40) 
Comparative cycle threshold (CT) values were obtained using QuantStudio Flex 
software (Thermo Fisher Scientific). 
2.13.5 qRT-PCR data analysis 
CT values were compared with a suitable housekeeper gene (run in parallel) to 
generate ΔCT values (ΔCT = CT of housekeeper − CT of gene of interest). These 
were analysed using the 2- ΔΔCT method (Livak and Schmittgen, 2001) in which 
ΔCT values are compared with that of an appropriate control to generate ΔΔCT 
values and relative quantification (RQ) values (RQ = 2- ΔΔCT). Standard errors are 
expressed as RQmin (RQmin = 2- (ΔΔCT + SEM)) and RQmax (RQmax = 2- (ΔΔCT - SEM)). 
2.14 Statistical analysis 
Statistical analyses were carried out using Graphpad Prism software. Data were 
assumed to be normally distributed, and were therefore compared using 
parametric tests; either two-tailed unpaired student’s t test (for two groups) or 
one-way analysis of variance (ANOVA; for three or more groups). For 
densitometry measurements (phosphorylation studies), normal distribution of 
datasets was verified prior to ANOVA using the Shapiro-Wilk test (performed 
using Microsoft Excel). Tukey’s post-test was used for multiple comparisons. 
Hemodynamic measurements made by telemetry were compared using two-way 
repeated measures ANOVA (basal GPR35 knockout study and amlexanox SHRSP 
study) or student’s t test on the slope of the linear regression calculated for 
individual animals (Ang II infusion study).
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Chapter 3 G protein- and β-arrestin-mediated 
responses to GPR35 stimulation 
3.1 Introduction 
As discussed in section 1.2, any one GPCR can couple to multiple cytoplasmic 
mediators that each feed into different signalling pathways. As a result of this 
heterogeneity, GPCR signal transduction is regulated on several different levels, 
which must be well understood if a receptor is to be pursued as a therapeutic 
target. Determining the intracellular signalling mechanisms involved in GPR35 
function will be key to elucidating its role in the cardiovascular system and to 
assessing its potential as a therapeutic target. 
Agonist-dependent phosphorylation of receptor intracellular domains is an 
important component of GPCR signalling that is now known to have profound 
effects on the desensitisation of G protein signalling, the internalisation and 
recycling of the receptor and the capacity of the receptor to promote G protein-
independent signalling (section 1.2) (Innamorati et al., 1998, Ren et al., 2005, 
Nobles et al., 2011). Phosphorylation of GPCRs at serine and threonine residues 
can potentially occur on any part of the intracellular domain, but receptors are 
most commonly phosphorylated on the third intracellular loop and/or the 
C-terminal tail (Tobin et al., 2008). Furthermore, the precise locations of the 
phosphorylated residues can influence downstream signalling and receptor 
function (Nobles et al., 2011, Prihandoko et al., 2016). Very little is known 
about the capacity of GPR35 to undergo agonist-dependent phosphorylation and 
what effect this might have on signalling responses such as the recruitment of 
β-arrestin and subsequent receptor internalisation. This chapter describes 
investigations into the agonist-dependent phosphorylation of GPR35 and how this 
defines the outcomes of GPR35 activation. The subsequent generation of a 
phosphorylation-deficient mutant (PDM) form of the receptor enabled further 
evaluation of the contribution of agonist-dependent phosphorylation to 
downstream responses to GPR35 activation. 
Besides phosphorylation, the coupling specificity of a particular GPCR clearly has 
a major impact on its downstream cellular effects. Selective inhibition or 
deletion of individual G proteins has therefore proven valuable in elucidating the 
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pathways and functional consequences associated with individual GPCRs. 
However, in the absence of selective pharmacological inhibitors, genetic 
manipulation is sometimes the only option, and this can be difficult and costly 
when relying on animal models. Recently, however, HEK293-derived cell lines 
that are CRISPR-edited to eliminate expression of individual G proteins and 
arrestins (generated by Asuka Inoue, Tohoku University, Japan) have been made 
available to the GPCR research community. These cell lines provide a novel, 
practical, cell-based model with which to address questions about GPCR 
signalling and functional selectivity, and were used in the present study to 
investigate the contributions of Gα12/13 and β-arrestin-1/2 to GPR35-mediated 
cellular responses. 
3.1.1 Aims 
The aims of this chapter were to: 
- Determine whether GPR35 undergoes agonist-dependent phosphorylation 
- Assess species- and agonist-specific differences in this phosphorylation 
- Determine the region(s) and specific sites at which this phosphorylation 
occurs 
- Assess the contributions of these phosphorylation sites to G12/13- and 
β-arrestin-mediated GPR35 signalling 
- Assess the contributions of phosphorylation, G12/13 and β-arrestin-1/2 to 
GPR35-mediated cellular responses. 
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3.2 Results 
3.2.1 Investigating agonist-dependent phosphorylation of 
GPR35 
Butcher et al. have reported on radiolabelling- and mass spectrometry-based 
methods for identifying phosphorylated residues on GPCRs, which they have 
successfully used to identify phosphorylation sites for a number of GPCRs 
(Butcher et al., 2014, Butcher et al., 2011a, Butcher et al., 2011b). These 
techniques require affinity purification of the receptor from cell lysates using a 
C-terminal haemagglutinin (HA) epitope tag. In order to utilise these methods to 
study agonist-dependent phosphorylation of GPR35, it was therefore necessary 
to generate an HA-tagged GPR35 construct and stably transfect it into HEK293 
cells in preparation for subsequent studies. To investigate potential species 
differences in GPR35 phosphorylation, these studies were performed with 
human, mouse and rat GPR35. HA-tagged human (h), mouse (m) and rat (r) 
GPR35 constructs (hGPR35-HA, mGPR35-HA and rGPR35-HA) were generated and 
stably transfected under a doxycycline-inducible promoter into a HEK293-
derived cell line. Doxycycline-inducible, homogeneous cell-surface expression of 
the tagged receptors was confirmed by immunocytochemistry (Figure 3-1). 
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Figure 3-1 GPR35-HA stable cell lines express GPR35-HA at the cell surface Anti-HA 
immunocytochemistry showing (A) hGPR35-HA, (B) mGPR35-HA and (C) rGPR35-HA expression 
at the cell surface. Expression of the constructs was induced by incubating with doxycycline (Dox) 
overnight at 37°C. Scale bar = 20 μm. 
Synthetic ligands of GPR35 have varying potencies and efficacies, which 
sometimes differ between the human, mouse and rat orthologues (Table 1-3 and 
Table 1-4). To determine potential species- and agonist-specific differences in 
phosphorylation level, [32P]-orthophosphate labelling was used to assess GPR35 
phosphorylation in response to a range of synthetic ligands with various 
pharmacological properties and species selectivities (Figure 3-2 A). hGPR35-HA, 
mGPR35-HA and rGPR35-HA all underwent agonist-induced phosphorylation in 
line with predictions based on reported pharmacological findings (Figure 3-2 B-
D). Notably, zaprinast induced a strong phosphorylation of all three species 
orthologues, while pre-treatment with the antagonist CID-2745687 abolished 
zaprinast-induced phosphorylation in the human orthologue only (Figure 3-2 B), 
supporting previous reports that this antagonist is highly human-selective 
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(Jenkins et al., 2012). Pamoic acid, doxantrazole and amlexanox induced a 
significantly lower level of phosphorylation at the human orthologue than 
zaprinast (Figure 3-2 B), in line with reports that these compounds act as partial 
agonists at hGPR35 in β-arrestin recruitment assays (Jenkins et al., 2012, 
MacKenzie et al., 2014). Pamoic acid, which is reported to be a human-selective 
partial agonist, also displayed selectivity towards hGPR35 in this assay, as it did 
not induce any phosphorylation of the mouse or rat orthologues (Figure 3-2 C-D) 
(Jenkins et al., 2012). 
As well as demonstrating ligand and species differences in phosphorylation, 
these hGPR35 autoradiographs and immunoblots demonstrate a previously 
unknown feature of GPR35. While the rodent orthologues both resolved in SDS-
PAGE as an apparently single polypeptide with a molecular mass of 
approximately 50 kDa (Figure 3-2 C-D), hGPR35 appeared to resolve as two 
separate polypeptides with molecular masses of approximately 40 and 60 kDa 
(Figure 3-2 A). All of the orthologues resolved at a higher molecular mass than 
the native mass of 34 kDa. Interestingly, the higher molecular mass human 
GPR35 variant appeared to be less abundant in the immunoblot, but there was 
no difference in intensity in the autoradiograph. This suggests that the higher 
molecular mass species is more efficiently phosphorylated than the lower 
molecular mass counterpart. 
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Figure 3-2 Human, mouse and rat GPR35 undergo agonist-dependent phosphorylation 
(A) Ligands tested and their notable pharmacological properties. (B, C, D) Representative 
autoradiographs (top panels) and anti-HA immunoblots (IB) (bottom panels) showing [32P] 
incorporation into (B) hGPR35-HA, (C) mGPR35-HA or (D) rGPR35-HA immunoprecipitates (IP). 
Cells were stimulated with the indicated agonists for 5 min prior to lysis. Antagonist-treated cells 
(CID and Zap+CID) were preincubated with antagonist for 15 min prior to stimulation with agonist. 
Quantification shows mean fold change of [32P] incorporation over vehicle-treated cells, measured 
by densitometric analysis of autoradiographs from n = 3 independent experiments +/- SEM. 
*p<0.05, **p<0.01, ***p<0.001 compared with vehicle; #p<0.05, ##p<0.01, ###p <0.001 compared 
with zaprinast in one-way ANOVA with Tukey’s multiple comparisons post-test. (Dox = doxycycline; 
Zap = 100 μM zaprinast; CID = 10 μM CID-2745687; Pam = 100 nM pamoic acid; Dxn = 100 μM 
doxantrazole; Aml = 100 μM amlexanox.) 
GPR35 has previously been reported to have different glycosylation states 
(Jenkins et al., 2011). To determine whether the different molecular mass bands 
observed in the phospholabelling experiments represented differentially 
glycosylated GPR35 species, human and mouse GPR35-HA were treated with 
N-glycosidase F and resolved by SDS-PAGE (Figure 3-3). Treatment with the 
glycosidase caused a decrease in molecular mass of both orthologues to match 
the predicted native mass of 34 kDa, indicating that mGPR35-HA is processed to 
make one predominant glycosylated species, whereas hGPR35-HA is processed 
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into two differentially glycosylated forms. The more heavily N-glycosylated 
hGPR35 species was less abundant, but more efficiently phosphorylated (Figure 
3-2 B). 
 
Figure 3-3 Human and mouse GPR35-HA are differentially N-glycosylated Anti-HA immunoblot 
of hGPR35-HA- and mGPR35-HA-expressing cell lysates in their glycosylated states or following 
treatment with N-GF (N-GF = N-glycosidase F). 
Agonist-dependent GPCR phosphorylation, and specifically the location of the 
phosphorylated residues, has been shown to influence the signalling and 
functional outcomes of GPCR activation (Nobles et al., 2011, Prihandoko et al., 
2016). Therefore, having determined that GPR35 is phosphorylated in response 
to agonist, it was of interest to investigate the location(s) of this 
phosphorylation in order to compare GPR35 with other GPCRs. Mass 
spectrometry was performed on tryptic peptides generated from affinity-purified 
hGPR35-HA to map the precise phosphorylation sites following stimulation with 
100 μM zaprinast (Figure 3-4). Five serine and threonine phosphorylation sites 
were identified, all of which were located in the helix 8/C-terminal tail region. 
These five residues comprised all of the serine and threonine residues present in 
these regions, including one residue (S294) that is substituted for arginine in 48% 
of the population as the result of a SNP that has been associated with 
cardiovascular disease (Figure 1-2) (Sun et al., 2008). Notably, phosphorylation 
of S300 and S303, which are present in the same tryptic peptide, was observed 
both individually and in tandem, indicating that multiple sites on hGPR35 can be 
phosphorylated simultaneously. 
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Figure 3-4 LC-MS/MS identifies five phosphorylation sites in the hGPR35 C-terminal tail following zaprinast stimulation Fragmentation tables associated with 
phosphorylated peptides. All theoretical ions are shown, and those identified in the analysis are highlighted in green. Phosphorylated residues are highlighted in red. 
Peptide prob. indicates percentage probability of a correct peptide based on the discriminant score; both are generated by Scaffold software. HA = haemagglutinin.
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Serine and threonine residues present in the ICLs were included in the peptide 
coverage from the mass spectrometry analysis, but no phosphorylation of these 
sites was observed. Thus, phosphorylation of hGPR35 appears to occur 
exclusively on the C-terminal tail. To test this hypothesis, a potentially 
‘phosphorylation-deficient’ mutant (PDM) of hGPR35-HA was generated, where 
each of the five identified phosphorylation sites was mutated to alanine (Figure 
3-5 A). In order to determine whether the rodent GPR35 orthologues are also 
exclusively phosphorylated in the C-terminal tail region, a mGPR35 PDM, with all 
serine and threonine residues in the C-terminal tail mutated to alanine, was also 
generated (Figure 3-5 A). The mutant constructs were stably transfected into a 
doxycycline-inducible HEK293 cell line, and doxycycline-inducible, cell-surface 
expression of the tagged receptors was confirmed by immunocytochemistry 
(Figure 3-5 B-C). 
 
Figure 3-5 GPR35(PDM)-HA stable cell lines express GPR35(PDM)-HA at the cell surface 
(A) PDM mutagenesis strategy. Residues highlighted in grey were mutated to alanine. Residues 
marked with an asterisk are those found to be phosphorylated in LC-MS/MS. (B,C) Anti-HA 
immunocytochemistry showing (B) human and (C) mouse GPR35(PDM)-HA expression at the cell 
surface. Expression of the constructs was induced by incubating with doxycycline (Dox) overnight 
at 37°C. Scale bar = 20 μm. 
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The human and mouse GPR35 phosphorylation-deficient mutants did not undergo 
detectable phosphorylation following zaprinast stimulation (Figure 3-6). The 
amount of the human mutant protein in the immunoprecipitate was much lower 
than that of the wild type counterpart (Figure 3-6 A). This was due to reduced 
viability of the mutant-expressing cell line, which may in itself be a meaningful 
finding as it suggests phosphorylation-deficient GPR35 might confer a survival 
defect. However, there was a detectable level of the mutant protein compared 
with the uninduced (−Dox) control cells (Figure 3-5 B and Figure 3-6 A), and no 
difference in [32P] incorporation between the vehicle- and zaprinast-treated 
cells (Figure 3-6). It was therefore concluded that neither human nor mouse 
GPR35 phosphorylation-deficient mutant was phosphorylated in response to 
agonist, and that GPR35 is exclusively phosphorylated at sites within the 
C-terminal tail. 
 
Figure 3-6 Human and mouse GPR35 phosphorylation-deficient mutants do not undergo 
agonist-dependent phosphorylation Representative autoradiographs (top panels) and anti-HA 
immunoblots (bottom panels) showing [32P] incorporation into (A) human or (B) mouse wild type 
(WT) or phosphorylation-deficient mutant (PDM) GPR35-HA immunoprecipitates. Cells were 
stimulated with 100 μM zaprinast (Zap) for 5 min prior to lysis. Quantification shows mean fold 
change of [32P] incorporation over vehicle-treated cells, measured by densitometric analysis of 
autoradiographs from n = 3 independent experiments +/- SEM. **p<0.01, ***p<0.001 in one-way 
ANOVA with Tukey’s multiple comparisons post-test. (Dox = doxycycline.) 
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3.2.2 The effects of GPR35 phosphorylation on G protein and 
β-arrestin recruitment 
For many GPCRs, agonist-dependent phosphorylation within the C-terminal tail 
region causes alterations in the binding of cytoplasmic signalling proteins, most 
commonly leading to increased recruitment of β-arrestin (Innamorati et al., 
1998, Ren et al., 2005, Nobles et al., 2011). In order to determine the impact of 
phosphorylation on β-arrestin-2 recruitment to GPR35, the contribution of each 
of the individual phosphorylation sites in human GPR35 identified by mass 
spectrometry (Figure 3-4) was assessed using site-directed mutagenesis in 
combination with a BRET-based β-arrestin-2 recruitment assay (Figure 3-7). This 
assay utilises two constructs: β-arrestin-2 fused with Renilla luciferase (RLuc) as 
a BRET donor, and a GPCR with a C-terminal eYFP tag as a BRET acceptor 
(section 2.6.2). Human GPR35-eYFP BRET acceptor constructs were generated in 
which each serine or threonine phosphorylation site (Figure 3-7 A) was mutated 
to alanine either individually or simultaneously to prevent phosphorylation. 
When HEK293 cells expressing these constructs and the BRET donor 
β-arrestin-2-RLuc were stimulated with zaprinast, each mutation appeared to 
have a different impact on β-arrestin-2 recruitment, as demonstrated by 
decreases in the maximal BRET response compared with the wild type receptor 
sequence (Figure 3-7 B-C). Every mutation except S294A significantly reduced 
maximal β-arrestin-2 recruitment, with S303A having the greatest individual 
effect. In the phosphorylation-deficient mutant, with all identified 
phosphorylation sites removed, BRET was reduced to almost baseline levels. A 
cell-surface ELISA against the N-terminal FLAG epitope tag demonstrated that all 
mutants were efficiently trafficked to the cell membrane (Figure 3-7 D), 
suggesting that this lack of β-arrestin-2 recruitment is due to alterations in 
GPR35 post-translational regulation and not simply a lack of expression at the 
cell surface. 
Since the S303A mutation appeared to have the greatest effect on β-arrestin 
recruitment, and this phosphorylation site exists within a cluster of serine and 
threonine residues that is conserved between the human and rodent orthologues 
(Figure 3-9 A), two double mutants (S300A/S303A and S303A/T307A) were made 
to determine whether these phosphorylation sites are a minimum requirement 
for β-arrestin-2 recruitment. While the S300A/S303A double mutant did not show 
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a significant reduction in β-arrestin-2 recruitment compared with the S303A 
single-site mutant, the S303A/T307A double mutant had a significantly impaired 
capacity for β-arrestin-2 recruitment compared with either of the single-site 
mutants. Furthermore, this double mutation was sufficient to reduce BRET to 
the level of the fully phosphorylation-deficient mutant (Figure 3-7 B-C), 
suggesting that phosphorylation of at least one of these two residues is 
necessary for β-arrestin-2 recruitment to GPR35 following zaprinast stimulation. 
 
Figure 3-7 Phosphorylation sites in the hGPR35 C-terminal tail are required for β-arrestin-2 
recruitment (A) Amino acid residues mutated to alanine in the hGPR35 BRET sensors. (B) 
Zaprinast concentration-response curves for hGPR35 wild type (WT) and serine to alanine 
mutants. (C) Maximal BRET stimulated by zaprinast treatment. (D) Anti-FLAG ELISA showing cell-
surface expression of hGPR35-eYFP mutants co-transfected with β-arrestin-2-RLuc compared with 
cells transfected with β-arrestin-2-RLuc only. All data are means pooled from n = 3 independent 
experiments performed in triplicate +/- SEM. ***p<0.001 compared with WT; ns = not significant in 
one-way ANOVA with Tukey’s multiple comparisons post-test. BRET = bioluminescence resonance 
energy transfer; ELISA = enzyme-linked immunosorbent assay; PDM = phosphorylation-deficient 
mutant. 
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To investigate the possibility that different phosphorylation sites play a role in 
responses to different agonists, the same mutant sensors were tested in 
response to stimulation by two partial agonists, pamoic acid and amlexanox 
(Figure 3-8 B). While the rank order of BRETMax for the different mutants was 
broadly similar with these agonists compared with zaprinast (Figure 3-7), there 
were some notable differences in the responses. S294A had a significant effect 
on β-arrestin-2 recruitment induced by the partial agonists, although this mutant 
still retained 75–80% of the wild type response (Figure 3-8). With pamoic acid as 
the stimulus, both of the double mutantions reduced BRET to the level of the 
phosphorylation-deficient mutant (Figure 3-8 A-B). With amlexanox, the 
phosphorylation-deficient mutant retained a low level of β-arrestin-2 
recruitment (23% of the wild type response); however, the S303A mutation alone 
was sufficient to reduce β-arrestin-2 recruitment to the level of the 
phosphorylation-deficient mutant (Figure 3-8 C-D). 
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Figure 3-8 The impact of hGPR35 phosphorylation sites on β-arrestin-2 recruitment is 
dependent on the type of agonist (A and C) Concentration-response curves of (A) pamoic acid 
and (C) amlexanox for hGPR35 wild type (WT) and serine to alanine mutants. (B and D) Maximal 
BRET stimulated by (B) pamoic acid and (D) amlexanox treatment. All data are means pooled from 
n = 3 independent experiments performed in triplicate +/- SEM. ***p<0.001 compared with WT; ns 
= not significant in one-way ANOVA with Tukey’s multiple comparisons post-test. BRET = 
bioluminescence resonance energy transfer; ELISA = enzyme-linked immunosorbent assay; PDM 
= phosphorylation-deficient mutant. 
To investigate whether the phosphorylation sites that impacted β-arrestin-2 
recruitment to human GPR35 have similar importance in the rodent orthologues, 
equivalent BRET sensor serine/threonine to alanine mutants of mouse and rat 
GPR35 were tested (Figure 3-9). Since the rodent orthologues have substantially 
more serine and threonine residues in their C-terminal tails than the human 
orthologue, their phosphorylation sites were grouped into four clusters that 
correspond to the hGPR35 phosphorylation sites as identified by mass 
spectrometry (Figure 3-9 A). Similarly to hGPR35, with both mGPR35 and 
rGPR35, mutating all of the sites simultaneously reduced zaprinast-induced 
β-arrestin-2 recruitment to almost baseline levels (Figure 3-9 B–E). Mutant A, 
with a mutation at a serine corresponding to hGPR35 S287, did not have 
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impaired β-arrestin-2 recruitment, and in fact appeared to show enhanced 
potency and efficacy of the zaprinast-mediated response for rGPR35 (Figure 3-9 
B-E). Mutant B, with mutations in a cluster corresponding to hGPR35 S294, had 
unaltered β-arrestin-2 recruitment for mGPR35 but slightly impaired β-arrestin-2 
recruitment for rGPR35. Mutant C, with mutations in the conserved ‘SQDS’ motif 
equivalent to hGPR35 S300/S303, was unable to recruit β-arrestin-2, with BRET 
reduced to the level of the phosphorylation-deficient mutants for both mGPR35 
and rGPR35. Mutant D, with mutations in a cluster at the extreme C-terminus 
corresponding to hGPR35 T307, had moderately impaired β-arrestin recruitment. 
Once again, all mutants were efficiently trafficked to the cell surface of HEK293 
cells (Figure 3-9 F-G). These results suggest that, similarly to human GPR35, the 
S303-equivalent sites in mouse and rat GPR35 are essential for β-arrestin-2 
recruitment, whereas the T307-equivalent cluster makes a significant 
contribution, but is not essential. 
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Figure 3-9 The impact of GPR35 phosphorylation sites on β-arrestin-2 recruitment is similar 
for different species orthologues (A) Amino acid residues mutated to alanine in the mGPR35 
and rGPR35 BRET sensors. (B and D) Zaprinast concentration-response curves for (B) mGPR35 
and (D) rGPR35 wild type (WT) and serine to alanine mutants. (C and E) Maximal BRET of (C) 
mGPR35 and (E) rGPR35 stimulated by zaprinast treatment. (F and G) Anti-FLAG ELISA showing 
cell-surface expression of (F) mGPR35-eYFP and (G) rGPR35-eYFP mutants co-transfected with 
β-arrestin-RLuc, compared with cells transfected with β-arrestin-RLuc only. All data are means 
pooled from n = 3 independent experiments performed in triplicate +/- SEM. ***p<0.001 compared 
with WT; ns = not significant in one-way ANOVA with Tukey’s multiple comparisons post-test. 
BRET = bioluminescence resonance energy transfer; ELISA = enzyme-linked immunosorbent 
assay; PDM = phosphorylation-deficient mutant. 
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While these detailed insights into the molecular determinants of β-arrestin-2 
recruitment to GPR35 are important in understanding context-dependent 
differences in GPR35 signalling, an additional aim of this work was to understand 
the downstream consequences of these differences, whether they are mediated 
by G proteins or β-arrestins and how differences in these multiple signals affect 
the cellular response. The phosphorylation-deficient mutant of human GPR35 
was used to address this question, as it cannot recruit β-arrestin and is therefore 
potentially a G protein-biased form of GPR35. However, before using this mutant 
in further studies, it was necessary to determine whether it retained the ability 
to recruit G protein. An unbiased approach to investigating G protein 
recruitment, which uses GPCR/Gα peptide intramolecular BRET sensors in 
HEK293 cells (Malik et al., 2013), has previously been utilised to show that of all 
the G proteins that couple to GPR35, Gα13 is recruited with the greatest efficacy 
(Mackenzie, A.E., Hudson, B. and Milligan, G., unpublished data). Therefore, a 
GPR35(PDM)/Gα13 intramolecular BRET sensor and an equivalent GPR35(PDM)/no 
peptide control sensor were constructed to investigate the effects of the 
C-terminal tail phosphorylation site mutations on G protein recruitment to 
GPR35 (Figure 3-10 A). The phosphorylation-deficient mutant was indeed able to 
couple to Gα13 peptide; moreover, removing the phosphorylation sites enhanced 
both the potency and the efficacy of the response to zaprinast compared with 
the wild type sensor (Figure 3-10 B and C). 
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Figure 3-10 Human GPR35 phosphorylation-deficient mutant retains the ability to couple to 
Gα13 (A) Schematic representation of intramolecular BRET sensor constructs (em = emission 
wavelength in nm). (B) Zaprinast concentration-response curves for hGPR35 no peptide (NP) or 
Gα13 28 amino acid peptide (G13) intramolecular BRET sensors; curves for wild type (WT) and 
phosphorylation-deficient mutant (PDM) are shown. (C) Maximal BRET stimulated by zaprinast 
treatment. All data are means pooled from n = 3 independent experiments performed in triplicate 
+/- SEM. ***p<0.001 compared with WT in two-tailed unpaired student’s t test. BRET = 
bioluminescence resonance energy transfer. 
In order to investigate whether this effect of C-terminal tail mutations also 
occurs in response to different agonists, the intramolecular BRET sensors were 
also tested with the partial agonists pamoic acid and amlexanox (Figure 3-11). 
As with zaprinast, the potency and efficacy of the response was significantly 
higher for the phosphorylation-deficient mutant than for the wild type sensor 
when either pamoic acid or amlexanox was used to induce G protein recruitment 
(Figure 3-11 A-D). Notably, the effect of the mutations on maximal BRET was 
amplified with the partial agonists (Figure 3-11 B and D), resulting in an efficacy 
comparable to that of zaprinast (Figure 3-11 E). 
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Figure 3-11 A phosphorylation-deficient GPR35 mutant is able to recruit Gα13 with full 
efficacy in response to partial agonists (A and C) Concentration-response curves of (A) pamoic 
acid and (C) amlexanox for hGPR35 no peptide (NP) or Gα13 intramolecular BRET sensors; curves 
for wild type (WT) and phosphorylation-deficient mutant (PDM) are shown. (B and D) Maximal 
BRET stimulated by (B) pamoic acid and (D) amlexanox treatment. All data are means pooled from 
n = 3 independent experiments performed in triplicate +/- SEM. ***p<0.001 compared with WT in 
two-tailed unpaired student’s t test. BRET = bioluminescence resonance energy transfer. 
3.2.3 Investigating G protein- and β-arrestin-mediated aspects of 
GPR35 signalling 
Previous studies on GPR35 have resulted in a basic understanding of its coupling 
profile and some of its downstream effects (Figure 1-6) (Divorty et al., 2015). 
However, these have not been studied in detail and some of our knowledge of 
the pathways involved is based on assumptions. Linking specific cellular effects 
of GPR35 with cytoplasmic mediators, particularly G proteins and β-arrestins, 
will be key to utilising this receptor as a drug target, especially with regard to 
the potential development of biased ligands as therapeutics. 
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The contributions of phosphorylation, Gα13 and β-arrestins to downstream 
responses elicited by GPR35 agonists were evaluated using CRISPR-edited HEK293 
cell lines deficient in the relevant signalling proteins. In order to investigate 
GPR35-specific signalling in these cells, it was necessary to stably transfect the 
relevant CRISPR-edited ‘knockout’ cell lines with GPR35 (Figure 3-12). Both wild 
type and phosphorylation-deficient FLAG-GPR35-eYFP constructs were 
transfected into the parental cell line (hereafter referred to as parental + WT or 
parental + PDM), and the wild type construct was transfected into the Gα12/13 
knockout (G12/13 KO) and β-arrestin-1/2 knockout (Arr KO) cell lines (hereafter 
referred to as G12/13 KO + WT or Arr KO + WT). The clonal cell lines generated 
were manually screened for homogeneous GPR35 expression at the cell surface 
based on their eYFP fluorescence. 
 
Figure 3-12 Schematic representation of modified GPR35-expressing cell lines. CRISPR-
edited Gα12/13 or β-arrestin-1/2 ‘knockout’ (KO) cell lines (or the parental, non-edited cell line) were 
stably transfected with FLAG-hGPR35-eYFP wild type (WT) or phosphorylation-deficient mutant 
(PDM). 
Prior to using these modified cell lines in subsequent studies, the absence of the 
relevant proteins and the expression of GPR35 were confirmed by 
immunoblotting (Figure 3-13). Gα12, Gα13, β-arrestin-1, β-arrestin-2 and FLAG-
GPR35 were all detectable in the transfected parental cell lines, although Gα12 
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appeared to be present at a lower level in the parental + GPR35 PDM cells 
compared with the other lines (Figure 3-13). Gα12 and Gα13 were absent and 
β-arrestin-1, β-arrestin-2 and FLAG-GPR35 were present in both G12/13 KO + WT 
clones. Due to the lower levels of the β-arrestins in G12/13 KO + WT clone 3, 
G12/13 KO + WT clone 2 was selected for use in the subsequent studies. 
β-arrestin-1 was absent and Gα12, Gα13 and FLAG-GPR35 were present in both Arr 
KO + WT clones. A faint signal was observed for β-arrestin-2 in these cell lines – 
however, due to the absence of β-arrestin-1, this band could not indicate 
contamination of the KO cell line by parental cells. It is likely that this 
observation was the result of non-specific activity of the antibody, but even if 
β-arrestin-2 was present in these cells, it was at a significantly reduced level 
compared with the parental cells. Since FLAG-GPR35 was poorly expressed in Arr 
KO + WT clone 5, Arr KO + WT clone 6 was selected for use in the subsequent 
studies. 
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Figure 3-13 Immunoblot analysis confirms identities of stably transfected CRISPR-edited 
knockout cell lines. Membrane fractions (Gα12, Gα13, FLAG) or cytosolic fractions (β-Arr-1, 
β-Arr-2, β-tubulin) of CRISPR-edited and GPR35-transfected cell lysates were immunoblotted for G 
protein, β-arrestin or FLAG-GPR35. As transfectants were clonally selected, different clones (cl.) of 
the knockout cell lines were assessed. Images are representative of n = 2 individual experiments. 
WT = FLAG-hGPR35-eYFP wild type; PDM = FLAG-hGPR35-eYFP phosphorylation-deficient 
mutant; Arr = arrestin. 
Having generated the CRISPR-edited, stably transfected cell lines, the aim of the 
study was to characterise signalling responses to GPR35 stimulation in these 
cells. Receptor internalisation is by far the best-characterised β-arrestin-
mediated response to GPCR activation (Luttrell and Lefkowitz, 2002), and so the 
manner in which this process is triggered by GPR35 stimulation was investigated. 
The GPR35 internalisation response was qualitatively examined by live-cell 
confocal microscopy (Figure 3-14). In the absence of agonist, GPR35 was 
homogeneously expressed at the cell surface in all cell lines. In the parental + 
WT cells, wild type GPR35 was rapidly internalised in response to zaprinast 
treatment, with GPR35-eYFP visibly internalised into endocytic vesicles after 
15 min (Figure 3-14). After 45 min, the majority of wild type receptor was 
present in the intracellular endocytic compartment. This was also the case in 
the G12/13 KO + WT cell line, except that peak internalisation appeared to be 
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reached after only 30 min. In the parental + PDM cells, some vesicles were 
visible after 15 min, but were substantially fewer in number than in the wild 
type cell line, with the majority of receptor remaining at the plasma membrane 
over 45 min. In the Arr KO + WT cell line, no zaprinast-induced internalisation of 
GPR35 could be detected (Figure 3-14). 
 
Figure 3-14 Both GPR35 phosphorylation and β-arrestin are required for zaprinast-induced 
GPR35 internalisation Internalisation of GPR35-eYFP was qualitatively assessed by live-cell 
confocal microscopy. Cells were stimulated with 100 μM zaprinast for 45 min and imaged at the 
time points indicated. Images are representative of n = 3 independent experiments. Scale bar = 
20 μm. WT = FLAG-hGPR35-eYFP wild type; PDM = FLAG-hGPR35-eYFP phosphorylation-
deficient mutant. 
Although qualitatively assessing GPR35 internalisation provides useful insights, a 
more accurate understanding of internalisation events requires quantitative 
analysis. The Arrayscan high-content imaging system was used to quantify GPR35 
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internalisation in the modified cell lines in order to build on the qualitative 
observations (Figure 3-15). This method uses an algorithm designed to identify 
the number of individual internalised vesicles in the eYFP channel, which is 
normalised against cell number using a nuclear stain. A zaprinast concentration-
response curve (Figure 3-15 A-B) demonstrated that while little or no 
internalisation was detected in the parental + PDM or Arr KO + WT cells, the 
maximal internalisation in the G12/13 KO + WT cells was significantly greater than 
that in the parental + WT cells. This was also apparent in a time-course of 
internalisation, which showed that GPR35 was internalised at a steady rate over 
40–50 min in both the parental + WT cells and the G12/13 KO + WT cells (Figure 
3-15 C). 
 
Figure 3-15 GPR35 phosphorylation, β-arrestin and Gα12/13 all influence the efficacy of the 
GPR35 internalisation response (A) Concentration-response curves of GPR35-eYFP 
internalisation after 45 min zaprinast treatment in modified cell lines. (B) Maximal GPR35 
internalisation after 45 min zaprinast treatment. (C) Time course of GPR35 internalisation 
stimulated by 100 μM zaprinast. (A–B) Data are means pooled from n = 3 independent 
experiments performed in triplicate +/- SEM; (C) Data are representative of n = 2 independent 
experiments performed in triplicate +/- SEM. ***p<0.001 compared with (B) Parental + WT or (C) 0 
min in one-way ANOVA. 
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These data suggest that β-arrestin-1/2 are essential for agonist-induced GPR35 
internalisation to occur (Figure 3-14 and Figure 3-15). This conclusion is 
consistent with the current belief that the β-arrestins are the primary regulators 
of GPCR internalisation (Goodman et al., 1996, Laporte et al., 1999). However, a 
potential criticism of this finding is that the Arr KO cells express a much lower 
level of FLAG-GPR35 (Figure 3-13) and thus are potentially less sensitive to 
zaprinast, which could account for the lack of internalisation response observed. 
To address this, β-arrestin-2 was transfected into the Arr KO cells in an attempt 
to ‘rescue’ the internalisation phenotype (Figure 3-16). Transient transfection of 
Arr KO + GPR35 WT cells with β-arrestin-2-mCherry, but not the empty vector 
pcDNA3, resulted in rapid internalisation of GPR35-eYFP in response to zaprinast 
(Figure 3-16), which was similar to that observed in the parental + GPR35 WT 
cell line (Figure 3-14). Even cells with relatively weak expression of 
β-arrestin-2-mCherry rapidly internalised GPR35-eYFP, suggesting that modest 
amounts of β-arrestin-2 are sufficient to induce internalisation of GPR35. These 
findings further support the conclusion that a lack of β-arrestin prevents agonist-
induced internalisation of GPR35. 
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Figure 3-16 Transfection of Arr KO + WT cells with β-arrestin-2-mCherry rescues the 
internalisation phenotype Arr KO cells expressing wild type GPR35-eYFP cells were transiently 
transfected with β-arrestin-2-mCherry or the empty vector pcDNA3. Cells were stimulated with 
100 μM zaprinast for 45 min and imaged at the time points indicated. Scale bar = 20 μm. 
After establishing the role of β-arrestin in GPR35 internalisation, 
Gα12/13-mediated downstream responses were examined to establish what role 
this aspect of GPR35 signalling might have in the regulation of cellular 
processes. Since Gα12/13 signalling is often associated with changes in cell 
morphology via reorganisation of the actin cytoskeleton (Gohla et al., 1999, 
Schappi et al., 2014), the distribution of actin was examined in the modified cell 
lines using TRITC-labelled phalloidin to stain filamentous (F)-actin (Figure 3-17). 
Substantial differences were observed in the actin distribution between the 
parental and knockout cell lines even before they were stably transfected with 
GPR35 (Figure 3-17, left-hand panels). The untransfected parental cells formed a 
relatively regular monolayer, with the cell edges clearly defined by F-actin 
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staining at the periphery of the cytoplasm. The untransfected G12/13 KO cells, 
however, had a much less ordered distribution of F-actin, with many short, 
disordered filaments distributed throughout the cytoplasm. The untransfected 
Arr KO cells were more similar to the parental cells, but with enriched F-actin at 
cell-cell contacts. 
Next, the GPR35-expressing cell lines were examined to determine the effect of 
agonist stimulation on F-actin distribution. An unexpected finding was that 
transfection with wild type GPR35 alone (without agonist stimulation) was 
sufficient to induce changes in actin cytoskeletal organisation in the parental 
cells (Figure 3-17, middle panels). These cells had a more spread-out 
morphology, and showed formation of some ordered stress fibres. This was also 
observed in the Arr KO + WT cell line, but not in the G12/13 KO + WT cell line, 
suggesting that these changes were mediated by Gα12/13. 
The effects of GPR35 activation on actin distribution were examined by 
stimulating the modified cells with zaprinast for 30 min (Figure 3-17, right-hand 
panels). In the parental + WT cells, zaprinast stimulation led to the formation of 
an increased number of actin fibres which were ordered into bundles. This effect 
was also observed in the Arr KO + WT cells. It was not observed in the parental + 
PDM cells, but this appeared to be due to shrinking and apoptosis of the cells. It 
is possible that this cytotoxic effect was related to the prolonged and 
unregulated activity of GPR35 in these cells, especially considering that the 
protein expression level of GPR35 was found to be much greater in these cells 
than in the Arr KO + WT cell line (Figure 3-13). Zaprinast stimulation had no 
effect on actin distribution in the G12/13 KO + WT cells, supporting the hypothesis 
that GPR35 stimulates reorganisation of the actin cytoskeleton via Gα12/13. 
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Figure 3-17 GPR35 promotes Gα12/13-mediated formation of F-actin stress fibres Modified cell 
lines were stained for F-actin using TRITC-phalloidin. Cells were untreated (left- hand and middle 
panels) or stimulated for 30 min with 100 μM zaprinast (right-hand panels). Examples of stress 
fibres are indicated by white arrowheads. Scale bars = 20 μm. 
The observation that transfection of the parental cells with WT GPR35 was 
sufficient to cause some actin reorganisation suggests that constitutive activity 
of GPR35, or the presence of a GPR35 agonist in the culture medium, might 
influence the actin cytoskeleton. To determine whether the observed changes to 
the cytoskeleton in untreated cells were mediated by GPR35 overexpression, the 
modified cell lines were cultured with the GPR35 inverse agonist ML-145 prior to 
staining (Figure 3-18). In all of the cell lines except G12/13 KO + WT, culturing the 
GPR35-expressing cells in ML-145 altered the actin distribution so that it 
resembled that of the equivalent untransfected cells. This further supports the 
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hypothesis that GPR35 overexpression is sufficient to induce reorganisation of 
the actin cytoskeleton. 
 
Figure 3-18 ML-145 inhibits changes to the actin cytoskeleton induced by GPR35 
overexpression Modified cell lines were cultured for 24 hours in normal maintenance medium 
(right-hand panels) or in normal maintenance medium + 1 μM ML-145 (left-hand panels) and then 
stained for F-actin using TRITC-phalloidin. Scale bar = 20 μm. 
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3.3 Discussion 
3.3.1 Agonist-dependent phosphorylation of GPR35 
The large majority of GPCRs have potential phosphorylation sites in their 
intracellular domains, and for several receptors these have been confirmed 
experimentally by radioisotope labelling, mass spectrometry and/or 
phosphorylation site-specific antibodies (Butcher et al., 2011a, Nobles et al., 
2011, Butcher et al., 2014, Bouzo-Lorenzo et al., 2016). This study is the first to 
investigate agonist-dependent phosphorylation of GPR35 and its downstream 
consequences. The data reported here show that, like many other GPCRs, GPR35 
undergoes agonist-dependent phosphorylation. The extent of this 
phosphorylation differs depending on the agonist and the species orthologue in a 
manner that reflects the relative efficacies and species selectivities of the 
different agonists determined in pharmacological assays. Most commonly, these 
pharmacological assays are based on measuring β-arrestin recruitment (Jenkins 
et al., 2012, Southern et al., 2013, MacKenzie et al., 2014). Therefore, the 
ability of agonists to induce phosphorylation of GPR35 can be said to correlate 
with their efficacy with regard to the recruitment of β-arrestin. This association 
has been further investigated in this chapter, and the findings are discussed 
below. 
While phosphorylation is often assumed to link directly with β-arrestin 
recruitment and subsequent functional consequences, several therapeutically 
important GPCRs, such D1R, D2R, β2AR and 5-HT2CR, can be constitutively 
phosphorylated by certain GRKs independently of agonist stimulation (Butcher et 
al., 2014, Li et al., 2015). This does not appear to be the case for human or 
mouse GPR35, as little or no constitutive phosphorylation of hGPR35 could be 
detected in radiolabelling assays. However, the rat orthologue did appear to 
incorporate some [32P]-orthophosphate in the absence of agonist stimulation, 
resulting in a smaller fold-change in response to agonist than that observed for 
hGPR35 or mGPR35. This might be explained by the fact that rGPR35 has more 
potential phosphorylation sites (serine and threonine residues) in its C-terminal 
tail than either hGPR35 or mGPR35, and that phosphorylation resulting from 
constitutive GRK activity is therefore amplified. However, it is not known 
whether this would occur in vivo and/or have a significant effect on endogenous 
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GPR35 function. This is something that should be considered when generalising 
findings from in vivo or ex vivo rat studies to humans. 
The location of phosphorylation sites varies widely between different GPCRs, in 
line with the diversity of the ICL and C-terminal tail regions within the family. 
The β2AR is phosphorylated at 13 sites distributed throughout its ICL3 and 
C-terminal tail (Nobles et al., 2011), whereas the M3 muscarinic receptor is 
heavily phosphorylated at up to 15 sites in its exceptionally long ICL3, but at 
only one site in its C-terminal tail (Butcher et al., 2011a). Both free fatty acid 
receptor 4 (FFA4) and the ghrelin receptor GHSR1a have two distinct clusters of 
phosphorylation sites occurring in different parts of the C-terminal tail, which 
differentially regulate downstream signalling (Butcher et al., 2014, Bouzo-
Lorenzo et al., 2016, Prihandoko et al., 2016). In the present study, mass 
spectrometry analysis identified five sites in the hGPR35 C-terminal tail that 
were phosphorylated following agonist stimulation. Removing these sites by 
mutating them to alanine eliminated [32P]-orthophosphate incorporation, 
suggesting that these residues are the principal or only sites of agonist-
dependent phosphorylation within GPR35. While these sites do not clearly group 
into two clusters based on their proximity to each other, as in FFA4 and GHSR1a, 
their potential to differentially regulate signalling was explored further in 
β-arrestin and Gα13 recruitment studies (discussed in section 3.3.2 and 3.3.3). 
3.3.1.1 Applications of mass spectrometry-based approaches to studying 
GPCR phosphorylation 
GPCR phosphorylation has been the subject of intense study for decades, and its 
roles in receptor desensitisation and internalisation have long been appreciated 
(Benovic et al., 1987, Innamorati et al., 1998, Seibold et al., 2000). However, 
new paradigms regarding the ability of site-specific phosphorylation to regulate 
G protein-independent signalling have recently emerged (Tobin et al., 2008, 
Liggett, 2011). In the past, truncation and mutagenesis studies have highlighted 
the importance of different ‘clusters’ of phosphorylation sites in directing 
cellular responses to the activation of some GPCRs (Innamorati et al., 1998, 
Orsini et al., 1999, Milasta et al., 2005). However, greater precision is required 
in order to further dissect the theory of the ‘phosphorylation barcode’ and 
determine its impact on signalling. Mass spectrometry-based approaches have 
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enabled the precise identification of individual phosphorylated residues for a 
number of receptors of interest (Busillo et al., 2010, Butcher et al., 2011a, 
Nobles et al., 2011, Butcher et al., 2014, Bouzo-Lorenzo et al., 2016). Applying 
these approaches to more GPCRs will likely reveal important distinctions in the 
way different sub-groups of GPCRs are phosphorylated and transduce their 
signals. For example, based on the findings of the present study, GPR35 appears 
to fall into a category of receptors that contain multiple short clusters of 
phosphorylation sites in their C-terminal tails that differentially regulate 
β-arrestin recruitment. Whether GPR35 phosphorylation also influences G 
protein-independent signalling, as it does for GSHR1a and FFA4, is yet to be 
determined.  
The accuracy afforded by mass spectrometry has facilitated the design of tools 
such as phosphorylation site mutants and phosphorylation site-specific 
antibodies for a number of GPCRs, which are now being used to study the impact 
of differential phosphorylation on signalling (Busillo et al., 2010, Butcher et al., 
2011a, Nobles et al., 2011, Prihandoko et al., 2016). Such tools will also be 
valuable in investigating the true importance of differential phosphorylation in 
vivo. For example, phosphorylation site-specific antibodies have been used to 
demonstrate differential phosphorylation of M3R in different mouse tissues 
(Butcher et al., 2011a). Furthermore, a phosphorylation-deficient M3R mutant 
has recently been used to generate a knock-in mouse, which is providing insight 
into the impact of M3R phosphorylation on learning and memory in vivo (Poulin 
et al., 2010, Bradley et al., 2016). As detailed phosphorylation profiles are 
generated and utilised in in vivo studies for more GPCRs, the therapeutic 
potential of targeting this aspect of GPCR signalling will become clear. 
3.3.2 β-arrestin recruitment to GPR35 
β-arrestin recruitment has been used extensively in multiple assay formats to 
identify and characterise ligands of GPR35 (Jenkins et al., 2010, Zhao et al., 
2010, Deng et al., 2012, Jenkins et al., 2012, Neetoo-Isseljee et al., 2013, 
MacKenzie et al., 2014). All of the synthetic agonists of GPR35 identified to date 
induce β-arrestin recruitment, and this response has become a reliable and 
robust measure of GPR35 activation. Furthermore, β-arrestin recruitment has 
long been known to have important functional consequences in the transduction 
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of the GPCR signal, from desensitisation and internalisation to G protein-
independent signalling. 
Despite β-arrestin being an important aspect of the cellular response to the vast 
majority of GPCRs, there does not appear to be a universal binding site to which 
it is recruited; interactions vary depending on the receptor in question, and are 
regulated through both conformational changes and covalent modifications. For 
example, the third intracellular loop is important for β-arrestin binding to the 
α2AR, M2R and M3R (Lee et al., 2000, DeGraff et al., 2002, Poulin et al., 2010), 
whereas a conserved tripeptide motif at the bottom of helix three is essential 
for β-arrestin binding to the N-formyl peptide receptor (Bennett et al., 2000). 
However, the largest interface and the most common point of interaction is the 
receptor C-terminal tail. Phosphorylation of residues in this region enhances 
β-arrestin recruitment, as discussed above. For some receptors, small clusters of 
serine and threonine residues in the C-terminal tail are essential for β-arrestin 
recruitment. For example, mutation of three threonines and one serine within 
the last seven residues of the orexin A receptor leads to a substantial reduction 
in β-arrestin recruitment and co-internalisation (Milasta et al., 2005). Similarly, 
for both GSHR1a and FFA4, mutation of two or three serine and threonine 
residues is sufficient to inhibit β-arrestin recruitment and receptor 
internalisation (Butcher et al., 2014, Bouzo-Lorenzo et al., 2016). For these 
receptors, however, different clusters appear to make varying contributions, 
with clusters closer to the C-terminus having a greater impact on β-arrestin 
recruitment. 
Having herein identified several phosphorylation sites in the hGPR35 C-terminal 
tail, the influence of each of these sites on β-arrestin recruitment was evaluated 
using a BRET-based β-arrestin-2 recruitment assay. Of the five phosphorylation 
sites identified by mass spectrometry, four made a significant contribution to 
the maximal efficacy of β-arrestin-2 recruitment regardless of agonist or species 
orthologue. Individual substitution of these sites had varying degrees of impact 
on β-arrestin recruitment in response to zaprinast, inhibiting BRET by between 
30% (S300) and 75% (S303). Substituting either all five of the sites or S303 and 
T307 (the two most C-terminal sites) simultaneously resulted in almost complete 
inhibition of β-arrestin recruitment. This suggests that agonist-dependent 
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phosphorylation of S303, and, to a lesser extent, T307, is necessary for 
β-arrestin binding to GPR35. This same hierarchical rank order of sites was 
observed both with different agonists and at different species orthologues, with 
S303 having the greatest impact on phosphorylation in response to all three 
agonists and in all three orthologues. The finding that individual phosphorylation 
sites make unequal contributions to β-arrestin recruitment further supports the 
emerging theory that site-specific phosphorylation, and not merely bulk negative 
charge, is necessary for β-arrestin to interact with GPCRs via the C-terminal tail. 
This provides evidence of a ‘phosphorylation barcode’ for GPR35, and thus 
highlights the potential capacity for context- or tissue-specific regulation of this 
receptor. This could have important implications in the search for a function for 
GPR35, given the diversity of its proposed roles in multiple tissues and 
physiological systems. 
One notable secondary observation from the mutagenesis studies is that S294 
substitution does not appear to have a significant effect on β-arrestin 
recruitment to human GPR35 in response to a full agonist, despite the fact that 
phosphorylation of this residue was detected by mass spectrometry. This is 
surprising, considering S294 is the residue affected by a SNP that has been 
associated with both IBD and coronary artery disease (Sun et al., 2008, Imielinski 
et al., 2009, Ellinghaus et al., 2013). One potential explanation for this SNP’s 
association with disease is that it alters GPR35 phosphorylation and thus 
β-arrestin recruitment, and thereby dysregulates either desensitisation or G 
protein-independent signalling. However, this hypothesis is not supported by the 
findings presented here. 
3.3.3 Gα13 recruitment to GPR35 
GPR35 coupling to Gα13 has previously been demonstrated using both a chimeric 
Gα13/Gαq G protein in a [Ca2+]i assay and an activation state-sensing GTP-Gα13 
antibody (Jenkins et al., 2011). The construction of a GPR35-Gα13 intramolecular 
BRET sensor provided an unbiased and direct method of measuring G protein 
recruitment to GPR35 without the use of a chimeric G protein (Mackenzie, A.E., 
Hudson, B. and Milligan, G., unpublished data; and this work). These studies 
confirmed that Gα13 is recruited to GPR35 in response to agonist, with a potency 
comparable to that observed for β-arrestin recruitment (zaprinast EC50 = 7.8 μM 
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and 4.7 μM, respectively). The present study also assessed the ability of the 
phosphorylation-deficient GPR35 mutant to recruit Gα13 using a GPR35(PDM)-
Gα13 sensor. While the mutant did not recruit β-arrestin-2, it retained the 
capacity to recruit Gα13, and in fact did so with enhanced potency and efficacy. 
This enhancement could reflect a low level of constitutive phosphorylation 
and/or β-arrestin recruitment that limits the propensity of wild type GPR35 to 
couple to Gα13. However, since the effects of the individual mutations were not 
assessed here, it is not known whether the sites influencing Gα13 coupling are 
the same as those that strongly impact β-arrestin-2 recruitment. Nonetheless, 
these findings suggest that constitutive phosphorylation is another potential 
means by which GPR35 signalling could be regulated in a context-specific 
manner, although it must be considered that these experiments were carried out 
in a highly artificial overexpression system, and it is unclear to what extent this 
might affect signalling in vivo. 
3.3.4 Internalisation of GPR35 
Studies into the internalisation of GPR35 utilised novel, HEK293-derived cell 
lines that were CRISPR-edited to delete either Gα12/13 or β-arrestin-1/2 and 
stably transfected with GPR35. These cell lines were used as a means of 
investigating the molecular determinants of GPR35 internalisation. The data 
presented here show that GPR35 is rapidly internalised in response to agonist 
stimulation in a phosphorylation- and β-arrestin-dependent manner. Both the 
parental cell line expressing phosphorylation-deficient GPR35 and the 
β-arrestin-1/2-deficient cell line expressing wild type GPR35 failed to internalise 
GPR35 in response to zaprinast stimulation in both qualitative and quantitative 
assays. This finding is consistent with well-documented roles for both 
GRK-mediated phosphorylation and β-arrestin in stimulating clathrin-mediated 
endocytosis (Goodman et al., 1996, Laporte et al., 1999, Seibold et al., 2000, 
Thomsen et al., 2016). However, although a significant level of internalisation of 
the phosphorylation-deficient mutant could not be detected in the quantitative 
assay, live-cell microscopy revealed that a small amount of receptor was 
internalised into endocytic vesicles in response to zaprinast. This residual 
response is presumably due to either a low level of phosphorylation at 
alternative sites within the ICLs, or a low level of phosphorylation-independent 
β-arrestin recruitment in these cells. It is important to note that this finding 
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shows that phosphorylation-deficient and β-arrestin-deficient cells do not have 
equivalent phenotypes, and this should be kept in mind in studies in which 
phosphorylation-deficient mutants are used as ‘G protein-biased’ receptors. 
Another noteworthy observation from these studies is that the magnitude of the 
internalisation response is significantly greater in the Gα12/13-deficient cells than 
in the parental cell line when both express wild type GPR35. This suggests that 
not only do phosphorylation and β-arrestin desensitise the G protein response, 
but conversely, Gα12/13 has a limiting effect on β-arrestin-mediated 
internalisation. Since Gα12 and Gα13 are ubiquitously expressed in vivo 
(Wettschureck and Offermanns, 2005), this is unlikely to have implications for 
endogenous GPR35 regulation. However, it reveals an interesting mechanistic 
detail that warrants further attention. If this effect occurs with other G proteins 
with more restricted expression patterns, it has implications for tissue-specific 
GPCR signalling – namely that the presence or absence of different G proteins 
could also alter the magnitude of the β-arrestin-mediated signalling response. 
One limitation of these experiments already noted was the inconsistent level of 
GPR35 expression across the cell lines being compared, particularly the 
relatively low expression level in the Arr KO + WT cell line. Weak expression of 
GPR35-eYFP occurred despite attempts to select high-expressing clones based on 
eYFP fluorescence, and reflects a practical challenge in successfully scaling up 
clones of this genotype. One possible reason for this is that a high level of GPR35 
expression combined with β-arrestin deficiency confers a selective disadvantage 
onto the cells. This could be a result of GPR35-mediated G protein signalling 
driven by the presence of an agonist in the culture medium, which in the 
absence of β-arrestin is not desensitised or terminated. Since Gα12/13 signalling is 
associated with reduced adhesion and increased migration, a high level of 
uncontrolled GPR35-Gα13 signalling would not be conducive to colony selection. 
In order to address this limitation and determine whether the lack of 
internalisation was due to the lack of β-arrestin or simply the weak GPR35 
expression, the Arr KO + WT cells were transiently transfected with β-arrestin-2 
in an attempt to restore the parental phenotype. Re-expression of β-arrestin-2 
was sufficient to enable agonist-induced internalisation of GPR35, which 
confirms that the internalisation defect was indeed due to a lack of β-arrestin 
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and not a result of insufficient GPR35 expression. While this finding was useful 
as a proof of concept, achieving comparable expression levels of receptor across 
all the modified cell lines would enable more robust and reliable analysis. The 
selection process used to generate these cell lines should therefore be optimised 
to facilitate more reliable screening and selection in the future. 
3.3.5 GPR35-mediated effects on the actin cytoskeleton 
As well as investigating the typical β-arrestin-mediated response of 
internalisation in these modified cell lines, a second aim was to investigate 
putative G protein-mediated cellular responses. GPR35 overexpression and 
agonism have been reported to alter the actin cytoskeleton in HEK293 cells as 
well as in cardiomyocytes and vascular smooth muscle cells, although the 
precise effect of this on cell morphology is inconsistent between studies (Min et 
al., 2010, Ronkainen et al., 2014, McCallum et al., 2015). These effects on the 
cytoskeleton are hypothesised to be due to the coupling of GPR35 to Gα13; 
however, Gα12/13, Gαq/11, and β-arrestins have all been shown to be capable of 
stimulating actin stress fibre formation (Buhl et al., 1995, Vogt et al., 2003, 
Barnes et al., 2005). The CRISPR-modified cell lines provided a means of 
determining whether Gα12 and Gα13 mediate the previously reported effects of 
GPR35 on the actin cytoskeleton. 
It was immediately obvious that even in the absence of exogenous GPR35 or any 
intentional stimulus, the untransfected cell lines differed in their actin 
distribution patterns. This was especially striking in the Gα12/13 KO cells, which 
had a very different shape and actin distribution than the parental and Arr KO 
cell lines. This is perhaps not surprising, considering the known importance of 
these G proteins in regulating actin dynamics and cell morphology (Gohla et al., 
1999, Schappi et al., 2014). The second observation was that transfection of 
GPR35 alone was sufficient to induce actin fibre formation in cells expressing 
Gα12/13 (including those not expressing β-arrestin-1/2), and that stimulation with 
zaprinast enhanced this effect. The fact that no actin rearrangement occurred in 
the Gα12/13 KO cell line upon either GPR35 transfection or zaprinast stimulation 
is evidence that these effects of GPR35 are mediated by Gα12 and/or Gα13. 
Furthermore, culturing the cells with the GPR35 inverse agonist ML-145 reversed 
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the effects of GPR35 overexpression, which further demonstrates that these 
effects were due to GPR35-dependent signalling. 
The fact that GPR35 overexpression alone is sufficient to alter the actin 
cytoskeleton in HEK293 cells has important implications for its potential roles in 
the cardiovascular system and CVD. GPR35 expression is induced in the heart 
during heart failure, and these findings suggest that this could contribute to the 
cellular remodelling in the heart that drives pathogenesis. (Min et al., 2010, 
Ronkainen et al., 2014). Furthermore, GPR35 agonism has recently been 
reported to have similar effects on actin reorganisation in human vascular 
smooth muscle cells, and so this pathway may also drive vascular remodelling in 
the development of diseases such as hypertension (McCallum et al., 2015). 
Gα12 and Gα13 are thought to mediate most of their effects, including those on 
the actin cytoskeleton, through the activation of Rho-GEFs and the subsequent 
activation of RhoA and its principal effector, ROCK (Buhl et al., 1995, Worzfeld 
et al., 2008, Siehler, 2009). Both RhoA and ROCK are known to be highly 
important in cardiovascular function and pathophysiology, with their activity 
stimulating vascular smooth muscle contraction, endothelial contractility and 
cardiac hypertrophy (Takefuji et al., 2012, Hartmann et al., 2015, Huveneers et 
al., 2015). There is already some evidence to suggest that GPR35 can activate 
the RhoA pathway in cells of the cardiovascular system – in human vascular 
smooth muscle cells, GPR35-mediated effects on migration were inhibited by the 
RhoA pathway inhibitors Y-27632 and Y-16 (McCallum et al., 2015). The findings 
reported here therefore combine with existing evidence to support an emerging 
model of GPR35 signalling in the cardiovascular system, whereby GPR35 couples 
to Gα13, which activates the RhoA/ROCK pathway in order to regulate the actin 
cytoskeleton. This in turn influences cardiovascular function by stimulating 
cardiovascular remodelling and/or vascular contractility. 
3.3.5.1 Challenges in studying the GPR35/Gα13/RhoA signalling axis 
Qualitatively assessing the actin cytoskeleton, as described here, is one of a 
limited number of endpoints that can be used to study the activity of Gα12/13-
coupled receptors such as GPR35. Direct and quantitative second-messenger 
assays to measure the activation of the Gαs, Gαi and Gαq/11 families have been 
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available for many years, but measuring Gα12/13 activation presents unique 
challenges. Most current methods rely on indirect measurement of downstream 
signalling outcomes. Assay systems based on measuring RhoA pathway activation, 
such as RhoA-GTP pull-down assays, have been used with relative success (Ren 
et al., 1999). However, these techniques carry the caveat that Gα12/13 is not the 
only family to activate this pathway, and so they cannot definitively prove 
Gα12/13 involvement. To overcome this limitation, such techniques could be 
combined with methods that selectively eliminate alternative pathways, such as 
selective inhibitors or ‘knockout’ cell lines like the ones used in this study. This 
would be an interesting avenue to pursue in future investigations into the 
GPR35/Gα13 pathway. Alternatively, label-free technologies such as dynamic 
mass redistribution offer an unbiased approach to studying G protein coupling, 
and could be particularly useful for studying receptors with an atypical coupling 
profile, such as GPR35 (Schröder et al., 2010). This technology has the added 
benefit of being non-invasive and therefore applicable to primary cells, enabling 
the study of GPCR signalling in more physiologically relevant systems than that 
afforded by existing approaches (Schröder et al., 2011). Such novel techniques 
hold promise for facilitating the study of challenging or poorly-characterised 
GPCRs. 
3.3.5.2 CRISPR-edited cell lines as a model in which to study GPCR 
signalling 
The findings described in this chapter highlight the potential value of the 
CRISPR-edited ‘knockout’ cell lines used in these studies. They demonstrate that 
the HEK293-derived cell lines can successfully be stably transfected with a GPCR 
of interest, and that whole-cell responses to receptor activation, such as actin 
cytoskeleton rearrangement, are altered in such systems. Cell lines deficient in 
all of the major G proteins and β-arrestin-1 and -2, as well as combinations 
thereof, have generously been made freely available to the GPCR research 
community. A range of these cell lines, including Gαq/11-deficient cells and the 
β-arrestin-1/2-deficient cells used in this work, are already being used to answer 
a variety of questions by several different groups (Schrage et al., 2015, Alvarez-
Curto et al., 2016). These cell lines offer a straightforward approach compared 
with previously used methods of generating G protein-deficient cell lines, such 
as isolation from knockout mouse embryos (Vogt et al., 2003). Such genetic 
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approaches are especially valuable when selective pharmacological inhibitors are 
not available, as is the case with Gα12/13. CRISPR-edited G protein-deficient cell 
lines therefore provide a novel and unique model that can be used to investigate 
important aspects of GPCR signalling such as coupling specificity and functional 
selectivity. 
The data presented here build on the current understanding of GPR35 signalling, 
which suggests that Gα13 and β-arrestin are the major receptor-coupling proteins 
responsible for GPR35-mediated effects on the cardiovascular system. These 
findings provide further insight into the intracellular events that follow agonist 
binding to GPR35. In addition, these studies have resulted in novel tools with 
which to further probe GPR35 function. 
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Chapter 4 Assessing the cardiovascular 
phenotype of a global GPR35 knockout mouse 
4.1 Introduction 
Since the generation of the first knockout mouse line in 1989, genetic mouse 
models have proven to be powerful tools in assigning gene and protein function 
(Thompson et al., 1989). Knockout mice have become invaluable in the drug 
discovery process, enabling the identification of targets with physiological 
significance and, for the most part, accurate prediction of the effects of 
pharmacological modulation. In a retrospective study into the targets of the 100 
best-selling drugs, the knockout mouse phenotype correlated with the 
therapeutic effect of the drug for the majority of protein targets (Zambrowicz 
and Sands, 2003). This approach has been applied successfully in order to 
interrogate the functions and therapeutic target potential of orphan GPCRs, and 
is particularly useful where a lack of available ligands hinders pharmacological 
studies (Ahmad et al., 2015). In the case of GPR35, the lack of synthetic 
antagonists with sufficient affinity at the rodent orthologue (section 1.4.3.2) 
makes the knockout mouse approach the best method with which to investigate 
the physiological consequences of blocking or eliminating GPR35 function. 
Although in vitro studies in cells of the cardiovascular system have suggested 
roles for GPR35 in the regulation of both cardiac and vascular structure and 
function (Ronkainen et al., 2014, McCallum et al., 2015), very little is currently 
known about the effects of GPR35 modulation on the cardiovascular system in 
vivo. The only study to date to report on the phenotype of a GPR35 global 
knockout mouse detected a significant and considerable 37.5 mmHg increase in 
systolic blood pressure compared with the wild type background strain, when 
assessed by Millar catheterisation of the right carotid artery under general 
anaesthesia (Min et al., 2010). However, this finding was not followed up with 
any in-depth analysis, despite the fact that it implicates GPR35 as a potential 
target in the therapeutic control of blood pressure. The same study also assessed 
heart weight, based on the finding that overexpression of GPR35 in neonatal rat 
cardiomyocytes led to cellular hypertrophy and reduced viability and may 
therefore play a role in cardiac remodelling (Min et al., 2010). However, heart 
weight to body weight ratio was unaffected in the GPR35 knockout mice 
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compared with the wild type strain. These findings suggest a potential role for 
GPR35 in the regulation of blood pressure, but fail to provide a comprehensive 
account of the cardiovascular pathophysiology resulting from an absence of 
GPR35 expression. This chapter describes more detailed investigations into the 
cardiovascular phenotype of the GPR35 global knockout mouse model, 
comprising studies into its haemodynamic properties and the structure and 
function of cardiovascular end organs (the heart, aorta, mesenteric resistance 
arteries and kidneys). 
Measurement of blood pressure in small animal models has been used extensively 
in the study of hypertension and related cardiovascular pathologies. There are 
two common approaches that may be utilised: non-invasive monitoring by means 
of tail-cuff plethysmography, and invasive monitoring using a fluid-filled intra-
arterial catheter (Krege et al., 1995, Mills et al., 2000). While tail-cuff 
plethysmography has the advantage of being non-invasive, the technique 
presents challenges with regard to minimising stress artefacts, which can reduce 
the sensitivity of measurements. Conversely, catheterisation combined with an 
exteriorised pressure transducer provides very sensitive measurements, but 
usually requires either long-term restraint or general anaesthesia and so is not 
considered to be optimally representative of normal physiological conditions 
(Kramer and Kinter, 2003, Constantinides et al., 2011). However, the 
development of a radiotelemetry-based approach involving remote transmission 
of pressure measurements from an implanted catheter and pressure transducer 
has provided a means of accurately monitoring haemodynamic parameters in 
conscious, unrestrained animals (Mills et al., 2000, Kramer and Kinter, 2003). 
Radiotelemetry has therefore become the preferred method for monitoring 
blood pressure in vivo. This technique was used in the present study to monitor 
blood pressure and other haemodynamic parameters in GPR35 knockout mice, 
alongside in vivo and ex vivo assessments of the structure and function of 
cardiovascular tissues in this model. 
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4.1.1 Aims 
The aims of this chapter were to: 
- Accurately assess the effects of global knockout of GPR35 on basal 
haemodynamic parameters using an implantable radiotelemetry device 
- Determine the effects of global knockout of GPR35 on basal 
cardiovascular function 
- Determine the effects of global knockout of GPR35 on the morphology of 
cardiovascular tissues. 
4.1.2 Study design 
The purpose of this study was to compare the basal cardiovascular phenotype of 
a GPR35 knockout mouse with that of the wild type background strain, C57BL/6. 
Only male animals were used in order to eliminate sex-specific variation. 
Homozygous wild type and knockout littermates were bred, and were of 
sufficient body weight to tolerate telemetry probe implantation by 12 weeks of 
age. Probes were implanted at 12 weeks of age, followed by a 7-day recovery 
period during which no measurements were taken (Figure 4-1). At 13 weeks of 
age, cardiac function was assessed by echocardiography, then probes were 
remotely switched on and haemodynamic parameters were monitored 
continuously for 7 days, followed by sacrifice and ex vivo analysis (Figure 4-1). 
Blood pressure, heart rate and locomotive activity are all subject to intrinsic 
circadian rhythms in rodents, and the presence of these rhythms are indicative 
of normal health and cardiovascular function (Takeda and Maemura, 2011). In 
order to assess the diurnal variation in the parameters measured, the telemetry 
data generated in this study were separated into two 12-hour periods 
representing the dark period (night) and the light period (day). Treatment was 
followed by sacrifice and ex vivo analysis at 14 weeks of age. 
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Figure 4-1 GPR35 KO study timeline 
4.2 Results 
4.2.1 Haemodynamic properties of the GPR35 knockout mouse 
Blood pressure and heart rate are two highly regulated haemodynamic indicators 
of cardiovascular function, which are altered in response to various physiological 
and pathophysiological stimuli. These parameters, as well as locomotive activity, 
were assessed in wild type and GPR35 knockout mice using telemetry (Figure 4-2 
and Figure 4-3). All of the parameters measured followed normal diurnal 
rhythms over the light/dark cycle in both wild type and GPR35 knockout mice 
(Figure 4-2 and Figure 4-3). Neither systolic, diastolic nor mean arterial blood 
pressure was significantly altered in GPR35 knockout mice compared with wild 
type mice (Figure 4-2). While systolic, diastolic and mean arterial blood pressure 
appeared to be higher in the GPR35 knockout mice at certain times during the 
period of monitoring (for example on day five), these differences were not 
consistent or significant over the duration of the study when compared using 
two-way repeated measures ANOVA. 
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Figure 4-2 Blood pressure is unaltered in GPR35 knockout mice. (A) Systolic blood pressure, 
(B) diastolic blood pressure and (C) mean arterial pressure were monitored over seven days using 
telemetry in wild type (blue circles) and GPR35 knockout (KO) (pink squares) mice. Data are 
presented as 12-hour means representing night (N) and day (D) periods; mean +/- SEM of n = 6 
(wild type) or n = 8 (KO) animals. Data were compared by two-way repeated measures ANOVA, 
but no significant differences were found.  
Similarly to blood pressure, heart rate and locomotive activity were not 
significantly altered in GPR35 knockout mice compared with wild type mice. 
Heart rate appeared to be somewhat lower in the GPR35 knockout mice (Figure 
4-3 A), but this trend was not significant when compared using two-way 
repeated measures ANOVA. Activity was also unaltered in the GPR35 knockout 
mice and followed normal diurnal rhythms in both groups, suggesting that the 
surgical procedure was well tolerated and that the one-week recovery period 
was sufficient to ensure an accurate representation of haemodynamic 
parameters under normal behavioural and physiological conditions (Figure 
4-3 B). 
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Figure 4-3 Heart rate and locomotive activity are unaltered in GPR35 knockout mice. (A) 
heart rate (bpm = beats per minute) and (B) activity were monitored over seven days using 
telemetry in wild type (blue circles) and GPR35 knockout (KO) (pink squares) mice. Data are 
presented as 12-hour means representing night (N) and day (D) periods; mean +/- SEM of n = 6 
(wild type) or n = 8 (KO) animals. Data were compared by two-way repeated measures ANOVA, 
but no significant differences were found.  
4.2.2 Cardiovascular function in the GPR35 knockout mouse 
In addition to blood pressure and heart rate, measurements of both cardiac and 
vascular function can be used to assess the state of the cardiovascular system in 
animal models. Alterations in left ventricular mass and left ventricular systolic 
function, assessed by echocardiography, are indicative of chronic cardiovascular 
dysfunction in both rodent models and human disease (Gao et al., 2011, Lam et 
al., 2011). In the present study, left ventricular mass, diameter and systolic 
function in wild type and GPR35 knockout mice were assessed in vivo by 
echocardiography, which was performed prior to commencement of telemetry 
recordings at 13 weeks of age (Figure 4-4). Potential differences in left 
ventricular structure were assessed by measuring left ventricular end diastolic 
wall thickness and diameter. Neither left ventricular wall thickness nor left 
ventricular diameter were significantly altered in GPR35 knockout mice 
compared with wild type mice (Figure 4-4 B and D). To quantify cardiac 
contractility, fractional shortening and ejection fraction of the left ventricle 
were calculated using measurements of the left ventricular end systolic and end 
diastolic diameters (Figure 4-4 C and D) and volumes (Figure 4-4 F and G) 
(method described in section 2.10.5). Fractional shortening and ejection fraction 
were both unaltered in GPR35 knockout mice compared with wild type mice 
131 
 
(Figure 4-4 E and H). Overall, these data suggest that global knockout of GPR35 
does not affect cardiac function under basal conditions. 
 
Figure 4-4 Cardiac function is unaltered in GPR35 knockout mice. (A) Representative M-mode 
echocardiography images taken on the longitudinal axis at the level of the papillary muscle. Scale 
bar = 3 mm. (B–H) Measurements derived from M-mode images: (B) end diastolic left ventricular 
(LV) wall thickness; (C) LV systolic diameter; (D) LV diastolic diameter; (E) fractional shortening of 
the left ventricle calculated from end systolic and diastolic diameters; (F) end systolic volume; (G) 
end diastolic volume; (H) ejection fraction calculated from end systolic and diastolic volumes. Data 
are mean +/- SEM of n = 6 (wild type) or n = 8 (GPR35 KO) animals. Data were compared by two-
tailed unpaired t test, but no significant differences were found. 
As well as previously being associated with cardiac hypertrophy and dysfunction, 
GPR35 has recently been reported to stimulate migration of vascular smooth 
muscle cells and proliferation of vascular endothelial cells, suggesting a possible 
role in the regulation of vascular function (McCallum et al., 2015). To assess 
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vasoreactivity in the GPR35 knockout mouse, constriction and relaxation 
responses of blood vessels from these mice were examined ex vivo using wire 
myography (Figure 4-5).  
In small mammals, second- to third-order mesenteric arteries are generally 
considered to be representative of the small resistance arteries that contribute 
to peripheral resistance in essential hypertension (Mulvany and Aalkjaer, 1990, 
Christensen and Mulvany, 2001). Therefore, constriction and relaxation 
responses of second- to third-order mesenteric arteries from GPR35 knockout 
mice were investigated (Figure 4-5 A and B). Mesenteric arteries from both wild 
type and GPR35 knockout mice showed increased intramural active effective 
pressure in response to noradrenaline, displaying sigmoidal concentration-
response curves (Figure 4-5 A). However, mesenteric arteries from GPR35 
knockout mice showed no significant differences in the constriction response to 
noradrenaline compared with those from wild type mice (Figure 4-5 A and E). 
Mesenteric arteries from both wild type and GPR35 knockout mice that were 
pre-constricted with 30 μM noradrenaline displayed limited relaxation responses 
to carbachol, which were not significantly different between the strains (Figure 
4-5 B). 
Due to the limited relaxation response observed with the mesenteric arteries, 
wire myography was also performed on aortas in order to accurately assess 
arterial relaxation responses in GPR35 knockout mice (Figure 4-5 C and D). 
Aortas were pre-constricted with 1 μM phenylephrine to induce maximal 
constriction. Maximal constriction to phenylephrine was not significantly 
different in aortas from GPR35 knockout mice compared with those from wild 
type mice (Figure 4-5 C). Aortas from both wild type and GPR35 knockout mice 
showed substantial concentration-dependent relaxation in response to carbachol 
(Figure 4-5 D). However, aortas from GPR35 knockout mice showed no significant 
differences in carbachol-induced relaxation compared with those from wild type 
mice (Figure 4-5 D and E). Overall, these data suggest that GPR35 knockout mice 
have normal vascular constriction and relaxation responses. 
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Figure 4-5 Vascular constriction and relaxation responses are unaltered in GPR35 knockout 
mice. Wire myography was performed on mesenteric arteries (A, B) or aortas (C, D) of wild type 
(blue circles) and GPR35 KO (pink squares) mice. (A) Constriction concentration-response curves 
of mesenteric arteries to noradrenaline. (B) Relaxation of noradrenaline-constricted mesenteric 
arteries to carbachol. (C) Constriction of aortas to 1 μM phenylephrine (PE). (D) Relaxation 
concentration-response curves of PE-constricted aortas to carbachol. (E) Statistical analysis of 
mean pEC50, Emax and area under curve (AUC) from concentration-response curves generated for 
each individual animal. Curve statistics were compared by two-tailed unpaired t test, but no 
significant differences were found. Data are mean +/- SEM of n = 4 (mesenteric arteries) or n = 3 
(aortas). 
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4.2.3 Gross morphology of cardiovascular tissues in the GPR35 
knockout mouse 
Hypertrophy and fibrosis of the heart, blood vessels and kidneys are end-organ 
indicators of cardiovascular dysfunction. To further investigate potential 
cardiovascular dysfunction in GPR35 knockout mice, gross morphology of 
cardiovascular tissues in these mice was examined. 
No differences were observed between wild type and GPR35 knockout mice in 
whole heart or left ventricular mass when normalised to either total body mass 
or tibia length (Figure 4-6 A and B). The cellular morphology of the myocardium 
was also unaffected, with no significant alteration in mean cardiomyocyte 
diameter in GPR35 knockout mice compared with wild type mice (Figure 4-6 C). 
Wild type and GPR35 knockout mice also had similarly low levels of both 
perivascular and interstitial cardiac fibrosis, as determined by staining of 
collagen deposits with picro-sirius red (Figure 4-7). Thus, GPR35 knockout mice 
appeared to have normal cardiac morphology, with no end-organ damage. 
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Figure 4-6 Cardiac mass and cardiomyocyte morphology are unaltered in GPR35 knockout 
mice. (A, B) Whole heart and left ventricle + septum (LV+S) mass were determined at sacrifice 
and normalised to (A) total body mass or (B) tibia length. (C) Transverse heart sections were 
stained with fluorescently-tagged wheat germ agglutinin (red) to visualise cardiomyocyte cell 
membranes, and with DAPI (blue) to visualise nuclei. Cell diameter was quantified by measuring 
the width of cardiomyocytes orientated on the short axis. Scale bar = 30 μm. Data are mean +/- 
SEM of n = 8 animals (mass) or n = 5 animals (cell diameter). Data were compared by two-tailed 
unpaired t test, but no significant differences were found. 
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Figure 4-7 Cardiac fibrosis is unaltered in GPR35 knockout mice. Transverse heart sections 
were stained with picro-sirius red to visualise collagen (red staining). Images of (A) perivascular 
and (B) interstitial regions were taken, and percent fibrosis was quantified as percentage of red 
pixels. Scale bars = 30 μm. Data are mean +/- SEM of n = 5 animals. Data were compared by two-
tailed unpaired t test, but no significant differences were found. 
Large vessel morphology in GPR35 knockout mice was assessed by staining aortas 
with hematoxylin and eosin, and potential vascular remodelling was examined by 
quantifying medial area (Figure 4-8). Aortas from both wild type and GPR35 
knockout mice had healthy morphology, and no significant difference in medial 
area was observed (Figure 4-8). 
 
Figure 4-8 Vascular morphology is unaltered in GPR35 knockout mice. Transverse aorta 
sections were stained with hematoxylin and eosin to visualise vascular morphology, and tunica 
media area was quantified by measuring the smooth muscle layer (bright pink staining). Scale bar 
= 100 μm. Data are mean +/- SEM of n = 5 animals. Data were compared by two-tailed unpaired t 
test, but no significant difference was found. 
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Since renal dysfunction and injury are secondary outcomes of cardiovascular 
dysfunction, renal mass and fibrosis in GPR35 knockout mice were also assessed 
(Figure 4-9). No differences in average kidney mass were observed between wild 
type and GPR35 knockout mice when normalised to either total body weight or 
tibia length (Figure 4-9 A and B). Levels of both interstitial and perivascular 
fibrosis were not significantly altered in GPR35 knockout mice compared with 
wild type mice (Figure 4-9 C and D). Thus, GPR35 knockout mice displayed 
normal renal morphology, which is indicative of normal blood pressure regulation 
and cardiovascular function. 
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Figure 4-9 Renal mass and fibrosis are unaltered in GPR35 knockout mice. (A, B) Average 
kidney mass was determined at sacrifice and normalised to (A) total body mass or (B) tibia length. 
(C, D) Transverse kidney sections were stained with picro-sirius red to visualise collagen (red 
staining). Images of (C) interstitial and (D) perivascular regions were taken, and percent fibrosis 
was quantified as percentage of red pixels. Scale bars = 50 μm. Data are mean +/- SEM of n = 8 
animals (mass) or n = 5 animals (fibrosis). Data were compared by two-tailed unpaired t test, but 
no significant differences were found. 
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4.3 Discussion 
4.3.1 GPR35 knockout mice have normal haemodynamic 
properties 
The aim of this chapter was to characterise the basal cardiovascular phenotype 
of a global GPR35 knockout mouse. The data presented here demonstrate that 
there are no significant differences in haemodynamic parameters, cardiac 
function, vascular contractility or cardiac, vascular or renal morphology in 
GPR35 knockout mice when compared with the wild type background strain. 
These findings support the conclusion that GPR35 knockout mice have a normal 
cardiovascular phenotype, and therefore GPR35 does not play a significant role 
in the homeostatic regulation of the cardiovascular system. 
The lack of a blood pressure phenotype in the GPR35 knockout mouse was 
particularly surprising, since Min et al. previously reported that they found the 
mean systolic blood pressure of this strain to be 37.5 mmHg higher than that of 
wild type littermates (Min et al., 2010). This is a substantial and physiologically 
meaningful difference, and formed part of the rationale for carrying out the 
present study. However, the finding was not replicated here. There are several 
reasons why these two studies might have had such different outcomes, 
stemming from the fact that they employed two very different methods of 
measuring blood pressure. The first used Millar catheterisation to record 
haemodynamic parameters at a single time point under terminal anaesthesia, 
whereas in the present study, blood pressure was monitored continuously for 
7 days. These differing approaches may account for the different conclusions 
reached in a number of ways. Blood pressure is highly variable throughout the 
24-hour light/dark cycle, with mean arterial pressure in mice varying by up to 
15 mmHg between light and dark periods and up to 40 mmHg over a whole 
24-hour period (Van Vliet et al., 2003). Furthermore, these variations are highly 
correlated with locomotive activity (Van Vliet et al., 2003). Therefore, the time 
of day that measurements are taken, and how active the animal is, can strongly 
impact the result obtained. For these reasons, continuous monitoring by 
telemetry over hours and/or days leads to considerably less statistical variation 
and a more accurate depiction of haemodynamic parameters than single-point 
readings (Van Vliet et al., 2006). However, irrespective of 24-hour variation, the 
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present study did detect differences in mean arterial pressure of up to 11 mmHg 
between wild type and GPR35 knockout mice in certain 12-hour periods. While 
the source of this day-to-day variation is unclear, this was not significant over 
the 7-day duration of the study. A similar pattern was observed for heart rate, 
with the heart rate of GPR35 knockout mice being up to 69 bpm lower than that 
of wild type mice during night-time periods, but not significantly different 
overall. This further emphasises the importance of monitoring haemodynamic 
parameters over time to gain a more accurate and physiologically representative 
understanding of cardiovascular regulation in mouse models. It is possible that 
deletion of GPR35 makes these mice more sensitive to transient environmental 
or metabolic influences on blood pressure and heart rate, since these 
parameters appear to be less stable from day to day in GPR35 knockout mice 
than in wild type mice. However, the study was conducted in multiple batches 
of animals, with recordings taking place over several different 7-day periods 
with different start days, so this instability is not due to any specific event (such 
as human disturbance on a particular day). The differences appear to be more 
pronounced during night-time (active) periods, which may reflect greater 
day/night blood pressure variability in GPR35 knockout mice. More detailed 
studies into the effects of GPR35 on blood pressure variability could yield further 
insight into this possible scenario. 
Besides the limitations of a single-point blood pressure measurement, an 
additional caveat to the previous study was that measurements were taken while 
the animals were under anaesthesia (although the anaesthetic agent and dose 
used are not reported) (Min et al., 2010). Isoflurane anaesthesia, which is 
frequently used in such studies, has previously been shown to have a significant 
effect on mean arterial pressure, as have the injectable agents 
ketamine/xylazine and pentobartital sodium (Janssen et al., 2004, 
Constantinides et al., 2011). For an uncharacterised strain such as the GPR35 
knockout mouse, it is not possible to rule out the prospect that the blood 
pressure difference observed by Min et al. was due to differences in the reaction 
to the anaesthesia, rather than an overall difference in physiological blood 
pressure, especially since it was the only cardiovascular parameter assessed. 
Telemetry provides the opportunity to obtain blood pressure readings in the 
complete absence of anaesthetic agents and after a suitable recovery period 
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following surgery. Therefore, it is possible to have greater confidence in the 
conclusion of the present study: that blood pressure is not significantly altered 
in GPR35 knockout mice. 
A limitation of this study, and a possible explanation for the lack of blood 
pressure effect observed, is that only one age range of mice was studied. All 
mice were between 12 and 14 weeks of age, the youngest age at which 
telemetry probes could be implanted. It is conceivable that pathological changes 
could become apparent in older animals. Min et al. do not report the age range 
of the mice used in their study (Min et al., 2010). To address this limitation, it 
would be necessary to repeat the study in aged mice. 
4.3.2 GPR35 knockout mice have normal cardiovascular 
function 
In addition to blood pressure and heart rate, several other parameters were 
assessed in the GPR35 knockout mouse in order to achieve a comprehensive 
basal characterisation of its cardiovascular phenotype. Echocardiographic 
assessment of left ventricular global systolic function found no differences in 
either fractional shortening or ejection fraction in the GPR35 knockout mice 
compared with the wild type strain. Since GPR35 expression in the heart has 
been linked to adverse cardiac remodelling, and heterologous overexpression of 
GPR35 has been shown to drive cardiomyocyte hypertrophy, one might expect 
GPR35 knockout mice to have altered cardiac mass or structure (Min et al., 
2010, Ronkainen et al., 2014). However, cardiac mass and cardiomyocyte 
morphology were found to be comparable to that of wild type mice. An obvious 
explanation for this is that GPR35 expression has thus far only been detected in 
the heart under pathophysiological conditions. Moreover, it has been shown to 
be upregulated in the heart in response to hypoxia-inducible factor 1 activation 
and following coronary artery ligation or trans-aortic constriction (TAC), 
suggesting that its expression may only be induced after the onset of disease 
(Ronkainen et al., 2014). This would explain the lack of effect observed in the 
heart under basal conditions. However, this raises the query of whether GPR35 
fulfils a protective or pathological role in the progression of adverse remodelling 
and heart failure. These processes can be modelled using surgical techniques 
such as TAC or by inducing hypertension through various means (Takefuji et al., 
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2012). Assessing the effects of such procedures in the GPR35 knockout mouse 
would therefore be a particularly interesting avenue to pursue in order to 
answer this question. 
As in the heart, global knockout of GPR35 also had no detectable effect on 
vascular function or morphology in this study. Neither constriction nor 
endothelium-dependent dilation was altered in the aortae or mesenteric 
resistance arteries of GPR35 knockout mice. This suggests that GPR35 does not 
contribute to vascular contractility under basal conditions. GPR35 expression has 
been detected in primary cell cultures of vascular endothelial cells and vascular 
smooth muscle cells; however, it has not been detected directly in vascular 
tissue (McCallum et al., 2015). A potential role of GPR35 in the vasculature in 
vivo therefore remains undefined, but, as in the heart, it may be necessary to 
induce disease for any GPR35-mediated effects to manifest. 
4.3.3 A normal phenotype does not prove a lack of function 
A lack of abnormal phenotype in a knockout mouse is not an uncommon 
occurrence – it has been estimated that some 10–15% of knockout mice 
generated display no discernible phenotypic alteration (although publication bias 
makes such estimates very broad) (Barbaric et al., 2007). There are several 
explanations for a knockout mouse not displaying an anticipated phenotype. 
There may truly be no effect of removing the gene due to the phenomenon of 
genetic redundancy, where a different gene is capable of performing the 
function of the absent gene. In particular, global constitutive knockout mice like 
the one used in this study allow for upregulation of functionally compensatory 
genes that can mask the phenotypic effect of the knockout (Rudnicki et al., 
1992, Nedvetzki et al., 2004). However, a more likely explanation for an 
apparent lack of abnormal phenotype in any given knockout mouse is that 
differences in physiology are present, but are not detected using the specific 
screening tools or outcomes used in the study. In this case, large-scale, unbiased 
functional screens of knockout mouse phenotypes that broadly cover the various 
therapy areas might prove useful in identifying gene functions and novel 
therapeutic targets. This approach has been used successfully to identify novel 
genes involved in processes such as platelet function, bone remodelling and 
neuropathic pain, to name but a few (Tang et al., 2010, Bassett et al., 2012, 
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White et al., 2013, Kostich et al., 2016). However, despite their value, these 
screens can still fail to identify any alteration. An alternative explanation for a 
lack of abnormal phenotype in these cases is that the abnormality may only 
become evident under certain environmental or physiological conditions. In such 
cases, a more focused and in-depth approach, such as the use of disease models 
to imitate altered physiological conditions, is required. Any of these 
explanations might apply to the GPR35 knockout mouse, and the lack of 
phenotypic alteration in cardiovascular function observed in this study should 
not be construed as a definitive lack of function. 
Does the apparent absence of a role in basal cardiovascular regulation suggest 
that GPR35 is not a potential therapeutic target in CVD? On the contrary, this 
finding may in fact strengthen its value, given the existing evidence for an 
association between GPR35 and CVD. If a gene is benign under normal 
conditions, but is upregulated and active under pathophysiological conditions, it 
is likely to have more specific on-target effects than a gene that is ubiquitously 
and/or constitutively expressed. This potential for increased specificity is one 
factor that makes orphan GPCRs attractive drug targets. Moreover, in 2003, 
Zambrowicz and Sands argued that many of the most successful drug targets 
(which have not changed substantially in the last 14 years) do not directly cause 
disease, but constitute molecular ‘switches’ that bring about a change in 
physiology that has the desired therapeutic effect (Zambrowicz and Sands, 
2003). This suggests that even though GPR35 modulation has no apparent 
influence on cardiovascular regulation in healthy mice, its role and therapeutic 
value may become evident when disease is induced. This reasoning gives rise to 
the conclusion that there is a need to determine the effects of GPR35 deficiency 
in CVD models, which forms the basis of the following chapter. 
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Chapter 5 Cardiovascular effects of angiotensin 
II infusion in a global GPR35 knockout mouse 
5.1 Introduction 
Following the studies described in the previous chapter, it was concluded that 
GPR35 knockout mice have normal blood pressure regulation or cardiovascular 
function under basal conditions. However, several previous studies have 
demonstrated effects of GPR35 in cells and tissues of the cardiovascular system 
(section 1.4.6.5). Some of these studies, particularly those reporting on in vivo 
effects in rodents and humans, have provided evidence for roles of GPR35 within 
pathophysiological contexts. Min et al. reported that GPR35 expression in heart 
tissue was higher in patients with heart failure compared with healthy control 
subjects (Min et al., 2010). Similarly, Ronkainen et al. reported increased 
cardiac expression of GPR35 in response to hypoxia and in in vivo rodent models 
of myocardial infarction and heart failure (Ronkainen et al., 2014). These 
findings suggest that GPR35 expression is induced in cardiovascular tissues under 
pathophysiological conditions, and so its role in the cardiovascular system may 
only manifest during cardiovascular disease. It remains unclear whether this 
induction of GPR35 contributes to the pathogenesis of disease, or whether it is 
an adaptive mechanism conferring a protective effect. Although several studies 
have investigated the effects of heterologous overexpression of GPR35 in cells of 
the cardiovascular system or GPR35 upregulation in vivo, the consequences of 
reduced GPR35 activity on the development of cardiovascular dysfunction have 
not been examined. In order to address this, an Ang II infusion model of 
hypertension and cardiovascular end-organ damage was used to determine the 
effects of global GPR35 deficiency on blood pressure regulation and 
cardiovascular function in the context of cardiovascular stress. 
Long-term exposure to elevated levels of Ang II is known to have various 
pathological effects on the cardiovascular system in vivo. These include 
increased vascular tone and blood pressure, which lead to vascular inflammation 
and remodelling, accelerated development of atherosclerosis and cardiac 
hypertrophy and injury following chronic exposure (Weiss et al., 2001, Crowley 
et al., 2006, Qi et al., 2011, Lima et al., 2016). Due to its systemic and wide-
ranging effects in the cardiovascular system, chronic infusion of Ang II in rodents 
145 
 
has been used extensively as a model for hypertension and cardiovascular 
disease (Weiss et al., 2001, Lu et al., 2015, Regan et al., 2015, Takayanagi et 
al., 2015, Lima et al., 2016). 
The dose of Ang II used in rodent studies is critical in achieving the required 
pathophysiological outcomes for a specific model. High doses of Ang II induce 
abdominal aortic aneurysm, and high infusion rates are frequently used in 
studies that attempt to model this pathology (Lu et al., 2015). However, the 
high doses used in this model are intrinsically associated with a significant risk of 
mortality caused by spontaneous rupture of the aneurysm, typically within the 
first week of treatment (Cao et al., 2010). Conversely, low infusion rates can 
model specific cardiovascular pathologies such as heart failure with preserved 
ejection fraction without inducing a pressor response (Regan et al., 2015). 
Intermediate doses of 400–1000 ng/kg/min for two to six weeks are typically 
used to induce a moderate-to-severe increase in blood pressure (20–50 mmHg), 
along with the associated pathological outcomes in end organs such as the heart 
and kidney (Crowley et al., 2006, Moore et al., 2015, Takayanagi et al., 2015). 
This chapter describes the effects of 2-week infusion of a low pressor dose of 
Ang II on the cardiovascular characteristics of both wild type and GPR35 
knockout mice. 
5.1.1 Aims 
The aims of this chapter were to: 
- Establish an Ang II infusion model in GPR35 knockout mice 
- Accurately assess the effects of Ang II infusion on haemodynamic 
parameters in wild type and GPR35 knockout mice using an implantable 
telemetry device 
- Determine the effects of Ang II infusion on cardiovascular function in wild 
type and GPR35 knockout mice 
- Determine the effects of Ang II infusion on cardiovascular end-organ 
damage in wild type and GPR35 knockout mice 
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5.1.2 Study design 
The purpose of this study was to compare the effects of 2-week Ang II infusion 
on blood pressure and cardiovascular function in the GPR35 knockout mouse, 
compared with those in the wild type background strain, C57BL/6. Since it was 
hypothesised that GPR35 knockout mice would have an exacerbated response to 
Ang II infusion, it was necessary to use as low a dose as possible to prevent 
mortalities due to abdominal aortic aneurysm. In order to be able to detect a 
response to Ang II infusion with minimal risk of mortality in the GPR35 knockout 
mice, a low pressor dose of 400 ng/kg/min of Ang II was used to induce a 
moderate blood pressure increase. 
Only male animals were used in order to eliminate sex-specific variation. 
Homozygous wild type and knockout littermates were bred, and were of 
sufficient body weight to tolerate telemetry probe implantation by 12 weeks of 
age. Probes were implanted at 12 weeks of age, followed by a 7-day recovery 
period during which no measurements were taken. At 13 weeks of age, cardiac 
function was assessed by echocardiography, then osmotic minipumps containing 
water or Ang II were implanted subcutaneously. Following minipump 
implantation, probes were remotely switched on and haemodynamic parameters 
were monitored continuously for 14 days (Figure 5-1). Blood pressure, heart rate 
and locomotive activity are all subject to intrinsic circadian rhythms in rodents, 
and the presence of these rhythms are indicative of normal health and 
cardiovascular function (Takeda and Maemura, 2011). In order to assess the 
diurnal variation in the parameters measured, the telemetry data generated in 
this study were separated into two 12-hour periods representing the dark period 
(night) and the light period (day). After 2 weeks of monitoring and infusion, a 
second echocardiographic assessment of cardiac function was performed, 
followed by sacrifice and ex vivo analysis at 15 weeks of age (Figure 5-1). 
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Figure 5-1 GPR35 KO Ang II infusion study timeline 
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5.2 Results 
5.2.1 Effects of Ang II infusion on haemodynamic properties in 
wild type and GPR35 knockout mice 
In order to assess the effects of Ang II infusion on blood pressure and heart rate 
in wild type and GPR35 knockout mice, haemodynamic parameters were 
monitored using an implantable telemetry system during 2-week infusion of 
either water or Ang II. One mortality occurred in the GPR35 knockout Ang II 
treatment group, which was confirmed by post-mortem examination to be due 
to a ruptured abdominal aortic aneurysm. Data from this animal were excluded 
from all analyses. 
All of the parameters measured followed normal diurnal rhythms over the 
light/dark cycle in all treatment groups (Figure 5-2 through Figure 5-5). In wild 
type mice, Ang II infusion induced a steady and moderate increase in blood 
pressure of approximately 20 mmHg over the 2-week period (Figure 5-2). This 
increase had a delayed onset, only becoming apparent from day nine of infusion 
onwards. At day 14 (following 2-week infusion), Ang II-infused mice had 
significantly higher systolic, diastolic and mean arterial blood pressures than 
water-infused mice (Figure 5-2 A, C and E). Overall, the change in blood 
pressure over time (calculated from the slope of the linear regression over 
14 days) was significantly greater for wild type mice infused with Ang II than 
those infused with water, with a mean increase of 1.42±0.39 mmHg/day versus 
−0.13±0.20 mmHg/day in systolic blood pressure, 1.24±0.27 mmHg/day versus 
0.11±0.15 mmHg in diastolic blood pressure and 1.29±0.33 mmHg/day versus 
−0.03±0.17 mmHg/day in mean arterial pressure (Figure 5-2 B, D and F). In 
GPR35 knockout mice, no differences between Ang II- and water-infused mice 
were observed in either blood pressure on day 14 or change over time, with a 
mean increase in mean arterial pressure of 0.58±0.35 mmHg/day in water-
infused mice and 0.12±0.24 mmHg/day in Ang II-infused mice (Figure 5-3). 
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Figure 5-2 Wild type mice develop Ang II-induced hypertension (A, B) Systolic, (C, D) diastolic 
and (E, F) mean arterial blood pressure were monitored in wild type (WT) mice infused with either 
water or Ang II over 2 weeks. Baseline measurements were taken on day 0 prior to minipump 
implantation (indicated by dotted line). (A, C, E) Data are presented as 12-hour means 
representing night (N) and day (D) periods of n = 7 animals +/- SEM; *p<0.05, ***p<0.001 in two-
tailed unpaired t test on day 14. (B, D, F) Change over 14 days was compared by two-tailed 
unpaired t-test on the slope of the linear regression (mmHg/day) for each individual animal, 
**p<0.01. 
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Figure 5-3 GPR35 knockout mice are resistant to AngII-induced hypertension (A, B) Systolic, 
(C, D) diastolic and (E, F) mean arterial blood pressure were monitored in GPR35 knockout (KO) 
mice infused with either water or Ang II over 2 weeks. Baseline measurements were taken on day 
0 prior to minipump implantation (indicated by dotted line). (A, C, E) Data are presented as 12-hour 
means representing night (N) and day (D) periods of n = 5 (KO + water) or n = 7 (KO + Ang II) 
animals +/- SEM; ns = not significant in two-tailed unpaired t test on day 14. (B, D, F) Change over 
14 days was compared by two-tailed unpaired t-test on the slope of the linear regression 
(mmHg/day) for each individual animal, but no significant differences were found. 
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Heart rate and locomotive activity were also monitored by telemetry (Figure 5-4 
and Figure 5-5). In wild type mice, there was no significant difference in heart 
rate on day 14 in Ang II-infused mice compared with water-infused mice (Figure 
5-4 A). In GPR35 knockout mice, heart rate on day 14 was significantly higher in 
Ang II-infused mice than in water-infused mice (508±13 bpm versus 453±17 bpm) 
(Figure 5-5 A). However, the change over time was not significantly different; 
heart rate decreased over time in all treatment groups, with a mean decrease of 
2.34±0.80 bpm/day and 2.11±1.28 bpm/day in water- and Ang II-infused wild 
type mice and 3.27±0.70 bpm/day and 0.93±0.89 bpm/day in water- and Ang II-
infused GPR35 knockout mice, respectively (Figure 5-4 B and D and Figure 5-5 B 
and D). No significant differences in activity were observed between the water 
and Ang II treatment groups in either wild type mice (Figure 5-4 C and D) or 
GPR35 knockout mice (Figure 5-5 C and D). Activity followed normal diurnal 
rhythms in all treatment groups (Figure 5-4 C and Figure 5-5 C), suggesting that 
the surgical procedures were well tolerated. 
152 
 
 
Figure 5-4 Ang II infusion does not affect heart rate or activity in wild type mice (A, B) Heart 
rate in beats per minute (bpm) and (C, D) activity were monitored in wild type (WT) mice infused 
with either water or Ang II over 2 weeks. Baseline measurements were taken on day 0 prior to 
minipump implantation (indicated by dotted line). (A, C) Data are presented as 12-hour means 
representing night (N) and day (D) periods; mean +/- SEM of n = 7 animals; ns = not significant in 
two-tailed unpaired t test on day 14. (B, D) Change over 14 days was compared by two-tailed 
unpaired t-test on the slope of the linear regression (bpm/day or arbitrary units/day) for each 
individual animal, but no significant differences were found (ns = not significant). 
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Figure 5-5 Ang II infusion does not affect heart rate or activity in GPR35 knockout mice 
(A, B) Heart rate in beats per minute (bpm) and (C, D) activity were monitored in GPR35 knockout 
(KO) mice infused with either water or Ang II over 2 weeks. Baseline measurements were taken on 
day 0 prior to minipump implantation (indicated by dotted line). (A, C) Data are presented as 12-
hour means representing night (N) and day (D) periods; mean +/- SEM of n = 5 (KO + water) or n = 
7 (KO + Ang II) animals; *p<0.05, ns = not significant in two-tailed unpaired t test on day 14. (B, D) 
Change over 14 days was compared by two-tailed unpaired t-test on the slope of the linear 
regression (bpm/day or arbitrary units/day) for each individual animal, but no significant differences 
were found. 
5.2.2 Effects of Ang II infusion on cardiovascular function in 
wild type and GPR35 knockout mice 
In addition to inducing hypertension, chronic Ang II infusion has previously been 
shown to lead to alterations in cardiovascular function that mimic those 
associated with cardiovascular disease (Regan et al., 2015, Lima et al., 2016, 
Takayanagi et al., 2016). Cardiac and vascular function in wild type and GPR35 
knockout mice subjected to Ang II infusion were investigated using in vivo and ex 
vivo methods, as described in Chapter 4. 
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Cardiac function was assessed by echocardiography on day 0, prior to minipump 
implantation, and on day 14, following two weeks of infusion and prior to 
sacrifice. In wild type mice, left ventricular wall thickness and diameter were 
not different on day 14 compared with day 0 after either water or Ang II infusion 
(Figure 5-6 B–D). However, both fractional shortening and ejection fraction were 
significantly reduced on day 14 compared with day 0 (by 6.3±2.2% and 5.0±1.8%, 
respectively; both p<0.05) in wild type mice infused with Ang II (Figure 5-6 E and 
H). The changes in fractional shortening and ejection fraction in Ang II-infused 
mice were significant when compared with those in water-infused mice 
(+0.4±1.6% and +0.3±1.2%, respectively; both p<0.05) (Figure 5-7). 
In GPR35 knockout mice, none of the echocardiographic measurements taken, 
including fractional shortening and ejection fraction, were significantly different 
on day 14 compared with day 0 (Figure 5-8). The changes in fractional shortening 
and ejection fraction were close to 0% in both water- and Ang II-infused GPR35 
knockout mice, and were not significantly different between groups (Figure 5-9). 
Thus, 2-week Ang II infusion led to significantly reduced fractional shortening 
and ejection fraction in wild type mice, but not in GPR35 knockout mice (Figure 
5-7 and Figure 5-9). 
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Figure 5-6 Fractional shortening and ejection fraction are significantly reduced in wild type 
mice following 2-week Ang II-infusion (A) Representative M-mode echocardiography images 
taken on the longitudinal axis at the level of the papillary muscle from wild type (WT) mice. Scale 
bar = 3 mm. (B–H) Measurements taken from M-mode images: (B) end diastolic left ventricular 
(LV) wall thickness; (C) end systolic and (D) end daistolic LV diameter; (E) fractional shortening of 
the left ventricle calculated from end systolic and diastolic diameters; (F) end systolic and (G) end 
diastolic volume; (H) ejection fraction calculated from end systolic and diastolic volumes. Data are 
mean +/- SEM of n = 8 (water) or n = 6 (Ang II) animals. *p<0.05 in two-tailed paired t test (day 0 
vs. day 14). 
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Figure 5-7 Two-week Ang II infusion leads to impaired cardiac function in wild type mice 
Change in (A) fractional shortening and (B) ejection fraction of wild type (WT) mice following 
2-week infusion of water (blue circles) or Ang II (green triangles). *p<0.05 in two-tailed unpaired 
t-test. 
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Figure 5-8 Echocardiographic measurements are not affected by 2-week Ang II-infusion in 
GPR35 knockout mice (A) Representative M-mode echocardiography images taken on the 
longitudinal axis at the level of the papillary muscle from GPR35 knockout (KO) mice. Scale bar = 
3 mm. (B–H) Measurements taken from M-mode images: (B) end diastolic left ventricular (LV) wall 
thickness; (C) end systolic and (D) end daistolic LV diameter; (E) fractional shortening of the left 
ventricle calculated from end systolic and diastolic diameters; (F) end systolic and (G) end diastolic 
volume; (H) ejection fraction calculated from end systolic and diastolic volumes. Data are mean +/- 
SEM of n = 6 animals. Data were compared by two-tailed paired t test (day 0 vs. day 14), but no 
significant differences were found. 
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Figure 5-9 GPR35 knockout mice are resistant to Ang II-induced impairment of cardiac 
function Change in (A) fractional shortening and (B) ejection fraction of GPR35 knockout (KO) 
mice following 2-week infusion of water (pink squares) or Ang II (purple triangles). Data were 
compared by two-tailed unpaired t-test, but no significant differences were found. 
To assess the effects of 2-week Ang II infusion on vasoreactivity in wild type and 
GPR35 knockout mice, constriction and relaxation responses of mesenteric 
arteries from water- and Ang II-infused mice were examined ex vivo by wire 
myography (Figure 5-10 and Figure 5-11). Mesenteric arteries from both wild 
type and GPR35 knockout mice infused with either water or Ang II showed 
increased intramural active effective pressure in response to noradrenaline, 
displaying sigmoidal concentration-response curves (Figure 5-10 A and B). 
Although mesenteric arteries from the Ang II-infused mice showed a trend 
towards increased maximal constriction for both wild type and GPR35 knockout 
strains, this was found not to be statistically significant (Figure 5-10 C). 
Mesenteric arteries from all treatment groups showed relaxation in response to 
carbachol when pre-constricted with 30 μM noradrenaline, displaying sigmoidal 
concentration-response curves (Figure 5-11 A and B). However, relaxation 
responses were observed only in a small proportion of vessels. Vessels that did 
not relax in response to carbachol were excluded from the analysis, leading to 
significantly reduced group sizes; therefore, statistical analysis could not be 
performed on the relaxation curves. However, Ang II-infused mice showed a 
trend towards reduced maximal relaxation for both wild type and GPR35 
knockout strains (Figure 5-11 C). Overall, the combined findings for constriction 
and relaxation responses suggest a trend towards increased tone and stiffness of 
resistance vessels from Ang II-infused mice for both wild type and GPR35 
knockout strains. Therefore, it was concluded that global knockout of GPR35 has 
no effect on vascular function in the context of Ang II-induced hypertension. 
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Figure 5-10 Vascular constriction responses are not affected by 2-week Ang II infusion in 
either wild type or GPR35 knockout mice Constriction concentration-response curves to 
noradrenaline of mesenteric arteries from (A) wild type (WT) or (B) GPR35 knockout (KO) mice 
following 2-week infusion with water or Ang II. (C) Statistical analysis of mean pEC50, Emax and area 
under curve (AUC) from concentration-response curves generated for each individual animal. 
Curve statistics were compared by two-tailed unpaired t test, but no significant differences were 
found. Data are mean +/- SEM of n = 5 animals. 
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Figure 5-11 Vascular relaxation responses are not affected by 2-week Ang II infusion in 
either wild type or GPR35 knockout mice Relaxation concentration-response curves to 
carbachol of mesenteric arteries from (A) wild type (WT) or (B) GPR35 knockout (KO) mice 
following 2-week infusion with water or Ang II. (C) Mean pEC50, Emax and area under curve (AUC) 
from concentration-response curves generated for each individual animal. Curve statistics could 
not be statistically compared due to insufficient group sizes. All data are mean +/- SEM of n = 2 
animals (n = 1 for WT + water). 
5.2.3 Effects of Ang II infusion on gross morphology of 
cardiovascular tissues in wild type and GPR35 knockout 
mice 
Ang II infusion has previously been shown to cause significant pathophysiological 
remodelling in cardiovascular tissues (Qi et al., 2011, Takayanagi et al., 2016). 
In order to assess Ang II-induced remodelling and end-organ damage in wild type 
and GPR35 knockout mice, gross morphology of the hearts, carotid arteries and 
kidneys of Ang II-infused mice was examined. 
In this study, Ang II infusion did not significantly affect whole heart or left 
ventricular mass in either wild type or GPR35 knockout mice (Figure 5-12 A–D). 
There was also no detectable induction of hypertrophy at the cellular level, with 
no significant increase in cardiomyocyte diameter observed in either strain 
(Figure 5-12 E). Cardiac fibrosis was similarly unaffected, with no significant 
increase in either perivascular or interstitial fibrosis induced by Ang II in wild 
type or GPR35 knockout mice (Figure 5-13). 
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Figure 5-12 Cardiac mass and cardiomyocyte morphology are not affected by 2-week Ang II 
infusion in either wild type or GPR35 knockout mice (A–D) Whole heart and left ventricle + 
septum (LV+S) mass of wild type (WT) (A, C) and GPR35 knockout (KO) (B, D) mice were 
determined at sacrifice and normalised to total body mass (A, B) or tibia length (C, D). (E) 
Transverse heart sections were stained with fluorescently-tagged wheat germ agglutinin (red) to 
visualise cardiomyocyte cell membranes, and with DAPI (blue) to visualise nuclei. Cell diameter 
was quantified by measuring the width of cardiomyocytes orientated on the short axis. Scale bar = 
20 μm. Data are mean +/- SEM of n = 7 animals (mass) or n = 5 animals (cardiomyocyte size). 
Data were compared by two-tailed unpaired t test, but no significant differences were found. 
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Figure 5-13 Cardiac fibrosis is not affected by 2-week Ang II infusion in either wild type or 
GPR35 knockout mice Transverse heart sections were stained with picro-sirius red to visualise 
collagen (red staining). Images of (A) perivascular and (B) interstitial regions were taken, and 
percent fibrosis was quantified as percentage of red pixels. Scale bar = 30 μm. Data are mean +/- 
SEM of n = 5 animals. Data were compared by two-tailed unpaired t test, but no significant 
differences were found. 
Large vessel morphology was assessed by staining carotid arteries with 
hematoxylin and eosin. Vascular morphology was unaffected by Ang II infusion, 
with no difference in medial area induced by Ang II infusion in either wild type 
or knockout mice (Figure 5-14).  
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Figure 5-14 Vascular morphology is not affected by 2-week Ang II infusion in either wild type 
or GPR35 knockout mice Transverse carotid artery sections were stained with hematoxylin and 
eosin to visualise vascular morphology, and tunica media area was quantified by measuring the 
smooth muscle layer (bright pink staining). Scale bar = 100 μm. Data are mean +/- SEM of n = 4 
animals. Data were compared by two-tailed unpaired t test, but no significant difference was found. 
The effects of Ang II infusion on renal hypertrophy and fibrosis were also 
assessed. As in the heart, no significant differences in renal mass were observed 
(Figure 5-15). There were also no detectable effects of Ang II infusion on either 
perivascular or insterstitial fibrosis in the kidneys of either wild type or GPR35 
knockout mice (Figure 5-16). 
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Figure 5-15 Renal mass is not affected by 2-week Ang II infusion in either wild type or 
GPR35 knockout mice Average kidney mass of wild type (WT) (A, C) and GPR35 knockout (KO) 
(B, D) mice were determined at sacrifice and normalised to total body mass (A, B) or tibia length 
(C, D). Data are mean +/- SEM of n = 7 animals. Data were compared by two-tailed unpaired t test, 
but no significant differences were found. 
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Figure 5-16 Renal fibrosis is not affected by 2-week Ang II infusion in either wild type or 
GPR35 knockout mice Transverse kidney sections were stained with picro-sirius red to visualise 
collagen (red staining). Images of (A) interstitial and (B) perivascular regions were taken, and 
percent fibrosis was quantified as percentage of red pixels. Scale bars = 50 μm. Data are mean +/- 
SEM of n = 5 animals. Data were compared by two-tailed unpaired t test, but no significant 
differences were found. 
5.2.4 Effects of Ang II infusion on receptor gene expression in 
wild type and GPR35 knockout mice 
One potential explanation for the finding that GPR35 knockout mice are resistant 
to Ang II-induced hypertension is that the AT1R is downregulated in these mice. 
This possibility was investigated by quantifying AT1aR mRNA (Agtr1a) expression 
in cardiovascular tissues of wild type and GPR35 knockout mice using qRT-PCR 
analysis (Figure 5-17 A). Agtr1a mRNA was detected in heart, aorta and kidney 
tissue of water-infused wild type mice (CT values of 24.4, 30.8 and 24.6, 
respectively) and GPR35 knockout mice (CT values of 24.0, 31.3 and 25.1, 
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respectively). Agtr1a expression in these tissues was not affected by Ang II 
infusion in either wild type or GPR35 knockout mice. However, significantly 
higher expression was detected in the heart tissue of untreated GPR35 knockout 
mice compared with untreated wild type mice (Figure 5-17 A). 
Based on previous reports that GPR35 is upregulated in the heart in some 
cardiovascular pathologies, Gpr35 expression in cardiovascular tissues of wild 
type mice subjected to 2-week infusion of water or Ang II was also assessed 
(Figure 5-17 B) (Min et al., 2010, Ronkainen et al., 2014). Gpr35 mRNA was 
detected in heart, aorta and kidney tissue of water-infused wild type mice (CT 
values of 32.4, 33.1 and 35.4, respectively); however, no significant increase in 
Gpr35 expression in response to Ang II infusion was observed (Figure 5-17 B). 
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Figure 5-17 Agtr1a and Gpr35 gene expression are not affected by 2-week Ang II infusion in 
either wild type or GPR35 knockout mice (A) Agtr1a gene expression relative to Ppib in wild 
type (WT) and GPR35 knockout (KO) mice subjected to 2-week infusion of water or Ang II. (B) 
Gpr35 gene expression relative to Ppib in WT mice subjected to 2-week infusion of water or Ang II. 
Data are mean +RQmax/-RQmin of n = 4 animals. Data were compared by one-way ANOVA with 
Tukey’s multiple comparisons post-test (A) or two-tailed unpaired t test (B); *p<0.05. 
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5.3 Discussion 
5.3.1 Low-dose Ang II infusion leads to hypertension in wild 
type mice 
Ang II infusion in mice has been used in many studies investigating different 
aspects of cardiovascular pathophysiology, including aortic aneurysm, 
hypertension and heart failure (Weiss et al., 2001, Lu et al., 2015, Regan et al., 
2015, Lima et al., 2016, Takayanagi et al., 2016). The cardiovascular effects of 
Ang II infusion vary depending on the infusion rate or dose of Ang II and the 
duration of infusion. In this study, C57BL/6 mice were infused with a low pressor 
dose of 400 ng/kg/min Ang II for two weeks. Blood pressure began to increase 
after 8 days, and a modest increase in blood pressure of approximately 20 mmHg 
was observed after two weeks. This is a slower onset and less drastic increase 
than has been reported previously, with doses of 490 ng/kg/min inducing a 
40 mmHg increase within 3 days, and 1000 ng/kg/min inducing a 50 mmHg 
increase within 5 days, as measured by either radiotelemetry or tail-cuff 
plethysmography (Crowley et al., 2006, Moore et al., 2015). The modest Ang II 
blood pressure response observed in this study is most likely a result of the 
slightly lower dose used, which was a necessary measure to take in order to 
minimise the risk of mortality in the event that GPR35 knockout mice had an 
exacerbated response to Ang II. However, this difference in outcome may also 
reflect strain- or facility-specific differences in the Ang II response. Many of 
these studies use wild type animals as littermate controls for transgenic or 
knockout animals, meaning they are highly inbred and therefore not identical to 
the generic background strain. There is also potential variation in the procedures 
associated with preparing the Ang II and osmotic minipumps, as well as the blood 
pressure measurements themselves. Caution should therefore be taken when 
comparing the results of different studies, and high internal validity should be 
the priority when interpreting the results of a particular study. 
As well as an increase in blood pressure, 2-week Ang II infusion also led to 
impaired left ventricular systolic function in wild type mice. Although no 
concomitant increase in cardiac mass or cardiomyocyte hypertrophy was 
observed, this observation is indicative of the pathological cardiac remodelling 
and cardiac dysfunction associated with chronic hypertension. Similarly to the 
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Ang II blood pressure response, the extent of left ventricular systolic dysfunction 
observed following Ang II infusion varies between different studies (González et 
al., 2015, Glenn et al., 2015, Khan et al., 2015). However, the modest decreases 
in fractional shortening and ejection fraction observed in this study were 
statistically significant when compared with changes over two weeks in water-
infused control mice. Although this is probably not a clinically meaningful 
alteration, it is suggestive of the initiation of pathophysiological processes, and 
is sufficient to serve as a wild type control against which to compare responses 
in the GPR35 knockout mouse. 
Unlike blood pressure and cardiac function, the remaining endpoints (vascular 
reactivity; cardiac, vascular and renal morphology; cardiac and renal fibrosis; 
and Atgr1a mRNA expression) were not significantly altered by two-week Ang II 
infusion in wild type mice at the selected dose. These parameters have all 
previously been reported to undergo changes in response to infusion of slightly 
higher doses of Ang II (Moore et al., 2015, Takayanagi et al., 2015, Mikolajczyk 
et al., 2016). This suggests that a dose of 400 ng/kg/min over two weeks is not 
sufficient to induce detectable changes in all cardiovascular end organs; rather, 
this dose results in an intermediate phenotype characterised by moderately 
increased blood pressure and mild cardiac dysfunction, without associated end-
organ damage. 
Gpr35 mRNA expression in the heart, aorta and kidney of wild type mice was 
also not significantly altered by 2-week Ang II infusion. Gpr35 expression in the 
heart has previously been reported to increase in response to coronary artery 
ligation or TAC in mouse models (Ronkainen et al., 2014). The data reported 
here suggest that this is an effect specific to models of severe cardiac injury or 
remodelling, and that the modest blood pressure and cardiac changes observed 
in this study were not sufficient to induce a detectable increase in Gpr35 
expression. However, Gpr35 mRNA was detected in all three tissues in both 
water- and Ang II-infused wild type mice. Low levels of Gpr35 expression in the 
heart and in primary vascular cells have been reported previously, and the 
findings presented here corroborate these reports (Taniguchi et al., 2006, 
McCallum et al., 2015). 
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5.3.2 GPR35 knockout mice are resistant to the effects of 
low-dose Ang II infusion 
Due to a previous report suggesting that GPR35 knockout mice have increased 
blood pressure (Min et al., 2010), the hypothesis of this study was that GPR35 
knockout mice are more sensitive to the effects of Ang II on the cardiovascular 
system. However, the data presented here demonstrate the opposite – GPR35 
knockout mice were resistant to the Ang II-induced increase in blood pressure 
and impairment of cardiac function observed in wild type mice. The changes in 
systolic, diastolic and mean arterial blood pressure over the 2-week infusion 
period were not significantly different in Ang II-infused mice compared with 
water-infused mice, whereas Ang II-infused wild type mice underwent increases 
of approximately 20 mmHg. Left ventricular fractional shortening and ejection 
fraction were similarly unaltered, with no significant differences between 
water- and Ang II-infused GPR35 knockout mice after 14 days, compared with 
significant differences of >6% in wild type mice.  
Given how little is known about the in vivo function of GPR35, there are many 
possible explanations for the lack of an Ang II response in the GPR35 knockout 
mouse. The fact that the Ang II response was completely abolished in these 
animals, rather than merely attenuated, suggests an important role for GPR35 in 
Ang II-mediated signalling – perhaps more important than was previously 
supposed, given its orphan status. The simplest explanation for this is that 
GPR35 directly interacts with the Ang II signalling axis, for example by acting as 
a co-receptor with the AT1R. The AT1R is known to heterodimerise with a wide 
range  of other Class A GPCRs, including dopamine D1R, β-ARs, cannabinoid 
receptor 1 and purinergic P2Y6 receptor (Zeng et al., 2003, Barki-Harrington et 
al., 2003, Rozenfeld et al., 2011, Nishimura et al., 2016). These interacting 
GPCRs alter AT1R signalling, either by stabilising the active AT1R conformation or 
by biasing the receptor to signal through a particular (sometimes atypical) G 
protein. Genetic deletion of the P2Y6 receptor has been shown to attenuate 
Ang II-induced effects on blood pressure and vascular function, and direct 
evidence for P2Y6/AT1R interaction has been reported (Nishimura et al., 2016). It 
is therefore possible to speculate that the similar effect on blood pressure in the 
present study are due to GPR35 interacting with AT1R. This has not been 
investigated previously, but would be relatively straightforward to test in vitro 
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using classical techniques for studying protein-protein interactions or one of 
many techniques that have been developed to probe GPCR oligomerisation 
(Marsango et al., 2015, Nakamura et al., 2016). 
An alternative explanation for the findings reported here is that GPR35 interacts 
with Ang II-mediated blood pressure regulation indirectly through its effects on 
other pathways. Previous studies linking GPR35 with inflammation (section 
1.4.6.3) provide another potential means by which GPR35 might alter Ang II-
induced effects on the cardiovascular system. GPR35 expression has been 
detected on both lymphocytes and several myeloid cells, as well as in vascular 
endothelial cells (Wang et al., 2006, Yang et al., 2010, Fallarini et al., 2010, 
McCallum et al., 2015). In addition, studies with GPR35 agonists have suggested 
possible roles in proinflammatory cytokine release, macrophage recruitment and 
leukocyte arrest onto the vascular endothelium (Barth et al., 2009, Fallarini et 
al., 2010, Maravillas-Montero et al., 2015). Vascular inflammation is now 
recognised as an important factor in the development of Ang II-induced 
hypertension and associated end-organ damage (McMaster et al., 2015, Wenzel 
et al., 2016). Various immune cells, including T cells, monocytes and natural 
killer cells, are recruited to vascular and perivascular tissues in response to 
Ang II infusion, and the resulting inflammation contributes to the vascular 
dysfunction that leads to hypertension (Guzik et al., 2007, Wenzel et al., 2011, 
Kossmann et al., 2013, Mikolajczyk et al., 2016). Therefore, the apparent 
requirement for GPR35 in Ang II-induced hypertension may in fact be due to a 
role in driving vascular inflammation, rather than a direct effect in vascular 
cells. This is an interesting possibility that has not previously been explored, and 
these findings could be followed up with future studies into the effects of GPR35 
on markers of vascular inflammation in models of hypertension. 
The finding that GPR35 knockout mice are protected from Ang II-induced 
impairment of cardiac function could be due to either direct effects in the 
myocardium or the absence of a blood pressure effect to initiate remodelling. 
However, previous studies demonstrating the induction of GPR35 expression in 
the heart during pathological cardiac remodelling suggest it has a direct function 
in this tissue (Min et al., 2010, Ronkainen et al., 2014). It is possible that GPR35 
has independent functions in the development of hypertension (via effects on 
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the vasculature) and during cardiac remodelling and heart failure (via effects in 
the heart). 
Regardless of the physiological mechanism underlying the roles of GPR35 in 
Ang II-induced hypertension and impaired cardiac function, the findings of this 
study suggest a pathological role for GPR35 in the development of CVD. Given 
previous reports that GPR35 couples selectively to Gα13 and regulates actin 
reorganisation in both cardiomyocytes and vascular smooth muscle cells, these 
cardiovascular effects of GPR35 are likely mediated by the Gα13/RhoA/ROCK 
pathway. Although the conclusion of this study conflicts with the previous blood 
pressure study in GPR35 knockout mice, existing evidence of pathological roles 
for Gα13/RhoA/ROCK signalling in the cardiovascular system provide a rationale 
for the finding that GPR35 knockout mice are protected from CVD (Wirth et al., 
2008, Surma et al., 2011, Takefuji et al., 2012). 
5.3.3 Is GPR35 a viable therapeutic target in hypertension? 
Although the mechanism by which inactivation of GPR35 attenuates Ang II-
induced hypertension remains unclear, the findings presented here suggest that 
targeting GPR35 could be a novel approach by which to therapeutically control 
blood pressure. The most obvious application of this would be to use GPR35 
antagonists to treat hypertension. It will therefore be necessary to test whether 
pharmacological manipulation of GPR35 activity can alter the development of 
hypertension in in vivo models of CVD. A study investigating pharmacological 
agonism of GPR35 in a rat model of hypertension is described in the following 
chapter. 
The lack of antagonists with affinity for rodent GPR35 orthologues will make 
investigating the therapeutic potential of GPR35 antagonism challenging. 
Ongoing screening efforts (supported by novel bioinformatic approaches to 
ligand identification as well as an improved understanding of the mechanisms of 
species selectivity) may yet yield equipotent GPR35 antagonists that will enable 
such studies (Ngo et al., 2016a, MacKenzie et al., 2014). However, a number of 
alternative approaches could also be explored in order to address this challenge. 
For example, blocking monoclonal antibodies, rather than small-molecule 
inhibitors, are an alternative means by which to inhibit GPCRs in vivo. In 
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particular, novel, single-domain ‘nanobodies’ derived from those that naturally 
occur in camelids are currently being pursued as experimental and therapeutic 
tools with which to alter GPCR function (Mujić-Delić et al., 2014, Manglik et al., 
2016). These have been successfully used to antagonise GPCRs (particularly 
chemokine receptors) both in vitro and in vivo, and thus provide a possible 
alternative to small molecule ligands with which to block GPR35 function 
(Maussang et al., 2013, Griffiths et al., 2016). 
In lieu of suitable molecules for blocking the rodent GPR35 orthologue, novel 
approaches may be used that enable in vivo testing of the existing human-
selective antagonists. ‘Humanised’ mice, in which the human receptor 
orthologue is knocked in either globally or to specific tissues, are already being 
used in GPCR research to answer a range of challenging questions (Tello et al., 
2013, Jun et al., 2014, Robinson et al., 2015). A humanised GPR35 knock-in 
mouse is currently being developed, and will enable the effects of 
pharmacological antagonism of GPR35 to be assessed in vivo for the first time. 
This, along with a better understanding of the physiological roles of GPR35, will 
reveal its true potential as a pharmacological target in CVD.
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Chapter 6 Cardiovascular effects of a GPR35 
agonist in the stroke-prone spontaneously 
hypertensive rat 
6.1 Introduction 
The findings described in the previous two chapters suggest that although a 
global deficiency of GPR35 has no effect on the basal regulation of 
cardiovascular function, it does attenuate some of the pathological outcomes of 
chronic cardiovascular stress. This implies a role for GPR35 in the development 
and progression of cardiovascular dysfunction in disease. These conclusions led 
to the hypothesis that, if GPR35 deficiency attenuates cardiovascular 
dysfunction, then increased GPR35 activity would exacerbate it. This hypothesis 
is explored in this chapter. Furthermore, in order to assess the therapeutic 
potential of GPR35 as a pharmacological target in CVD, it is important to 
establish whether its activity can be pharmacologically modulated in vivo. To 
address this question, it was of interest to determine the effects of 
pharmacological agonism of GPR35 in vivo, within the physiological context of 
CVD. This chapter describes the cardiovascular effects of long-term 
administration of a GPR35 agonist in a rodent model of CVD. 
The stroke-prone spontaneously hypertensive rat (SHRSP) is a well-characterised 
genetic model of cerebrovascular disease and essential hypertension that has 
been used extensively in the study of cardiovascular pathologies including 
stroke, hypertension and end-organ damage (Yamori and Horie, 1977, Jacob et 
al., 1991, Rocha et al., 1998, Flores-Munoz et al., 2012, McLachlan et al., 2014). 
The SHRSP model is an inbred strain isolated from Wistar-Kyoto rats, which 
begins to develop high blood pressure at 4–7 weeks of age and demonstrates 
moderate-to-severe hypertension (>200 mmHg) by 10–12 weeks of age (Yamori 
and Horie, 1977, Christiansen et al., 2002). It is therefore a highly useful model 
in which to study the progression of cardiovascular dysfunction from an early 
age, without the need for exogenous interventions such as salt-loading. The 
mechanisms of hypertension in the SHRSP are polygenic and are still not fully 
understood, although a large number of genetic studies have identified several 
loci that contribute to the hypertensive phenotype (Jacob et al., 1991, Graham 
et al., 2007, Yamamoto et al., 2013). Similarly to human essential hypertension 
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(also a complex polygenic condition), blockade of the renin-angiotensin-
aldosterone system is effective in reducing blood pressure and end-organ 
damage in this model (Flores-Munoz et al., 2012, McLachlan et al., 2014). These 
similarities between the SHRSP and human essential hypertension make it an 
ideal model in which to study the potential role of GPR35 in hypertension and 
cardiovascular pathophysiology. 
As discussed previously (section 1.4.3.1), a number of synthetic agonists with 
efficacy at the rat GPR35 orthologue have now been identified (Jenkins et al., 
2010, Southern et al., 2013, MacKenzie et al., 2014). The partial agonist 
amlexanox is among the most potent of these in β-arrestin recruitment assays 
(EC50 = 23 nM (MacKenzie et al., 2014)), and has previously been shown to have 
good oral bioavailability and pharmacokinetic properties (Khandwala et al., 
1997, Southern et al., 2013). For these reasons, amlexanox was selected as the 
agonist for this study. Amlexanox is a mast cell stabiliser first developed and 
used clinically in Japan as an anti-inflammatory and anti-allergic agent (Makino 
et al., 1987, Bell, 2005). It is currently used as a topical anti-inflammatory 
treatment for aphthous ulcers (marketed as Aphthasol®), but has been shown to 
have clinical efficacy both as a topical treatment and as an oral tablet (Bell, 
2005, Meng et al., 2009). A pharmacokinetic study of the 5% oral paste in 
humans showed sufficient gastrointenstinal absorption to reach serum 
concentrations of up to 120 ng/mL (402 nM) from a single dose of 100 mg, and a 
half-life of 3.5 hours (Khandwala et al., 1997). 
Amlexanox is not a novel drug, and as such it has several known targets other 
than GPR35. It binds with high affinity to the non-canonical IκB kinases (IKKs) 
IKK-ε and TANK-binding kinase-1 (TBK-1), which are associated with obesity and 
insulin resistance (Reilly et al., 2013). It inhibits these kinases with an IC50 of 1–
2 μM, and has been shown to stimulate increased fat metabolism, increased 
insulin sensitivity and weight loss in obese mice at doses of 25–50 mg/kg/day 
(Reilly et al., 2013). In addition, amlexanox has recently been reported to 
inhibit GRK5 with an IC50 of 13 μM (Homan et al., 2014). However, the potency 
of amlexanox at these alternative targets is in the micromolar range – at least 
100-fold lower than the concentrations required to activate rat GPR35 
(MacKenzie et al., 2014). Therefore, careful dosing should limit potential off-
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target effects mediated by these kinases in in vivo studies in the SHRSP. This 
chapter describes an in vivo study into the cardiovascular effects of amlexanox 
treatment in the SHRSP. 
6.1.1 Aims 
The aims of this chapter were to: 
- Accurately assess the effects of amlexanox treatment on haemodynamic 
parameters in the SHRSP using an implantable telemetry device 
- Determine the effects of amlexanox treatment on cardiovascular end-
organ damage in the SHRSP 
- Assess potential off-target effects of amlexanox on fat metabolism in the 
SHRSP 
6.1.2 Study design 
The dose of amlexanox used in this study was critical in minimising potential off-
target effects of the treatment. It has been reported that oral doses of 25–
50 mg/kg/day are sufficient to achieve serum concentrations of >5 μM in mice 
(Reilly et al., 2013). Therefore, an oral dose of 2.5 mg/kg/day was estimated to 
be required for a serum concentration of approximately 500 nM, which would 
achieve maximum efficacy at GPR35 without inhibiting other, lower-potency 
targets. To minimise stress artefacts in blood pressure measurements, 
amlexanox was administered orally in food. Control animals received an 
equivalent volume of vehicle (DMSO) in the same manner. 
In this study, amlexanox was administered to SHRSP in order to determine the 
effects of GPR35 agonist on blood pressure and end-organ damage in a model of 
essential hypertension. Only male animals were used in order to eliminate sex-
specific variation. Oral administration of vehicle or amlexanox commenced at 
6 weeks of age and continued daily for 6 weeks (Figure 6-1). The body weight of 
animals limits the age at which telemetry probes can be safely implanted; 
therefore systolic blood pressure was monitored by tail-cuff plethysmography 
prior to treatment and weekly for the first 3 weeks of treatment. At 9–10 weeks 
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of age, telemetry probes were implanted and haemodynamic parameters were 
monitored continuously by telemetry for the following 3 weeks of treatment 
(Figure 6-1). In order to assess the diurnal variation in the parameters measured, 
the telemetry data generated in this study were separated into two 12-hour 
periods representing the dark period (night) and the light period (day). 
Treatment was followed by sacrifice and ex vivo analysis at 12 weeks of age. 
 
Figure 6-1 SHRSP amlexanox study timeline 
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6.2 Results 
6.2.1 Effects of amlexanox treatment on haemodynamic 
properties in the SHRSP 
Blood pressure and other haemodynamic parameters were monitored in 
conscious SHRSP over six weeks of amlexanox administration (Figure 6-2 and 
Figure 6-3). All parameters followed normal diurnal rhythms over the light/dark 
cycle in both vehicle-treated and amlexanox-treated SHRSP (Figure 6-2 and 
Figure 6-3). Systolic blood pressure measured by tail-cuff plethysmography was 
not significantly different between the groups at day 0 prior to commencement 
of treatment (Figure 6-2 A). Systolic blood pressure increased over weeks 1–3 of 
treatment, but was not significantly different between the groups during this 
time (Figure 6-2 A). However, by the commencement of telemetry recordings at 
week 4 (9–10 weeks of age), systolic blood pressure in both groups reached a 
plateau that was significantly higher in amlexanox-treated SHRSP than in 
vehicle-treated animals, by a difference of approximately 12.5 mmHg (Figure 
6-2 A). Mean arterial pressure was also significantly higher in amlexanox-treated 
SHRSP, whereas diastolic blood pressure showed a trend towards being higher 
but was not significantly different according to statistical analysis (Figure 6-2 B). 
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Figure 6-2 Blood pressure is significantly increased by amlexanox treatment in SHRSP (A) 
Systolic blood pressure, (B) diastolic blood pressure and (C) mean arterial pressure were 
monitored over six weeks (A) or three weeks (B, C) in SHRSP treated with vehicle (blue circles) or 
2.5 mg/kg/day amlexanox (red triangles) using tail-cuff plethysmography and/or telemetry. Tail-cuff 
data are presented as weekly averages of 24-hour means and telemetry data are presented as 
weekly averages of 12-hour means representing night (N) and day (D) periods; mean +/- SEM of n 
= 8 animals. *p<0.05, **p<0.01 in two-way repeated measures ANOVA. 
Heart rate and locomotive activity were also monitored by telemetry during 
weeks 4–6 of amlexanox treatment (Figure 6-3). No significant differences in 
either heart rate or activity were observed between vehicle-treated and 
amlexanox-treated SHRSP (Figure 6-3). Activity was subject to normal diurnal 
rhythms in both groups, suggesting the surgical procedure was well tolerated and 
the haemodynamic parameters observed are representative of those under 
normal behavioural conditions (Figure 6-3 B). 
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Figure 6-3 Heart rate and locomotive activity are not affected by amlexanox treatment in 
SHRSP (A) Heart rate in beats per minute (bpm) and (B) locomotive activity were monitored over 
three weeks in SHRSP treated with vehicle (blue circles) or 2.5 mg/kg/day amlexanox (red 
triangles) using telemetry. Data are presented as weekly averages of 12-hour means representing 
night (N) and day (D) periods; mean +/- SEM of n = 8 animals. Data were compared by two-way 
repeated measures ANOVA, but no significant differences were found. 
6.2.2 Effects of amlexanox treatment on cardiovascular 
end-organ damage in the SHRSP 
The SHRSP is known to have increased levels of cardiovascular end-organ damage 
such as pathological cardiac remodelling and fibrosis (Flores-Munoz et al., 2012, 
McLachlan et al., 2014). In order to determine whether amlexanox treatment 
exacerbates these markers of advanced cardiovascular damage, gross 
morphology of the heart and kidney in amlexanox-treated SHRSP was examined. 
Both whole heart and left ventricular mass were significantly increased in 
amlexanox-treated SHRSP when normalised to total body mass (Figure 6-4 A). 
Increases were also observed when normalised to tibia length, although this 
difference was only statistically significant for left ventricular mass and not 
whole heart mass (Figure 6-4 B). There was a trend towards increased 
cardiomyocyte diameter, although the difference observed was small and not 
statistically significant (Figure 6-4 C). Overall, these data suggest that 
amlexanox treatment exacerbated gross cardiac hypertrophy in the SHRSP. 
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Figure 6-4 Cardiac mass is significantly increased by amlexanox treatment in SHRSP (A, B) 
Whole heart and left ventricle + septum (LV+S) mass were determined at sacrifice and normalised 
to (A) total body mass or (B) tibia length. (C) Transverse heart sections were stained with 
fluorescently-tagged wheat germ agglutinin (red) to visualise cardiomyocyte cell membranes, and 
with DAPI (blue) to visualise nuclei. Cell diameter was quantified by measuring the width of 
cardiomyocytes orientated on the short axis. Scale bar = 50 μm. Data are mean +/- SEM of n = 8 
animals (mass) or n = 5 animals (cardiomyocyte size). *p<0.05, **p<0.01 in two-tailed unpaired t 
test. 
Cardiac fibrosis is another marker of cardiac dysfunction that is present under 
basal conditions in the SHRSP (Flores-Munoz et al., 2012, McLachlan et al., 
2014). However, amlexanox treatment did not have a significant effect on either 
perivascular or interstitial fibrosis in the SHRSP myocardium (Figure 6-5). 
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Figure 6-5 Cardiac fibrosis is not affected by amlexanox treatment in the SHRSP Transverse 
heart sections were stained with picro-sirius red to visualise collagen (red staining). Images of (A) 
perivascular and (B) interstitial regions were taken, and percent fibrosis was quantified as 
percentage of red pixels. Scale bars = 100 μm. Data are mean +/- SEM of n = 5 animals. Data 
were compared by two-tailed unpaired t test, but no significant differences were found. 
In order to determine the effects of amlexanox on end-organ damage in the 
kidney, renal mass and fibrosis were assessed (Figure 6-6). No differences in 
average kidney mass were observed between vehicle-treated and amlexanox-
treated SHRSP when normalised to either total body weight or tibia length 
(Figure 6-6 A and B). Perivascular fibrosis in the kidney was significantly 
increased in amlexanox-treated SHRSP (Figure 6-6 C). Interstitial fibrosis was 
very low in both groups, and was not affected by amlexanox treatment (Figure 
6-6 D). 
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Figure 6-6 Renal perivascular fibrosis is significantly increased by amlexanox treatment in 
the SHRSP (A, B) Average kidney mass was determined at sacrifice and normalised to (A) total 
body mass or (B) tibia length. (C, D) Transverse kidney sections were stained with picro-sirius red 
to visualise collagen (red staining). Images of (C) interstitial and (D) perivascular regions were 
taken, and percent fibrosis was quantified as percentage of red pixels. Scale bars = 50 μm. Data 
are mean +/- SEM of n = 8 animals (mass) or n = 5 animals (fibrosis). *p<0.05 in two-tailed 
unpaired t test. 
6.2.3 Effects of amlexanox treatment on fat metabolism in the 
SHRSP 
Higher doses of amlexanox have previously been shown to reduce both total 
body mass and body fat mass in mouse models of genetic and diet-induced 
obesity through the inhibition of the alternative targets IKK-ε and TBK-1 (Reilly 
et al., 2013). In order to address the possibility that the findings described in 
this chapter are due to inhibition of non-GPR35 targets, potential effects of 
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amlexanox treatment on body weight and fat pad mass in the SHRSP were 
assessed (Figure 6-7). Total body mass was not affected by amlexanox treatment 
(Figure 6-7 A). No significant differences in either retroperitoneal or epididymal 
fat pad mass were observed between vehicle-treated and amlexanox-treated 
SHRSP, whether normalised to total body mass or tibia length (Figure 6-7 B). 
These data suggest that the low dose of amlexanox used in this study was not 
sufficient to induce detectable off-target effects on fat metabolism in the 
SHRSP. 
 
Figure 6-7 Body mass and fat pad mass are not affected by amlexanox treatment in the 
SHRSP (A) Total body mass and (B, C) retroperitoneal and epididymal fat pad mass were 
determined at sacrifice, and fat pad mass was normalised to either (B) total body mass or (C) tibia 
length. Data are mean +/- SEM of n = 8 animals. Data were compared by two-tailed unpaired t test, 
but no significant differences were found. 
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6.3 Discussion 
6.3.1 Amlexanox induces increased blood pressure and end-
organ damage in SHRSP 
The findings presented here show that oral administration of the GPR35 agonist 
amlexanox leads to increased blood pressure and cardiovascular end-organ 
damage in the SHRSP, a rat model of essential hypertension. After 6 weeks of 
treatment, systolic blood pressure was approximately 12.5 mm/Hg higher in 
amlexanox-treated animals than in vehicle-treated animals. In a clinical setting, 
blood pressure differences of this magnitude have a significant effect on the risk 
of cardiovascular events, complications and all-cause mortality (Ettehad et al., 
2016). In addition, this blood pressure-raising effect was sufficient to induce 
increases in cardiac mass and perivascular fibrosis in the kidney, both of which 
are indicators of cardiovascular stress and early markers of pathological 
remodelling in the SHRSP (Graham et al., 2004, Hultström, 2012). This suggests 
that pharmacological agonism of GPR35 exacerbates pre-existing CVD, indicating 
a pathological role for GPR35 in the development of hypertension and associated 
end-organ damage. 
The mean blood pressure of the 10–12 week-old SHRSPs used in this study was 
considerably lower than that reported for the original SHRSP strain (Yamori and 
Horie, 1977). This discrepancy can be explained by differences in the techniques 
used to measure blood pressure as well as colony-specific genetic and 
phenotypic variation. The SHRSP colony at the University of Glasgow, which has 
been bred in-house for over 20 years, has previously been reported to have 
milder hypertension than the original strain, with systolic blood pressures of 140–
160 mmHg at 10–12 weeks of age (Flores-Munoz et al., 2012, McLachlan et al., 
2014). The blood pressures observed in this study are in line with these previous 
reports, which suggests that the blood pressure values were recorded 
accurately. 
Although a significant difference in blood pressure was observed after telemetry 
probe implantation and recovery (10–12 weeks of age), this difference was not 
evident in younger SHRSP when systolic blood pressure was measured by tail-cuff 
plethysmography (6–9 weeks of age). It is not clear whether this is due to a lag 
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between the commencement of amlexanox treatment and the increase in blood 
pressure, or the lower sensitivity of the tail-cuff method. Nonetheless, this study 
further supports the view that radiotelemetry is a sensitive method capable of 
detecting relatively small differences in blood pressure, in spite of the limitation 
that it can only be used in small animals after they have reached a certain size 
threshold (Kramer and Kinter, 2003). Once again, the rapid restoration of diurnal 
rhythms in haemodynamic parameters and locomotive activity suggest that the 
telemetry probe implantation procedure was well tolerated. 
6.3.2 Are the effects of amlexanox on SHRSP mediated by 
GPR35? 
A limitation of this study is that amlexanox is known to act at several targets 
other than GPR35 (Reilly et al., 2013, Homan et al., 2014). Therefore, it is not 
possible to ascertain that these effects on the cardiovascular system are 
specifically mediated by GPR35. However, the study was designed to minimise 
off-target effects of amlexanox by using a dose that would lead to serum levels 
that were sufficient to activate GPR35 (EC50 = 23 nM (MacKenzie et al., 2014)) 
but not the alternative targets (IC50 = 1–13 μM (Reilly et al., 2013, Homan et al., 
2014)). In addition, body mass and fat pad mass were measured at the end of 
the study in order to monitor potential off-target effects at IKK-ε and TBK1, 
which have previously been associated with increased fat metabolism in mice. 
Although higher doses of amlexanox have previously been shown to increase fat 
metabolism in obese mice (Reilly et al., 2013), no detectable effects of 
amlexanox on fat metabolism were observed in this study, with similar 
epididymal and retroperitoneal fat pad masses in vehicle- and amlexanox-
treated animals following six weeks of treatment. However, this is a very basic 
assessment of fat metabolism, and more in-depth investigation would be 
required to confirm that the effect on blood pressure was not mediated by these 
kinases. For example, it would be informative to determine whether fat pad 
mass, weight gain and expression of lipid metabolism-associated genes are 
altered by this lower dose of amlexanox in rats fed a high-fat diet. 
Amlexanox is also an inhibitor of GRK5, which is known to be expressed and play 
important roles in cardiovascular tissues (Hullmann et al., 2016). However, 
previous studies show that GRK5 activity is associated with increased blood 
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pressure and severe cardiac hypertrophy (Keys et al., 2005, Hullmann et al., 
2014). In particular, it has been demonstrated to have GPCR-independent effects 
on hypertrophic gene expression which drive pathological hypertrophy and the 
progression of heart failure (Traynham et al., 2015). Therefore, off-target 
inhibition of GRK5 by amlexanox would potentially have had the opposite effects 
to those observed in this study. Furthermore, the potency of amlexanox at rat 
GPR35 is approximately 1000-fold greater than at GRK5 (Homan et al., 2014, 
MacKenzie et al., 2014). These factors make it very unlikely that the increased 
blood pressure and end-organ damage observed here are due to amlexanox-
mediated inhibition of GRK5. 
In most in vivo agonist studies, it is customary to validate findings by blocking 
the observed effects of the agonist with a pharmacological antagonist. However, 
as discussed in previous chapters, the human-selective nature of available GPR35 
antagonists makes this approach impossible using existing tools. An alternative 
approach would be to determine whether these effects also occur in the absence 
of GPR35 expression using the GPR35 knockout mouse. However, like many 
GPR35 ligands, amlexanox also displays significant species selectivity, and is 
approximately 10-fold less potent at the mouse orthologue than at the rat 
orthologue (Milligan group, unpublished data). Therefore, a higher dose would 
be required to achieve equivalent efficacy in mice, which would increase the 
likelihood of off-target effects. Furthermore, the findings discussed in Chapters 
4 and 5 suggest that pre-existing CVD is necessary for GPR35-mediated effects to 
be observed. Therefore, a CVD model such as Ang II infusion would have to be 
used alongside agonist administration in the knockout mouse, which would 
introduce additional variables.  
In lieu of suitable methods for blocking amlexanox agonism at GPR35, 
confidence in the GPR35-specific nature of these findings could be improved by 
replicating the results with different GPR35 agonists. However, most of the 
available agonists are either not potent enough to be used safely in vivo or have 
known alternative targets that are likely to influence cardiovascular function – 
for example, one of the first-discovered and most frequently used GPR35 
agonists, zaprinast, is a PDE5 inhibitor with low micromolar potency, which has 
cGMP-mediated effects on vascular and myocardial contraction (Mohan et al., 
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1996, Medina et al., 2000, Ziolo et al., 2003). Since this study commenced, the 
novel GPR35 agonists lodoxamide and bufrolin – also mast cell stabilisers – have 
been reported to have comparable potency to amlexanox at rat GPR35, and have 
also been shown to be equipotent at the rat and human orthologues (MacKenzie 
et al., 2014). These agonists could be used in the SHRSP to determine whether 
other GPR35 agonists have similar effects to amlexanox on blood pressure and 
end-organ damage. However, little is known about the oral bioavailability and 
pharmacokinetic properties of these agonists, and it will be necessary to 
characterise these properties if lodoxamide and bufrolin are to be used in future 
in vivo studies. 
6.3.3 Possible mechanisms of GPR35-mediated effects of 
amlexanox in the SHRSP 
Although the present study did not investigate the precise mechanism by which 
GPR35 might exert its effects on cardiovascular function, the observed 
pathological effects of amlexanox (and presumably GPR35) in the SHRSP are 
consistent with the current understanding of GPR35 signalling. Previous reports, 
as well as the findings presented in Chapter 3, suggest that GPR35 alters cell 
size, shape and differentiation state via its activation of Gα13 and the 
RhoA/ROCK pathway (Jenkins et al., 2011, Ronkainen et al., 2014, McCallum et 
al., 2015). Although increases in vascular tone and basal regulation of blood 
pressure are primarily mediated by Gαq/11-coupled receptors such as the AT1R 
and endothelin-1 receptors, these GPCRs often also couple to Gα12/13. Whilst 
Gα12/13 are not required for basal regulation of blood pressure, they have been 
shown to play a major role in the development of cardiovascular dysfunction. 
For example, the pathophysiological effects of TAC-induced heart failure and 
Ang II-induced hypertension have been shown to be Gα13-dependent and 
mediated by RhoA (Takefuji et al., 2012). Similarly, Wirth et al. demonstrated 
that salt-induced hypertension is dependent on both Gα12/13 and their effector, 
the Rho-GEF LARG (Wirth et al., 2008). Therefore, GPR35-mediated activation of 
Gα13 and the RhoA/ROCK pathway in cardiovascular tissues is a reasonable 
explanation for the effects of amlexanox in SHRSP reported here. 
Although this proposed signalling mechanism can account for the effects of 
GPR35 agonism on blood pressure and end-organ damage, it is not clear whether 
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the effects observed in this study are due to GPR35 activity in the heart, 
vasculature or other tissues. Once again, these results suggest both a direct 
effect of GPR35 on blood pressure, and end-organ damage in cardiovascular 
tissues, which may be secondary to the increase in blood pressure or due to 
independent GPR35 activity in these tissues. As discussed in section 5.3.2, the 
current understanding of GPR35 function in the cardiovascular system suggests it 
may make independent contributions to the regulation of both vascular function 
and cardiac hypertrophy, either through modulation of signalling in vascular cells 
and cardiomyocytes or through indirect effects on vascular inflammation via its 
expression on immune cells (Wang et al., 2006, Yang et al., 2010, Fallarini et 
al., 2010). More detailed investigation of the effects of GPR35 in different cell 
types will be necessary in order to determine the specific functions of GPR35 in 
different tissues. 
6.3.4 The therapeutic potential of GPR35 in CVD 
The finding that pharmacological agonism of GPR35 exacerbates pre-existing 
CVD suggests that, conversely, antagonism of GPR35 could be a novel 
therapeutic strategy to combat CVD. The next logical step in these studies will 
be to test whether antagonism or inactivation of GPR35 can prevent or reverse 
the development of hypertension and its associated end-organ damage. The 
SHRSP is an ideal model in which to investigate this, due to the early age at 
which hypertension begins to develop, and the model’s similarities with human 
hypertension (discussed in section 6.1). However, once again, a lack of suitable 
pharmacological tools means this is currently not possible. A variety of 
alternative approaches, as discussed in section 5.3.3, will hopefully circumvent 
this issue and enable the value of GPR35 as a therapeutic target in CVD to be 
assessed.
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Chapter 7 Final discussion 
The aims of this work were to investigate GPR35 signalling in vitro, examine the 
role of GPR35 in the cardiovascular system, and determine the contribution of 
GPR35 to cardiovascular pathophysiology in a relevant model, in order to 
evaluate the potential of GPR35 as a therapeutic target in CVD. Each of these 
aims was addressed by the studies described in the preceding chapters. This 
chapter summarises the main conclusions of this thesis and their implications. 
Although GPR35 has been the subject of in vitro studies for several years, 
previous work has primarily focused on identifying ligands and coupling partners, 
and relatively little is known about its influence on downstream signalling and 
cellular responses. The studies described in Chapter 3 add to the existing 
knowledge of GPR35 signalling, identifying previously unknown aspects of the 
molecular and cellular responses to GPR35 activation and providing a rationale 
for how this receptor influences the cardiovascular system. The findings 
demonstrate the role of agonist-dependent phosphorylation in the regulation of 
different cellular outcomes of GPR35 activation. Mutagenesis studies established 
how different phosphorylation sites in the GPR35 C-terminal tail contribute to 
β-arrestin recruitment, and provide additional evidence for the ‘phosphorylation 
barcode’ hypothesis (Tobin et al., 2008, Liggett, 2011). This offers a potential 
explanation for how GPR35 appears to have several different coupling profiles 
and physiological functions, depending on which tissue or cell type is being 
studied. 
Although GPR35 has previously been shown to couple to Gα13 (Jenkins et al., 
2011), the experiments described in Chapter 3 are the first to directly 
demonstrate that this coupling leads to reorganisation of the actin cytoskeleton 
in HEK293 cells. Reorganisation of the actin cytoskeleton in cardiomyocytes has 
previously been linked to GPR35 overexpression and function (Min et al., 2010, 
Ronkainen et al., 2014). Therefore, GPR35/Gα13-mediated activation of the 
RhoA/ROCK pathway, either in cardiomyocytes or in vascular cells, is likely to be 
responsible for GPR35-mediated effects on the cardiovascular system. This is 
further supported by the findings presented in Chapter 5, which suggest that 
knocking out GPR35 has protective effects similar to those of cardiomyocyte- 
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and vascular smooth muscle-specific knockout of Gα12/13 (Wirth et al., 2008, 
Takefuji et al., 2012). 
The main limitation of the existing studies investigating GPR35 signalling (both in 
this thesis and in the wider literature) is that they have mostly been conducted 
in artificial cell culture models such as HEK293 cells. Although the simplicity and 
ubiquity of these models provide a convenient means by which to study basic 
aspects of GPCR signalling, they are not representative of normal physiological 
function. Therefore, it should now be a priority to translate some of these 
studies into more physiologically relevant contexts, such as primary cell models, 
to determine whether findings are applicable in vivo. This is particularly 
important for GPR35, as it has been shown to have very different functions in 
different tissues; for example, it is thought to couple to Gαi/o in DRG neurons, 
but Gα13 in vascular smooth muscle cells (Ohshiro et al., 2008, McCallum et al., 
2015). Therefore, observations made in HEK293 cells may not necessarily be 
generalisable to the different cell types in which GPR35 is expressed. Developing 
a better understanding of how GPR35 signals in primary cells of the 
cardiovascular system (and in other physiological systems) will be critical in 
assessing its role in CVD and its potential as a therapeutic target. 
In addition to a large number of in vitro studies on GPR35 signalling, a number of 
studies have investigated the functions of GPR35 in vivo, primarily focusing on 
its proposed role in the peripheral nervous system and pain transduction (Cosi et 
al., 2011, Resta et al., 2016). However, these studies were based on 
administration of the GPR35 agonists kynurenic acid and zaprinast, which are 
known to have alternative targets (ionotropic glutamate receptors and PDE5, 
respectively (Medina et al., 2000, Schwarcz et al., 2012)), and do not directly 
demonstrate GPR35 involvement. The in vivo studies described in Chapters 4, 5 
and 6 investigate the role of GPR35 in a different physiological system: the 
cardiovascular system. Although existing reports have suggested roles for GPR35 
in both hypertension and heart failure (Min et al., 2010, Ronkainen et al., 2014), 
the actual consequences of GPR35 activity (or lack thereof) had not previously 
been investigated in detail. The studies described here demonstrate a role for 
GPR35 in CVD using multiple approaches: the GPR35 knockout mouse, two 
different models of CVD and a GPR35 agonist study. Taken together, these 
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findings show that although GPR35 does not appear to be important in basal 
cardiovascular regulation, it plays an important role in the development of CVD. 
The data demonstrate that a lack of GPR35 expression in the GPR35 knockout 
mouse prevents the development of Ang II-induced hypertension and associated 
cardiac dysfunction (Chapter 5), whereas increased GPR35 activity through 
pharmacological agonism in the SHRSP exacerbates pre-existing hypertension 
and associated end-organ damage (Chapter 6). These findings indicate that 
GPR35 activity is involved in the pathophysiological processes contributing to the 
development of CVD. 
Despite investigating the effects of GPR35 deficiency on various aspects of the 
cardiovascular system, the GPR35 knockout mouse studies were not successful in 
determining a mechanism for the apparent pathological influence of GPR35. For 
example, knocking out GPR35 does not appear to impact directly on vascular 
reactivity either under basal conditions or in the early stages of hypertension 
development. However, based on existing evidence and the in vitro studies 
described in Chapter 3, it seems likely that a GPR35/Gα13/RhoA/ROCK signalling 
pathway is involved. However, a number of alternative mechanisms, such as 
crosstalk with the other GPCRs or effects on vascular inflammation through 
actions in immune cells, could potentially explain the pathological function of 
GPR35 in CVD. Future work should aim to determine which of these mechanisms 
is responsible for the role of GPR35 in the development of CVD, or whether 
multiple mechanisms are involved. 
A major limitation of these in vivo studies is the lack of validation using a GPR35 
antagonist. Before GPR35 can be pursued as a therapeutic target, it will be 
necessary to confirm that the effects seen here are specifically due to the 
actions of GPR35. As discussed in Chapters 5 and 6, novel technologies such as 
humanised mice and blocking antibodies will soon provide a means to antagonise 
GPR35 in vivo. Future research should therefore focus on establishing the 
therapeutic benefit of GPR35 antagonism in models of CVD. 
The overall aim of this work – to assess the therapeutic potential of GPR35 in 
CVD – is driven by the shortcomings of current therapies for hypertension and 
heart failure. As discussed in Chapter 1, these diseases remain a major health 
burden despite decades of research and many existing therapies (Campbell et 
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al., 2016, Hunt et al., 2009). Most of the existing therapies are based on 
modulation of either the renin-angiotensin system or the adrenergic system, and 
are usually used in combinations of between two and five different drugs from 
different classes (Williams et al., 2004, Hunt et al., 2009). However, a 
significant problem is that many patients are intolerant or unresponsive to these 
combinations; 20–30% of patients with hypertension are estimated to be resistant 
to treatment (Calhoun et al., 2008, Eirin et al., 2016). Therefore, the 
identification of novel therapeutic targets in distinct receptor systems has the 
potential to add to and/or improve upon the existing repertoire of treatments. 
The findings reported here suggest that GPR35 is indeed a potential novel 
therapeutic target in CVD, and that GPR35 antagonists might be used to combat 
hypertension and/or associated diseases caused by pathological cardiac 
remodelling. 
In addition to the pro-hypertensive actions of GPR35 shown in this work, 
previous reports have demonstrated that GPR35 is upregulated in the heart both 
in heart failure patients and in an animal model of heart failure (Min et al., 
2010, Ronkainen et al., 2014), suggesting that GPR35 and its endogenous agonist 
play a direct role in pathological cardiac remodelling. Therefore, similarly to the 
use of AT1R biased agonists, targeting GPR35 may have a dual benefit in the 
treatment of heart failure – both countering systemic hypertension and acting 
directly on the heart to prevent remodelling. Investigating the progression of 
pathological cardiac remodelling in the absence of GPR35 activity (either in the 
GPR35 knockout mouse or with antagonists, when they become available) could 
reveal enhanced therapeutic potential for GPR35. 
In this work, GPR35 knockout mice were found to have a similar phenotype to 
Gα13 cardiomyocyte-specific knockout mice in terms of resistance to Ang II-
induced cardiac remodelling (Takefuji et al., 2012). Assuming that the 
pathological effects of GPR35 are indeed mediated by the Gα13/RhoA/ROCK 
pathway, targeting these downstream mediators may be an alternative approach 
to modulating GPR35 function. ROCK has previously been proposed as a 
therapeutic target in CVD, and the approved ROCK inhibitor fasudil prevents 
hypertension-induced cardiac and vascular remodelling, as well as many other 
cardiovascular pathologies, in animal models (Higashi et al., 2003, 
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Phrommintikul et al., 2008, Surma et al., 2011). However, ROCK is very widely 
expressed, and while this may contribute to its many apparent therapeutic 
benefits, GPR35 is a much more specific and therefore preferable target. 
Further investigation of the links between GPR35 function and RhoA/ROCK 
activation in the cardiovascular system may reveal additional therapeutic 
opportunities. 
Although the findings reported here focus on GPR35 as a therapeutic target in 
CVD, it is important to consider the other proposed physiological functions of 
this receptor, of which there are many (discussed in section 1.4.6). GPR35 has 
been implicated in a range of processes, from pain transduction to 
gastrointestinal inflammation (Divorty et al., 2015, Mackenzie and Milligan, 
2015), and these other potential functions mean that administering a GPR35 
antagonist in a therapeutic setting would potentially have on-target effects that 
are unintended or undesirable. However, since the roles of GPR35 in other 
tissues are far from being well defined, it is impossible to predict such effects. 
Therefore, any future antagonist studies with a view to using GPR35 as a 
therapeutic target should include detailed investigation not just of 
cardiovascular function, but of other processes potentially affected by 
modulation of GPR35 activity. Furthermore, the role of the endogenous agonist 
must be considered – the levels of the endogenous agonist in the circulation and 
in relevant tissues in the disease state, and its affinity for GPR35, will determine 
whether an antagonist is therapeutically effective. Though these studies have 
not shed further light on the potential endogenous agonist(s) of GPR35, it is 
hoped that further advances in elucidating the function of this orphan receptor 
might provide insight on this matter. 
An additional lesson to be learned from the findings of these studies is that the 
function of an orphan receptor may not be immediately obvious, but it may be 
revealed under the appropriate conditions. The findings of Chapter 4 suggested 
that the GPR35 knockout mouse has normal cardiovascular function, but a 
pathophysiological role was revealed after inducing hypertension. This approach 
may be useful in investigating the other proposed functions of GPR35; for 
example, if attempting to confirm a suggested role in inflammatory bowel 
disease, it may be worthwhile to assess the phenotype of the GPR35 knockout 
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mouse under basal conditions and in a chemically-induced disease model such as 
dextran sodium sulphate-induced colitis (Wirtz et al., 2007). This applies not 
just to GPR35, but to the other >120 non-olfactory orphan GPCRs with unknown 
physiological functions (Davenport et al., 2013, Alexander et al., 2015). 
Expression patterns might provide a useful starting point; however, a lack of 
expression also does not definitively prove a lack of function. The role of GPR35 
in CVD was not immediately obvious from its expression pattern, as the receptor 
appears to be poorly expressed in cardiovascular tissues until the onset of 
disease. Alternatively, as with GPR35, clues to the function of orphan receptors 
might be found in genetic disease associations. It is important to continue 
searching for orphan receptor functions, using both conventional and novel 
approaches, in order to fully exploit the therapeutic value of the GPCR 
superfamily. 
Although years of research have failed to find a definitive function for GPR35, 
recent work has led to significant advances in our understanding of its 
pharmacology, signalling and physiology. Several studies using in vivo models 
have highlighted its physiological importance and therapeutic potential in a 
range of diseases. It will be interesting to discover whether its diverse roles – in 
inflammation, nociception and cardiovascular dysfunction – turn out to have a 
common mechanism. Alongside physiological studies, multiple screening efforts 
and thorough pharmacological characterisation have resulted in the 
development of a large and varied repertoire of tool compounds. These, in 
combination with novel experimental approaches, will facilitate future studies 
of GPR35 function; however, there is a need to move the focus away from 
artificial models towards physiologically and clinically relevant contexts. This 
will enable assessment of the true translational value of GPR35 as a therapeutic 
target, and hopefully lead to novel treatment strategies for chronic diseases.
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